

# Queensland Health List of Approved Medicines

Drug	Form	Strength	Restriction
abacavir	oral liquid		* For use in accord with PBS Section 100 indications *
		20 mg/mL	See above
	tablet		See above
abacavir + lamivudine		300 mg	See above
	tablet		* For use in accord with PBS Section 100 indications *
		600 mg + 300 mg	See above
abacavir + lamivudine + zidovudine			* For use in accord with PBS Section 100 indications *
	tablet		See above
		300 mg + 150 mg + 300 mg	See above
abatacept	injection		
		250 mg	* For use in accord with PBS Section 100 indications *
abciximab			(a) Interventional Cardiologists for complex angioplasty
			(b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures.
	injection		* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		10 mg/5 mL	See above
abemaciclib			For discharge and outpatient use as per the PBS indications where ribociclib is not suitable or not tolerated.
			Usual individual patient approval (IPA) process applies for continuation of therapy in admitted patients.
	tablet		See above
		50 mg	See above
		100 mg	See above
		150 mg	See above
abiraterone	tablet		For use by medical oncologists as per the PBS indications for outpatient and discharge use only
		250 mg	See above
		500 mg	See above
acalabrutinib	capsule		
		100 mg	Specialist haematologists for discharge and outpatient use as per the PBS indications.
acamprosate			Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.
	enteric tablet		See above
		333 mg	See above
acarbose			For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents
	tablet		See above
		50 mg	See above
		100 mg	See above
acetazolamide			

Drug	Form	Strength	Restriction
acetic acid	injection		
	tablet	500 mg	
		250 mg	
	ear drops	3% 15mL	
acetylcysteine	solution	2% 100mL	
		green 3% 1 litre	
		6% 1 Litre	
		6% 200mL	
aciclovir	injection		For management of paracetamol overdose <i>See above</i>
		2 g/10 mL	<i>See above</i>
		6 g/30 mL	<i>See above</i>
	cream	5%	Infectious disease physicians, haematologists and oncologists <i>See above</i>
	eye ointment	3%	For use on the advice of Ophthalmologists only. <i>See above</i>
	injection		Herpes simplex encephalitis Cutaneous or mucosal herpes simplex in immunosuppressed patients Disseminated herpes zoster in immunocompromised patients Varicella zoster encephalitis or pneumonia in all patients
		250 mg/10 mL	<i>See above</i>
		500 mg/20 mL	<i>See above</i>
acitretin	tablet	200 mg	For treatment of patients with: Genital herpes simplex infections Herpes zoster in immunocompetent patients in whom the duration of rash is less than 72 hours Herpes zoster in immunocompromised patients Ophthalmic herpes zoster
		800 mg	<i>See above</i>
	capsule	10 mg	Specialist Dermatologists and Specialist Physicians <i>See above</i>
		25 mg	<i>See above</i>
activated charcoal	oral liquid		
		200 mg/mL	250mL
activated charcoal + sorbitol	oral liquid	200 mg/mL + 400 mg/mL	250mL
adalimumab	injection	20 mg/0.4 mL	For use in accord with PBS General Schedule/Section 100 indications Note: 'Amgevita' is the sole brand listed on the LAM for the 20mg strength.
		40 mg/0.8 mL	For use in accord with PBS General Schedule/Section 100 indications Note: 'Idacio' is the sole brand listed on the LAM for the 40mg strength.
adefovir			* For use in accord with PBS Section 100 indications *

Drug	Form	Strength	Restriction
adenosine	tablet		See above
		10 mg	See above
	injection	6 mg/2 mL 30 mg/10 mL	Nuclear medicine for use in cardiac stress testing.
adrenaline (epinephrine)	injection	1 in 10 000 (1 mg/10 mL) injection and minijet 1 in 1000 (1 mg/mL) 150 microgram/0.3 mL	EpiPen Jr® brand - For discharge and outpatient use as per the PBS indications. Note: EpiPen Jr® has a substantially different administration technique to that of Anapen Junior®. Specific training is required for each brand of autoinjector. For patients previously prescribed an adrenaline autoinjector, subsequent prescriptions should be for the same brand, where possible.
		300 microgram/0.3 mL	EpiPen® brand - For discharge and outpatient use as per the PBS indications. Note: EpiPen® has a substantially different administration technique to that of Anapen®. Specific training is required for each brand of autoinjector. For patients previously prescribed an adrenaline autoinjector, subsequent prescriptions should be for the same brand, where possible.
		500 microgram/0.3 mL	Anapen 500® brand - For discharge and outpatient use as per the PBS indications. Note: Anapen® has a substantially different administration technique to that of EpiPen®. Specific training is required for each brand of autoinjector. For patients previously prescribed an adrenaline autoinjector, subsequent prescriptions should be for the same brand, where possible.
afibercept	injection	3.6 mg/0.09 mL syringe	Specialist ophthalmologists for outpatient use as per the PBS indications.
		4 mg/0.1 mL vial	See above
agalsidase alfa	injection	3.5 mg/3.5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
agalsidase beta	injection	5 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
		35 mg	See above
albendazole	tablet		(a) Treatment of adults and children with <i>Ancylostoma caninum</i> (Eosinophilic enterocolitis), <i>Ancylostoma duodenale</i> / <i>Necator americanus</i> (Hookworm), <i>Ascaris lumbricoides</i> (Roundworm), <i>Trichuris trichiuria</i> (Whipworm) or <i>Enterobius vermicularis</i> (Pinworm). (b) Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with <i>Echinococcus granulosus</i> (Hydatids). (c) Alternative treatment of adults and children with <i>Strongyloides stercoralis</i> .
		200 mg	See above
		400 mg	See above
alcohol (ethanol)	gel		
	injection	61.5% 75mL and 125mL	
		96% 10mL 100% 5mL	
	lotion		
	solution	47.5%-1% 1 litre	

Drug	Form	Strength	Restriction
		specially methylated (S.V.M.) 15mL specially methylated (S.V.M.) 20 litre 20 litre and 1 litre rectified (S.V.R.) 96% 2 litre and 20 litre absolute 1 litre industrial methylated 1 litre industrial methylated 4 litre absolute 20 litre specially methylated 70% 2 litre  with 10% propanol - foam  70% 1 litre 70% 50mL 70% 400mL	
alectinib	capsule	150 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications *
alemtuzumab	injection	12 mg/1.2 mL	* For use in accord with PBS Section 100 indications *
alendronate	tablet	70 mg	* For use as per the PBS indications *
alfentanil	injection	1 mg/2 mL 5 mg/10 mL	Specialist Anaesthetists and their trainees for use as an analgesic supplement given by incremental intravenous boluses or continuous infusion. * CONTROLLED DRUG * For poor risk patients (eg elderly and ischaemic heart disease) * CONTROLLED DRUG *
alginic acid compound (sodium alginate)	liquid	500mL liquid	For infant use only  <i>See above</i> <i>See above</i>
alglucosidase alfa	injection	50 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
allopurinol	tablet	100 mg 300 mg	
alogliptin	tablet	6.25 mg 12.5 mg 25 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
alprazolam	tablet	1 mg 500 microgram	Specialist Psychiatrists <i>See above</i> <i>See above</i>
alprostadil	injection	10 microgram 20 microgram 500 microgram/mL	Specialist Urologists and Spinal Injuries Units for in-hospital use for training purposes <i>See above</i> Neonatal and Paediatric Staff Specialists to use to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in

Drug	Form	Strength	Restriction
alteplase	pre-filled syringe	1mg in 1mL	neonates who have congenital heart defects and who depend upon a patent ductus for survival. For prevention of central venous catheter malfunction and central venous catheter associated bacterial infection in children on maintenance haemodialysis who are under the care of Specialist Renal Physicians. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
			<i>See above</i> <i>See above</i>
alteplase	injection		Note: Due to the current shortage of tenecteplase injection, this LAM listing has been amended. Usage of this product should be in line with the ADDG memorandum (dated 19/09/22) attached. a) treatment of acute ST elevation myocardial infarction;b) treatment of acute massive pulmonary embolism.c) fibrinolytic management of obstructed IV access;d) treatment of acute ischaemic stroke under the authority of a physician (including Emergency Department physicians) trained and experienced in acute stroke management or in accordance with an approved written protocol, and in line with the Australian "Clinical Guidelines for Stroke Management". e) fibrinolytic treatment of complex pleural effusions. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
aluminium hydroxide	tablet	10 mg	<i>See above</i>
		50 mg	<i>See above</i>
aluminium hydroxide + magnesium hydroxide + simethicone (double strength)	chewable tablet	600 mg	For lowering of serum organic phosphates in patients with chronic renal failure <i>See above</i> <i>See above</i>
		400 mg + 400 mg + 40 mg	
aluminium hydroxide + magnesium trisilicate + magnesium hydroxide	oral liquid	250 mg/5 mL + 120 mg/5 mL + 120 mg/5 mL	
amantadine	capsule	100 mg	For the treatment of Parkinson Disease <i>See above</i> <i>See above</i>
ambrisentan	tablet		* For use in accord with PBS Section 100 indications *
		5 mg	<i>See above</i>
		10 mg	<i>See above</i>
amidotrizoic acid	solution	660 mg/mL + 100 mg/mL	For use as a radiographic contrast medium for examination of the gastrointestinal tract; For use by general surgeons for adhesive small bowel obstruction (obtain individual patient supplies from pharmacy for administration as a single 100mL dose). * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the

Drug	Form	Strength	Restriction
CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *			
amikacin	injection	500 mg/2 mL	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. Caution: Only use DBL brand for nebulised route as it has a lower sodium metabisulfite content. Use other brands for injectable route. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
amiloride	tablet	5 mg	
amiloride + hydrochlorothiazide	tablet	5 mg + 50 mg	
amino acids (synthamin 17) with electrolytes 100g (446 Cal.)/litre, (Na 70,K 60, Mg 5, Cl 70, Ac 150, PO4 30 mmol/L)	injection	10.35 g/500 mL + 5.75 g/500 mL + 5.15 g/500 mL + ...	For prolonged intravenous therapy when oral or enteral feeding is not possible
amino acids (Synthamin 17) without electrolytes 100g/litre (Ac 82, Cl 40mmol/L)	injection	10.35 g/500 mL + 5.75 g/500 mL + 5.15 g/500 mL + ...	For prolonged intravenous therapy when oral or enteral feeding is not possible
aminolevulinic acid	powder for oral liquid	1.5 g	Neurosurgeons who have undergone training in fluorescence guided surgery for use in patients with suspected high grade glioma in whom complete resection of enhancing tissue is feasible. <i>See above</i>
aminophylline	injection	250 mg/10 mL	
amiodarone	oral liquid suspension	5mg/mL 80mL	Paediatric cardiac specialists <i>See above</i> <i>See above</i>
amiodarone	injection	150 mg/3 mL	All preparations restricted to Cardiologists for resistant cardiac arrhythmias <i>See above</i>
	tablet	100 mg 200 mg	<i>See above</i> <i>See above</i>
amisulpride	oral liquid	100 mg/mL	* For use as per the PBS indications *
	tablet	100 mg 200 mg 400 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i>
amitriptyline			

Drug	Form	Strength	Restriction
amlodipine	tablet	10 mg 25 mg 50 mg	
	tablet	5 mg 10 mg	
amorolfine	solution	5%	Dermatologists for the treatment of proven fungal infections <i>See above</i> <i>See above</i>
amoxicillin	capsule	250 mg 500 mg	
	powder for oral liquid	250 mg/5 mL 500 mg/5 mL	
amoxicillin + clavulanic acid	injection	1 g + 200 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
		2 g + 200 mg 500 mg + 100 mg	<i>See above</i> <i>See above</i>
	powder for oral liquid	125 mg/5 mL + 31.25 mg/5 mL 400 mg/5 mL + 57 mg/5 mL	In conjunction with an antimicrobial stewardship (AMS) team protocol <i>See above</i>
		tablet	500 mg + 125 mg 875 mg + 125 mg
amphotericin B	injection "Fungizone"	50 mg	For treatment of fungal infections where lipid amphotericin preparations are not initially indicated * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below: Amphotericin B - "Fungizone" 50mg Inj Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj
	lozenge "Fungilin"	10 mg	Treatment of oral moniliasis
amphotericin B	powder for tissue culture	50mg	
amphotericin B lipid complex "Abelcet"	injection	100 mg/20 mL	For treatment/prophylaxis of fungal infections * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below:

Drug	Form	Strength	Restriction
			Amphotericin B - "Fungizone" 50mg Inj Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj
amphotericin B liposomal "AmBisome"	injection	50 mg	Use where therapy with "Abelcet" cannot be tolerated. For treatment/prophylaxis of fungal infections * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below: Amphotericin B - "Fungizone" 50mg Inj Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj <i>See above</i> <i>See above</i>
ampicillin	injection	1 g 500 mg	
amsacrine (AMSA)	injection	75mg in 1.5mL	
anakinra	injection	100 mg/0.67 mL	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
anastrozole	tablet	1 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i>
antithymocyte immunoglobulin equine	injection	250 mg/5 mL	
antithymocyte immunoglobulin rabbit	injection	25 mg	Transplant Specialists, Oncologists and Haematologists for: a) Prophylaxis of graft rejection in renal transplantation patients with a history of graft rejection; and b) Treatment of steroid resistant or moderate to severe renal transplant rejection. <i>See above</i> <i>See above</i>
apomorphine	injection	30 mg/3 mL pen device and cartridge 50 mg/5 mL ampoule 50 mg/10 mL syringe 100 mg/20 mL vial	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
apraclonidine	eye drops	0.5% 5mL and 10mL	Specialist Ophthalmologists <i>See above</i> <i>See above</i>
aprepitant	capsule	165 mg	For use as per the PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
aprepitant	oral liquid suspension		



Drug	Form	Strength	Restriction
		20mg/mL, 30mL	Paediatric oncology staff for the prevention and treatment of antineoplastic induced nausea and vomiting in paediatric patients under the care of the oncology service when other oral dosage forms are inappropriate. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
aqueous cream (A.P.F) with coal tar solution	cream		
		aqueous cream (A.P.F.) with coal tar 3% solution 100g	
aqueous cream (A.P.F.)	cream	100g 500g	
aqueous cream (A.P.F.) with salicylic acid and coal tar solution	cream		
		6%-6% 100g	
aqueous cream (A.P.F.) with menthol	cream		
		1% 100g	
aqueous cream (A.P.F.) with salicylic acid and sulfur	cream		
		3%-10% 100g 5%-5% 100g	
argatroban			For use as an alternative anticoagulant therapy for management of heparin-induced thrombocytopenia (HIT) in patients where rivaroxaban or fondaparinux is inappropriate. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	injection (SAS)		<i>See above</i>
		250mg in 2.5mL	<i>See above</i>
arginine hydrochloride			For pituitary function testing
	injection		<i>See above</i>
		60% (15 g/25 mL)	<i>See above</i>
aripiprazole			
	modified release injection		
		300 mg	Specialist Psychiatrists for the treatment of schizophrenia
		400 mg	<i>See above</i>
	tablet		
		5 mg	On the advice of psychiatrists and paediatricians for second-line treatment, following a trial of risperidone or clinical contraindications to the use of risperidone, for managing behavioural disturbance in autism spectrum disorder in children and adolescents up to 18 years of age. Note: Restrict use to where other tablet strengths cannot be used. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		10 mg	a) For use as per the PBS indications. b) On the advice of psychiatrists and paediatricians for second-line treatment, following a trial of

Drug	Form	Strength	Restriction
			risperidone or clinical contraindications to the use of risperidone, for managing behavioural disturbance in autism spectrum disorder in children and adolescents up to 18 years of age. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		15 mg	See above
		20 mg	See above
		30 mg	See above
arsenic	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above
		10 mg/10 mL	See above
artemether + lumefantrine	tablet		For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
		20 mg + 120 mg	See above
artesunate	powder for injection		For use in accord with Category A Special Access Scheme (SAS) arrangements. Approval from the Medical Superintendent (or delegate) must also be received in line with the Individual Patient Approval (IPA) guidelines. Initiation of therapy should be on the advice of an Infectious Diseases Physician. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * QHMAC guidance on artesunate provided below - see 'Guidelines and Other Resources' section.
		60mg	See above
articaine + adrenaline (epinephrine)	injection		
		4% (88 mg/2.2 mL) + 1 in 100 000 (22 microgram/2.2 mL)	For dental use
artificial saliva	liquid		
		2 Litres "oralube" 125mL	
ascorbic acid	chewable tablet		
		500 mg	
aspirin	dispersible tablet		
		300 mg	
	tablet		
		100 mg	
atazanavir	capsule		
		200 mg	* For use in accord with PBS Section 100 indications *
		300 mg	See above
atazanavir + cobicistat	tablet		* For use in accord with PBS Section 100 indications *
		300 mg + 150 mg	See above
atenolol	tablet		

Drug	Form	Strength	Restriction	
atenolol	oral liquid suspension	50 mg	Paediatric cardiac specialists <i>See above</i>	
		2mg/mL 200mL	<i>See above</i>	
atezolizumab	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *	
		1.2 g/20 mL	<i>See above</i>	
		840 mg/14 mL	<i>See above</i>	
atomoxetine	capsule	10 mg	For use as per the PBS indications (ADHD)	
		18 mg	<i>See above</i>	
		25 mg	<i>See above</i>	
		40 mg	<i>See above</i>	
		60 mg	<i>See above</i>	
atorvastatin	tablet		* For use as per the PBS indications *	
		10 mg	<i>See above</i>	
		20 mg	<i>See above</i>	
		40 mg	<i>See above</i>	
		80 mg	<i>See above</i>	
atovaquone + proguanil	tablet	250 mg + 100 mg	For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist	
atracurium	injection		Specialist Anaesthetists and Country Medical Superintendents	
		25 mg/2.5 mL	<i>See above</i>	
		50 mg/5 mL	<i>See above</i>	
atropine sulfate	eye drops	1% unit dose 0.5mL x 20 and 15mL	0.5mL x 20 unit dose: For inpatient use only	
			15mL: Unrestricted	
	injection		1 mg/10 mL	Caution: Oral ingestion of atropine eye drops for clozapine-induced hypersalivation has been associated with accidental oral ingestion of a toxic quantity causing patient harm. Consider hyoscine hydrobromide chewable tablets as a LAM-listed alternative.
			1.2 mg/mL	
			600 microgram/mL	
tablet		600 microgram	For organophosphate poisoning	
avelumab	injection	200 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *	
azacitidine	injection		* For use in accord with PBS Section 100 indications *	
		100 mg	<i>See above</i>	

Drug	Form	Strength	Restriction
azathioprine	injection	50 mg	
	tablet	25 mg 50 mg	
azathioprine	oral liquid suspension	5mg/mL, 100mL (QH-CP)	For oral or enteral dosing where administration of the solid dose form is not appropriate. Refer to 'Don't Rush to Crush' and local procedures for guidance. Note: Monitor patient on transition between different dose forms. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
azithromycin	injection	500 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
	powder for oral liquid	200 mg/5 mL	For use as per the PBS indications for trachoma; and For the treatment and prophylaxis of laboratory proven or suspected Bordetella pertussis infection in children and infants. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet	500 mg  600 mg	(a) For treatment of Chlamydia trachomatis where alternative therapy is ineffective or inappropriate; (b) Cystic fibrosis specialists treating cystic fibrosis patients (six years and older) as prophylaxis of exacerbations of chronic Pseudomonas aeruginosa infection; (c) For the treatment of laboratory proven Bordetella pertussis infection in adults; (d) For the prophylaxis of Bordetella pertussis infection in susceptible contacts of proven cases as advised by an infectious diseases or public health physician; (e) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults; (f) Specialist immunology staff for antimicrobial prophylaxis in patients with chronic infection-related pulmonary disease (e.g. bronchiectasis) in the setting of primary antibody deficiency (i.e. common variable immune deficiency, x-linked agammaglobulinemia and related conditions) where non-tuberculosis mycobacterial infection has been excluded. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * For use in accord with PBS Section 100 indications; Specialist Staff for prophylaxis of Mycobacterium Avium Complex in severe immune deficiency
aztreonam	injection	1 g	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
baclofen	intrathecal injection	10 mg/5 mL 50 microgram/mL	* For use in accord with PBS Section 100 indications * Spinal unit patients only
	tablet	10 mg	Suppression of voluntary muscle spasm in multiple sclerosis Spinal lesions causing skeletal hypertonus

Drug	Form	Strength	Restriction
			Spastic and dys-synergic bladder dysfunction
		25 mg	See above
balanced salt solution concentrate (plus) 500mL	irrigation solution		Ophthalmologists
			See above
		Sodium Chloride 0.64%; Potassium Chloride 0.075%;Magnesium Chloride 0.03%; Calcium Chloride 0.048%;Sodium Acetate 0.39%;Sodium Citrate 0.17%	See above
balsalazide	capsule		For use as per the PBS indications (for ulcerative colitis)
		750 mg	See above
balsam of peru	ointment		
		15g	
baricitinib	tablet		On the advice of a specialist physician for the treatment of COVID-19 in accordance with recommendations in the National Clinical Evidence Taskforce COVID-19 Guidelines
		2 mg	See above
		4 mg	See above
basiliximab	injection		
		20 mg	Specialist Nephrologist staff as induction therapy for renal transplant recipients.
beclometasone	inhalation		
		50 microgram/actuation	
	nasal spray		
		100 microgram/actuation	
		50 microgram/actuation	
bendamustine	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		25 mg	See above
		100 mg	See above
benralizumab	injection		
		30 mg/mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
benzathine benzylpenicillin	injection		
		1.2 million units/2.3 mL	
benzatropine	injection		
		2 mg/2 mL	
	tablet		
		2 mg	
benzoic acid + salicylic acid	ointment		
		6% + 3%	
benzoin Sumatra + storax prepared + Aloes cape	tincture		
		9.78% + 4.6% + 6.22%	25mL

Drug	Form	Strength	Restriction
benzoyl peroxide	gel	5%	50g
benzylamine	mouthwash	0.15%	200mL: For the treatment of mucositis associated with radiotherapy and cytotoxic chemotherapy <i>See above</i>
benzyl benzoate	lotion	25%	200mL <i>See above</i> <i>See above</i>
benzylpenicillin	injection	1.2 g 3 g 600 mg	
betamethasone acetate + betamethasone sodium phosphate	injection	3 mg/mL + 3.9 mg/mL (total betamethasone 5.7 mg/mL)	
betamethasone dipropionate	cream	0.05% 15g and 50g, 0.05% modified cream 30g	
	lotion	0.05%	30mL
	ointment	0.05% 15g and 50g and modified ointment 30g	Betamethasone Dipropionate (Diprosone) Ointment 15g and 50g - unrestricted Betamethasone Dipropionate Glycol (Diprosone OV) Ointment 30g - Specialist Dermatologists
betamethasone valerate	cream	0.02%	100g
		0.05%	15g
		0.1%	30g
ointment	0.1%	30g	
	cream	0.03%-0.9% 50g	
betaxolol	eye drops	0.5%	
bethanechol	tablet	10 mg	Inpatient use only. <i>See above</i> <i>See above</i>
bevacizumab	injection	100 mg/4 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		400 mg/16 mL	<i>See above</i> <i>See above</i> <i>See above</i>
bicalutamide	tablet		

Drug	Form	Strength	Restriction
		50 mg	For metastatic (equivalent to Stage D) prostatic carcinoma in combination with GnRH (LH-RH) agonist therapy or post bilateral orchidectomy.
bicarbonate	capsule	840 mg	
	injection	8.4% (8.4 g/100 mL)	
bicarbonate + calcium lactate pentahydrate + glucose + potassium chloride + sodium chloride	solution	0.015% + 0.032% + 0.085% + ...	For initial supply post ENT surgery; and sinus irrigation for children with chronic rhinosinusitis which may co-exist with cystic fibrosis and asthma. Note: Pack of 12 sachets (starter kit) only
bicarbonate + citric acid + tartaric acid	powder for oral liquid	1.76 g + 630 mg + 720 mg + ...	
bictegravir + emtricitabine + tenofovir alafenamide	tablet	50 mg + 200 mg + 25 mg	* For use in accord with PBS Section 100 indications *  <i>See above</i> <i>See above</i>
binimetinib	tablet	15 mg	Specialist oncologists * For discharge and outpatient use as per the PBS indications *
biperiden	tablet	2 mg	
bisacodyl	enema	10 mg/5 mL	For inpatient use only <i>See above</i>
	enteric tablet	5 mg	
	suppository	10 mg	
bisacodyl + docusate	suppository	10 mg + 100 mg	
bisacodyl-magnesium citrate (pack containing 3 x 5mg bisacodyl tablets and 1 x sachet magnesium citrate effervescent (equiv to 3g magnesium oxide) "Go Kit")	*combination pack*	pack containing 3 x 5mg bisacodyl tablets and 1 x sachet magnesium citrate effervescent (equiv to 3g magnesium oxide)	
bismuth subcitrate (colloidal)	tablet	107.7mg	For radiologically or endoscopically proven ulcer <i>See above</i> <i>See above</i>
bismuth subnitrate + iodoform			

Drug	Form	Strength	Restriction
	paste	250 mg/g + 500 mg/g	
bismuth subnitrate and iodoform	dressing	1-2-1 (12.5mm x 1m)	
bisoprolol	tablet	2.5 mg 5 mg 10 mg	* For use as per the PBS indications * See above See above
bivalirudin	injection	250 mg	a) For patients undergoing non-urgent percutaneous coronary intervention; or b) For use as an alternative anticoagulant therapy for management of heparin-induced thrombocytopenia (HIT) in patients where rivaroxaban or fondaparinux is inappropriate. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
bleomycin	injection	15 000 international units	Interventional radiologists and/or surgeons as a first-line sclerotherapy agent for the treatment of microcystic lymphatic malformations and as an alternative sclerotherapy agent for treatment of other subtypes of veno-lymphatic malformations (at the discretion of the treating clinician). or For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS or For treatment of malignant lymphoma or squamous carcinoma unresponsive to any other therapy or, when owing to severe depression of bone marrow, other therapy cannot be used * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
blood detection in faeces - hematest	tablet	50	
blood detection in faeces - coloscreen	tape	pack of 2 x 100 tests	
blood detection in urine - hemastix	diagnostic strip	test strips	
bone cement with antibiotic - gentamicin 0.5g "Palacos MV+G" "Palacos R+G"	40g	gentamicin 0.5g - Palacos MV+G ; Palacos R+G	For use in hip, and high risk knee, arthroplasty.



Drug	Form	Strength	Restriction
bone cement with antibiotic - gentamicin 1g "CMW1" "CMW2" "CMW3"	40g	gentamicin 1g "CMW1" "CMW2" "CMW3"	For use in hip, and high risk knee, arthroplasty.  <i>See above</i> <i>See above</i>
bone cement with antibiotic - tobramycin 1g "Antibiotic Simplex"	40g	tobramycin 1g "Antibiotic Simplex"	For use in hip, and high risk knee, arthroplasty.
boric acid 5% in 96% ethanol	ear drops	5% 15mL	
boric acid, olive oil, zinc oxide with salicylic acid	ointment	2.5% 100g	
boric acid, olive oil, zinc oxide with salicylic acid and coal tar solution	ointment	2.5%-2.5% 50g	
bortezomib	injection	1 mg 2.5 mg 3 mg 3.5 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
bosentan	tablet	62.5 mg 125 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
botulinum toxin type A	injection	100 units	a) For use in outpatients, day admitted patients or inpatients admitted for less than 24 hours duration in accord with PBS Section 100 indications b) Specialist Colorectal Surgeons for the treatment of female patients with chronic anal fissure (where Crohn disease has been excluded) who have failed a two month trial of conservative therapy (including glyceryl trinitrate ointment 0.2%). Maximum of two treatment doses. c) Specialist ophthalmologists only for protective ptosis. d) Specialist paediatric surgeons and paediatric gastroenterologists for treatment in children with pain (proctalgia fugax) secondary to anal sphincter spasm or anal fissure refractory to standard treatment with laxatives. e) Gastroenterologists for management of achalasia in patients who are not candidates for surgical myotomy or endoscopic dilatation treatment. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
box jellyfish antivenom	injection	20 000 units, vial	

Drug	Form	Strength	Restriction
brentuximab vedotin	injection	50 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
brexpiprazole	tablet	1 mg 2 mg 3 mg 4 mg	For use as per the PBS indications following failure of aripiprazole, risperidone, olanzapine, amisulpride or lurasidone. <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
brilliant green + crystal violet	paint	0.5% + 0.5%	
brimonidine	eye drops	0.2%	5mL
bromhexine	tablet	8 mg	
bromocriptine	capsule	10 mg	
	tablet	2.5 mg	
brown snake antivenom	injection	1000 units, vial	
budesonide	inhalation solution	1 mg/2 mL 500 microgram/2 mL	For patients with severe chronic asthma requiring long term steroid therapy and unable to use other forms of inhaled steroid therapy; Specialist Staff and emergency unit doctors for the treatment of moderate to severe croup <i>See above</i> <i>See above</i>
	orally disintegrating tablet	1 mg 500 microgram	For use in eosinophilic oesophagitis as per the PBS indications. <i>See above</i> <i>See above</i>
	powder for inhalation	100 microgram/actuation 200 microgram/actuation 400 microgram/actuation	
budesonide + formoterol	inhalation	50 microgram/actuation + 3 microgram/actuation 100 microgram/actuation + 3 microgram/actuation 200 microgram/actuation + 6 microgram/actuation	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
	powder for inhalation	100 microgram/actuation + 6 microgram/actuation 200 microgram/actuation + 6 microgram/actuation 400 microgram/actuation + 12 microgram/actuation	<i>See above</i> <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
bumetanide	tablet	1 mg	
bupivacaine	injection	0.25% (50 mg/20 mL) 0.5% (50 mg/10 mL) 0.5% (100 mg/20 mL)	
	injection	0.125% (250 mg/200 mL) 0.25% (250 mg/100 mL)	
	intrathecal injection	0.5% (20 mg/4 mL)	
bupivacaine (Baxter)	infusion	(0.0625%) 125mg in 200mL	
bupivacaine + adrenaline (epinephrine)	injection	0.25% (50 mg/20 mL) + 1 in 400 000 (50 microgram/20 mL) 0.5% (11 mg/2.2 mL) + 1 in 200 000 (11 microgram/2.2 mL) 0.5% (100 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL)	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
bupivacaine + fentanyl	injection	0.125% (25 mg/20 mL) + 100 microgram/20 mL	* CONTROLLED DRUG *
bupivacaine + fentanyl	epidural infusion	0.125% (250mcg/200mL) + 400mcg/200mL 0.125% (250mcg/200mL) + 1000mcg/200mL	* CONTROLLED DRUG * <i>See above</i> <i>See above</i>
bupivacaine + glucose "marcaine spinal 0.5% heavy"	injection	0.5% + 8% 4mL	
buprenorphine	injection	300 microgram/mL	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
	patch	5 microgram/hour	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care, for patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		10 microgram/hour 20 microgram/hour	<i>See above</i> <i>See above</i>
	sublingual tablet	2 mg	a) For use in accord with PBS Section 100 indications; b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *

Drug	Form	Strength	Restriction
		8 mg	See above
		200 microgram	Therapy to be initiated/managed by a persistent pain management service for use in patients with chronic severe pain which is not responding to non-opioid or first/second line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		400 microgram	a) For use in accord with PBS Section 100 indications; b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *
buprenorphine (Bupival Monthly)			For use in accord with PBS Section 100 indications. Caution: Bupival Weekly, Bupival Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable. Note: These presentations are only for administration by subcutaneous injection. * CONTROLLED DRUG * Queensland Opioid Dependence Treatment Guidelines 2023
	modified release injection		See above
		64 mg/0.18 mL	See above
		96 mg/0.27 mL	See above
		128 mg/0.36 mL	See above
		160 mg/0.45 mL	See above
buprenorphine (Bupival Weekly)			For use in accord with PBS Section 100 indications. Caution: Bupival Weekly, Bupival Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable Note: These presentations are only for administration by subcutaneous injection. * CONTROLLED DRUG * Queensland Opioid Dependence Treatment Guidelines 2023
	modified release injection		See above
		8 mg/0.16 mL	See above
		16 mg/0.32 mL	See above
		24 mg/0.48 mL	See above
		32 mg/0.64 mL	See above
buprenorphine (Sublocade)			For use in accord with PBS Section 100 indications. Caution: Bupival Weekly, Bupival Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable Note: These presentations are only for administration by subcutaneous injection. *CONTROLLED DRUG* Queensland Opioid Dependence Treatment Guideline 2023
	modified release injection		See above
		100 mg/0.5 mL	See above
		300 mg/1.5 mL	See above
buprenorphine + naloxone			
	sublingual film		a) For use in accord with PBS Section 100 indications. b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *
		2 mg + 500 microgram	See above
		8 mg + 2 mg	See above
burosumab			
	injection		For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.

Drug	Form	Strength	Restriction
busulfan	tablet	10 mg/mL, vial	See above
		20 mg/mL, vial	See above
		30 mg/mL, vial	See above
C1 esterase inhibitor	injection	2 mg	
		500 units	For inpatient use in line with National Blood Authority funded indications (Type I or Type II hereditary angioedema).
		1500 units	See above
		2000 units	For use in line with National Blood Authority funded indications (Type I or Type II hereditary angioedema).
		3000 units	See above
cabazitaxel	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		60 mg/1.5 mL	See above
cabergoline	tablet	1 mg	For the treatment of Parkinson Disease
		2 mg	See above
		500 microgram	Specialist endocrinologists for treatment of prolactinomas or hyperprolactinaemia as per the PBS indications where the patient is intolerant of bromocriptine despite maximum tolerated therapy; For lactation suppression as per the PBS indications
cabotegravir	tablet		* For use in accord with PBS Section 100 indications *
		30 mg	See above
cabotegravir (&) rilpivirine	modified release injection + rilpivirine modified release injection	600 mg/3 mL + 900 mg/3 mL	* For use in accord with PBS Section 100 indications *
caffeine	injection		Specialist Paediatric Staff for use in premature babies born under 36 weeks gestation who have apnoea of prematurity when enteral caffeine is inappropriate
		40 mg/2 mL	See above
caffeine citrate	oral liquid solution	20mg per mL, 50mL	Specialist Paediatric Staff for use in premature babies born under 36 weeks gestation who have apnoea of prematurity
calamine lotion (B.P.)	lotion	calamine lotion (B.P)	200mL
calamine with coal tar solution	lotion	calamine with coal tar solution 3%	
calamine with zinc oxide and almond oil			100g
	cream		See above

Drug	Form	Strength	Restriction
		calamine with zinc oxide and almond oil	See above
calcipotriol	cream	0.005%	Specialist Dermatologists for use as per the PBS indications See above See above
calcipotriol + betamethasone dipropionate	foam	0.005% + 0.05%	Specialist Dermatologists for outpatients for the treatment of chronic stable plaque type psoriasis vulgaris of the scalp as per the PBS indications. See above
	ointment	0.005% + 0.05%	30g: Specialist Dermatologists for the treatment of chronic stable plaque type psoriasis vulgaris as per the PBS indications. See above
calcitonin salmon	injection	100 units/mL	
calcitriol	capsule	0.25 microgram	
calcitriol	oral solution (SAS)	1 microgram/mL, 15mL	For use in patients unable to swallow capsules. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * See above
calcium	effervescent tablet	2.3 g + 1.8 g (total calcium 1 g)	For treatment of hypocalcaemia. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	tablet	1.25 g (calcium 500 mg) 1.5 g (calcium 600 mg)	
Calcium carbonate oral suspension (Auspman) 100mg/mL, 200mL	oral liquid suspension	200mL	For treatment of hypocalcaemia in children too young to swallow tablets or capsules.
calcium chloride	injection	1 g/10 mL	
calcium gluconate monohydrate	injection	931 mg/10 mL (Calcium 2.2mmol/10mL)	
calcium polystyrene sulfonate	powder	999.3 mg/g	For use when polystyrene sulfonate sodium is inappropriate. See above See above
camphor compound linctus A.P.F. with or without syrup	oral liquid	Camphor compound linctus A.P.F.	100mL See above See above
capecitabine	tablet		General use for TGA approved indications. See above

Drug	Form	Strength	Restriction
		150 mg	See above
		500 mg	See above
capreomycin	injection		
capsaicin		1 g	45g: For use in treatment of neuralgic pain
	cream		See above
		0.075%	See above
captopril	oral liquid		95mL: For patients unable to take a solid dose form of an ACE inhibitor
	tablet	5 mg/mL	See above
		12.5 mg	
		25 mg	
		50 mg	
carbachol	eye drops		15mL
		3%	See above
	intraocular injection		Specialist Ophthalmologists
		0.01% (150 microgram/1.5 mL)	See above
carbachol 1.5% 15mL	eye drops		
		1.5% 15mL	
carbamazepine	modified release tablet		
		200 mg	
		400 mg	
	oral liquid		
		100 mg/5 mL	
	tablet		
		100 mg	
		200 mg	
carbimazole	tablet		
		5 mg	
carbomer-980	eye gel		10g: Specialist Ophthalmologists
		0.2%	See above
			See above
carboplatin	injection		
		50 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		150 mg/15 mL	See above
		450 mg/45 mL	See above
carboprost (15-methyl prostaglandin F2α)			Specialist Obstetricians and Gynaecologists and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology, for second line management of severe life-threatening primary postpartum haemorrhage within the guidance of the Queensland Maternity and Neonatal Clinical Guideline "Primary Postpartum Haemorrhage".
			* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	injection		See above

Drug	Form	Strength	Restriction
		250microgram/mL	See above
carfilzomib	injection	10 mg 30 mg 60 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above See above
carmellose sodium (Cellufresh)	eye drops	0.5%	0.4mL: Specialist ophthalmologists
carmellose sodium (Celluvisc)	eye drops	1%	0.4mL: Specialist Ophthalmologists
carmustine	injection	100 mg	
carvedilol	tablet	3.125 mg 6.25 mg 12.5 mg 25 mg	* For use as per the PBS indications * See above See above See above See above
carvedilol	oral liquid suspension	carvedilol 1.67mg per mL	90mL: Paediatric cardiac specialists See above See above
casirivimab + imdevimab (Ronapreve)	injection	120 mg/mL + 120 mg/mL	On the advice of an infectious diseases physician for the treatment of COVID-19 in accordance with recommendations in the National Clinical Evidence Taskforce COVID-19 Guidelines
caspofungin	injection	50 mg 70 mg	For use in adults and paediatrics on the advice of an infectious diseases physician or a clinical microbiologist for treatment of severe systemic candida infections that are resistant to fluconazole therapy, or where fluconazole is strongly contraindicated; or in accord with an infectious diseases approved protocol. See above See above See above
castor oil	oil	castor oil	200mL See above See above
castor oil and zinc oxide	ointment	castor oil and zinc oxide	100g See above See above
cefaclor	powder for oral liquid	125 mg/5 mL	100mL: For treatment of respiratory tract infections in patients unable to swallow cefuroxime tablets and who are hypersensitive to penicillin (excluding immediate hypersensitivity) See above
cefalexin	capsule	250 mg	



Drug	Form	Strength	Restriction
	powder for oral liquid	500 mg	Children too young to swallow tablets or capsules
		250 mg/5 mL	<i>See above</i>
cefalotin	injection		On the advice of an infectious diseases physician or microbiologist in situations where it may be preferred to cefazolin. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		1 g	<i>See above</i>
cefazolin	injection		
		1 g	
Cefazolin (with preservative) (QH-CP)	eye drops		Ophthalmologists.
		5%, 10mL	<i>See above</i>
cefepime	injection		
		1 g	(a) On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol (b) For patients under the care of Specialist Renal Physicians for empiric treatment of paediatric peritoneal dialysis peritonitis according to the statewide paediatric clinical pathway. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
		2 g	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
cefotaxime	injection		* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		1 g	<i>See above</i>
		2 g	<i>See above</i>
cefoxitin	injection		For treatment of (a) infections caused by non-tuberculous mycobacteria; (b) biliary reconstructive surgery in children; (c) on the advice of an infectious diseases physician or a clinical microbiologist
		1 g	<i>See above</i>
ceftazidime	injection		* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		1 g	<i>See above</i>
		2 g	<i>See above</i>
ceftriaxone	injection		* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		1 g	<i>See above</i>
cefuroxime	tablet		For treatment of respiratory tract infections in patients hypersensitive to penicillin (excluding immediate hypersensitivity)
			<i>See above</i>

Drug	Form	Strength	Restriction
		250 mg	See above
celecoxib	capsule	200 mg	a) For use as a single peri-operative dose for the management of post-operative pain b) Short term treatment of acute pain in patients undergoing or who have undergone a surgical procedure
cemiplimab	injection	350 mg/7 mL, vial	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above
cerliponase alpha	injection solution	150mg/5mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
cetirizine	oral liquid	5 mg/5 mL	200mL: For use in children where other antihistamines are inappropriate.
	tablet	10 mg	Where other antihistamines are inappropriate.
cetomacrogol	cream	100g 500g	
cetomacrogol cream with clioquinol	cream	1% 100g	
cetomacrogol with crude coal tar	cream	cetomacrogol cream with crude coal tar 1% 100g	
cetomacrogol with salicylic acid	cream	3% 100g 12% 50g	
cetomacrogol with salicylic acid and coal tar solution	cream	3%-3% 100g 3%-6% 100g	
cetuximab	injection	100 mg/20 mL 500 mg/100 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
cetylpyridinium + benzocaine	mouthwash	0.05% + 0.4%	200mL
chloral hydrate	oral liquid	1 g/10 mL	200mL
chlorambucil	tablet	2 mg	
chloramphenicol			

Drug	Form	Strength	Restriction
	ear drops	0.5%	5mL
	eye drops	0.5% 0.5mL x 20 0.5% 10mL	Inpatient use only
	eye ointment	1%	4g: For ophthalmic use only
chlorhexidine	cream	1% 50g	
	digluconate alcohol free mouthwash	0.2% 200mL	(a) Mucositis in oncology patients and in paediatric intensive therapy units; (b) As an antibacterial mouthwash following maxillo-facial surgery; (c) As an in-clinic antibacterial rinse when undergoing dental treatment for correctional centre patients, paediatric patients or those with a religious objection to ethanol.
	gluconate mouthwash	0.2% 200mL	
	hand and body wash/skin cleanser	2% 125mL 2% 500mL	
	lotion	1% 200mL obstetric	
	pre op-wash	4% 50 mL	
	surgical hand scrub/surgical hand wash	4% 1.5L 4% 125mL 4% 500mL	Restricted to specially approved areas See above See above
chlorhexidine in alcohol	handrub	chlorhexidine 0.5% alcohol 70% -125mL, 500mL	
	solution PINK	chlorhexidine 2% alcohol 70% - 30mL, 100mL, 500mL	
	solution RED	chlorhexidine 0.5% alcohol 70% - 100mL, 500mL chlorhexidine 2% alcohol 70% - 30mL, 100mL	
chlorhexidine sterile aqueous	solution	0.02% 100mL 0.02% - 500 mL, 1 Litre 0.1% - 30 mL, 100 mL, 1 Litre	Can be used for bladder irrigation
chlorhexidine + cetrimide	solution	0.015% (150 mg/L) + 0.15% (1.5 g/L) - 30mL, 500mL, 1Litre	
chloroquine	tablet	250 mg	
chlorpromazine	oral liquid strong		200mL See above

Drug	Form	Strength	Restriction
chlorpromazine		20mg per mL	See above
	injection		
	oral liquid	50 mg/2 mL 5 mg/mL	100mL, 500mL To view LAM status of QH Central Pharmacy manufactured STRONG syrup: Refer to separate listing for chlorpromazine - oral liquid strong - 20mg per mL, 200mL
	tablet	10 mg 25 mg 100 mg	
chlortalidone	tablet	25 mg	
cholera vaccine	oral liquid	3 mL vial	
ciclosporin	capsule	10 mg 25 mg 50 mg 100 mg	
	eye drops	0.1%, 0.3mL unit dose	On the advice of an ophthalmologist for discharge and outpatient use as per the PBS indications.
	injection	50 mg/mL	* For use in accord with PBS Section 100 indications * Acute severe ulcerative colitis with inadequate or no response to intravenous hydrocortisone by day 4 of treatment.
		250 mg/5 mL	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guideline principles for the quality use of off-label medicines (www.catag.org.au) *
	oral liquid	100 mg/mL	Acute severe ulcerative colitis with inadequate or no response to intravenous hydrocortisone by day 4 of treatment. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
cidofovir	injection	375 mg/5 mL	Ear, nose and throat surgeons and respiratory physicians for the treatment of recurrent respiratory papillomatosis on the approval of an infectious diseases physician or antimicrobial stewardship team. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
cinacalcet			For use in accord with PBS General Schedule/Section 100 indications
	tablet	30 mg	See above See above

Drug	Form	Strength	Restriction
cinchocaine + zinc oxide	ointment	60 mg	See above
		90 mg	See above
		50g	See above
ciprofloxacin	ear drops	0.5% + 20%	See above
			(a) For use in paediatric patients under the care of an ENT specialist as per the PBS indications (b) For use as per the Qld Govt/RFDS Primary Clinical Care Manual in Aboriginal and Torres Strait Islander persons only.
	injection	0.3%	See above
			* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	tablet	200 mg/100 mL	See above
		250 mg	See above
500 mg		See above	
ciprofloxacin + hydrocortisone	ear drops	750 mg	See above
			For treatment of infection and inflammation of the ear by the Deadly Ears ENT outreach service (Acute Otitis Externa, Otitis Media with granulation tissue or myringitis present) where the tympanic membrane is perforated and/or a tympanostomy tube is present and framycetin sulfate + gramicidin + dexamethasone - ear drops - 0.5% + 0.005% + 0.05% (Sofradex®/ Otodex®), and flumetasone pivalate + clioquinol - ear drops - 0.02% + 1% (Locacorten-Vioform®) are not suitable.
			* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
			See above
cisatracurium	injection	0.2% + 1%	See above
			Specialist Anaesthetists and Country Medical Superintendents
		5 mg/2.5 mL	See above
		10 mg/5 mL	See above
cisplatin	injection	150 mg/30 mL	See above
			* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		50 mg/50 mL	See above
citalopram	tablet	100 mg/100 mL	See above
			For major depressive disorders
		10 mg	See above
		20 mg	See above
citric acid	oral liquid	40 mg	See above
		2.64 g/30 mL	For patients at risk of aspiration requiring emergency procedures
citric acid + lauryl sulfoacetate sodium + sorbitol			
	enema		

Drug	Form	Strength	Restriction
citric acid powder 1kg	powder	450 mg/5 mL + 45 mg/5 mL + 3.125 g/5 mL	
cladribine	injection	citric acid 1kg 10 mg/5 mL 10 mg/10 mL	Haemodialysis Unit cleaning solution  * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
clarithromycin	tablet	250 mg	Haemophilus infections where alternatives such as tetracycline or erythromycin are inappropriate or not tolerated; Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults.
clindamycin	capsule	150 mg	Specialist Staff and Endorsed Podiatrists * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	cream	2%	For gynaecological conditions
	injection	600 mg/4 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
clobazam	tablet	10 mg	Specialist Neurologists for the treatment of refractory Lennox-Gastaut epilepsy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i> <i>See above</i>
clofazimine	capsule	50 mg	Only available for the World Health Organisation (WHO) program for leprosy <i>See above</i> <i>See above</i>
clomifene	tablet	50 mg	Persons approved by Director General of Health and Medical Services <i>See above</i> <i>See above</i>
clomipramine	tablet	25 mg	Cataplexy associated with narcolepsy; obsessive-compulsive disorder; phobic disorders in adults. <i>See above</i> <i>See above</i>
clonazepam	injection	1 mg/mL	
	oral liquid	2.5 mg/mL (0.1 mg/drop)	a) Children too young to swallow tablets; b) The prevention of epilepsy; c) The treatment of anxiety, seizures, hiccups and neuropathic pain in patients unable to swallow tablets. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label

Drug	Form	Strength	Restriction
	tablet	2 mg 500 microgram	medicines (www.catag.org.au) *
clonidine	injection	150 microgram/mL	
	tablet	100 microgram 150 microgram	
clopidogrel	tablet	75 mg	
clostridium botulinum type A toxin-haemagglutinin complex	injection	300 units 500 units	For use in outpatients, day admitted patients or inpatients admitted for less than 24 hours duration in accord with PBS Section 100 indications. <i>See above</i> <i>See above</i>
clotrimazole	cream lotion	1%	20mL Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	pessary	100 mg	Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	vaginal cream	1%	35g Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
clozapine	tablet	25 mg 100 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
coal tar (B.P.) solution	solution	200mL	
coal tar solution and salicylic acid	ointment	6%-2% 100g	
cocaine	mouthwash	cocaine hydrochloride 2%	100mL * CONTROLLED DRUG *
	powder	cocaine hydrochloride powder 100mg	* CONTROLLED DRUG *
cocaine	eye drops	5%	2mL * CONTROLLED DRUG *

Drug	Form	Strength	Restriction
cocaine + atropine + phenylephrine	eye drops	cocaine 4% + atropine 4% + phenylephrine 10%	2mL * CONTROLLED DRUG * <i>See above</i>
codeine	tablet	30 mg	For gastrointestinal hypermotility disorders. Not to be used for pain control. In view of safety concerns, codeine is not recommended for use in children under 12 years of age or in breastfeeding women. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i>
colchicine	tablet	500 microgram	
colecalfiferol	oral liquid	5 microgram/0.04 mL 25 microgram/0.2 mL	15mL: For neonates on discharge 50mL
colecalfiferol	capsule	25 microgram (1000 units) 1.25mg (50,000 units)	
Colecalciferol (SAS)	injection	2.5mg/mL (100,000 International Units/mL)	For single high dose therapy in: a) Cystic Fibrosis patients, or b) paediatric patients where daily supplemental therapy has failed or is inappropriate. For use in paediatric patients where daily supplemental therapy and oral single high dose therapy with colecalciferol has failed or is inappropriate. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i>
colestyramine	powder for oral liquid	4 g	
colistin	injection	150 mg (4.5 million units)	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	powder for inhalation "Tadim"	1 million units	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved written protocol, as second-line treatment to nebulised tobramycin for treatment of pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis. Cases where colistimethate therapy would be appropriate include demonstrated resistance by pseudomonas to tobramycin, adverse reactions due to tobramycin or where aminoglycoside therapy is otherwise contraindicated.
Colonoscopy preparation - macrogol-3350 + sodium chloride + potassium chloride + sodium sulfate	powder for oral liquid	52.9 g + 2.6 g + 740 mg (potassium 9.9 mmol) + ...	



Drug	Form	Strength	Restriction
colonoscopy preparation kit - containing 3 x 70 g sachets macrogol 3350 powder concentrate and 3 bisacodyl 5mg tablets and 1 sachet magnesium citrate "Glycoprep-O Kit"	*combination pack*	containing 3 x 70 g sachets macrogol 3350 powder concentrate and 3 bisacodyl 5mg tablets and 1 sachet magnesium citrate "Glycoprep-O Kit"	
colonoscopy preparation kit - powder for oral liquid: dose 1 – macrogol 100g; dose 2 sachet A – macrogol 40g; dose 2 sachet B – sodium ascorbate 48.1g + ascorbic acid 7.5g) "Plenvu"	*combination pack*	colonoscopy preparation kit - powder for oral liquid: dose 1 – macrogol 100g; dose 2 sachet A – macrogol 40g; dose 2 sachet B – sodium ascorbate 48.1g + ascorbic acid 7.5g) "Plenvu"	For bowel preparation in patients who have undergone bariatric surgery. <i>See above</i>
colonoscopy preparation kit containing 3 x 70 g sachets macrogol 3350 powder concentrate and 2 x 20 g sachets each with sodium picosulfate 10.3 mg and magnesium "Prepkit Orange"	*combination pack*	containing 3 x 70 g sachets macrogol 3350 powder concentrate and 2 x 20 g sachets each with sodium picosulfate 10.3 mg and magnesium	
conjugated estrogens	tablet	300 microgram 625 microgram	
copper sulfate	crystals (large)	25g	
cornea preserving solution	solution	cornea preserving solution 20mL	For corneal transplantation only <i>See above</i> <i>See above</i>
cortisone	tablet	5 mg 25 mg	
COVID-19 vaccine	injection	.	For use in accordance with the Emergency Order - COVID-19 Vaccination Service Providers - COVID-19 vaccine and influenza vaccine <i>See above</i>
crizotinib	capsule	200 mg 250 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
cromoglycate	eye drops		
	inhalation	2% 5 mg/actuation	
crude coal tar in soft paraffin	ointment	1% 100g 2.5% 100g 5% 50g	
cyclizine			Paediatric specialist staff for use in children as second line therapy in prevention and treatment of postoperative nausea and vomiting, and third line therapy in chemotherapy-induced emesis. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
	injection		See above
	tablet	50 mg/mL 50 mg	See above See above
cyclopentolate	eye drops	0.5% 1%	Specialist Ophthalmology staff for use in paediatric inpatients and outpatients undergoing treatment in eye clinic. 0.5mL: For inpatient use only
			Specialist Ophthalmologists
cyclopentolate with phenylephrine	eye drops		See above
		0.2%-1%, 5mL (QH-CP) 1%-2.5%, 5mL (QH-CP)	See above See above
cyclophosphamide	injection	1 g 2 g 500 mg	(a) * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * (b) For the treatment of severe organ- or life-threatening autoimmune diseases and immunopathies. See above
	tablet	50 mg	See above
cycloserine	capsule	250 mg	For treatment after approval by the Medical Advisory Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: <a href="mailto:NDPC@health.qld.gov.au">NDPC@health.qld.gov.au</a> Contact information for Regional TB Control Units is available here. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
cyproheptadine	tablet	4 mg	
cyproterone			For treatment of idiopathic precocious puberty or inoperable carcinoma of the prostate

Drug	Form	Strength	Restriction
	tablet		See above
		50 mg	See above
		100 mg	See above
cytarabine	injection	100 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
dabigatran	capsule		* For use as per the PBS indications *
		75 mg	See above
		110 mg	See above
		150 mg	See above
dabrafenib	capsule		Specialist Oncologists for discharge and outpatient use as per the PBS indications.
		50 mg	See above
		75 mg	See above
dacarbazine	injection	200 mg	
dactinomycin	injection	500 microgram	
d-alpha-tocopherol	capsule	67 mg (100 units)	For malabsorption syndrome
d-alpha-tocopheryl acetate	oral liquid	115 mg/mL	
danaparoid sodium	injection	750 anti-Xa units/0.6 mL	a) For use as VTE prophylaxis in patients with a history of heparin-induced thrombocytopenia (HIT) where rivaroxaban or fondaparinux is inappropriate; or b) For use as an alternative anticoagulant therapy for management of HIT in patients where rivaroxaban or fondaparinux is inappropriate. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation; or c) Anticoagulation for intermittent haemodialysis in patients with a history of HIT * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
danazol	capsule	100 mg	Treatment of visually proven (ie by laparoscopy) endometriosis if surgery has been unsuccessful or contraindicated and the required endpoint of treatment is fertility; and For primary intractable menorrhagia
		200 mg	See above
dantrolene	capsule	25 mg	
		50 mg	
	injection		

Drug	Form	Strength	Restriction
		20 mg	Specialist Anaesthetists
dapagliflozin	tablet	10 mg	* For use as per the PBS indications *
dapsone	tablet	25 mg 100 mg	
daratumumab	injection	1.8 g/15 mL (subcutaneous) 100 mg/5 mL 400 mg/20 mL	For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i>
darbeoetin alfa	injection	10 microgram/0.4 mL pre-filled syringe 20 microgram/0.5 mL pre-filled syringe and pen 30 microgram/0.3 mL pre-filled syringe 40 microgram/0.4 mL pre-filled syringe and pen 50 microgram/0.5 mL pre-filled syringe 60 microgram/0.3 mL pre-filled syringe and pen 80 microgram/0.4 mL pre-filled syringe and pen 100 microgram/0.5 mL pre-filled syringe and pen 150 microgram/0.3 mL pre-filled syringe and pen	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
darolutamide	tablet	300 mg	* For discharge and outpatient use as per the PBS indications * <i>See above</i>
darunavir	tablet	150 mg 600 mg 800 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
darunavir + cobicistat	tablet	800 mg + 150 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
darunavir + cobicistat + emtricitabine + tenofovir alafenamide	tablet	800 mg + 150 mg + 200 mg + ...	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
dasatinib	tablet	20 mg 50 mg 70 mg 100 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
daunorubicin			

Drug	Form	Strength	Restriction
	injection	20 mg/10 mL	
death adder antivenom	injection	6000 units, vial	
deferasirox	dispersible tablet	125 mg 250 mg 500 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
	tablet	90 mg 180 mg 360 mg	<i>See above</i> <i>See above</i> <i>See above</i>
deferiprone	oral liquid	100 mg/mL	* For use in accord with PBS Section 100 indications * <i>See above</i>
	tablet	1 g 500 mg	<i>See above</i> <i>See above</i>
degarelix	injection	80 mg 120 mg	For the treatment of outpatients only with advanced carcinoma of the prostate in whom androgen deprivation is warranted and who comply with the PBS authority indications. <i>See above</i> <i>See above</i> <i>See above</i>
denosumab	injection	60 mg/mL 120 mg/1.7 mL	* For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
Depilatory	cream	(e.g. Veet) 100mL	Emergency or surgical staff to release hair tourniquet in paediatric patients. <i>See above</i>
desferrioxamine	injection	2 g 500 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
desflurane	inhalation solution	1 mL/mL	For use by, or under the supervision of, Specialist Anaesthetists experienced in its use, preferably in day surgery and long procedures of more than four hours duration. <i>See above</i> <i>See above</i>
desmopressin	injection	4 microgram/mL 15 microgram/mL	For use for haemostasis by specialist haematologists or on the advice of a specialist haematologist. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
	nasal drops		

Drug	Form	Strength	Restriction
dexamethasone	sublingual wafer	100 microgram/mL	For treatment of cranial diabetes insipidus as per the PBS indications
		120 microgram	For primary nocturnal enuresis as per the PBS indications. Clinicians should bear in mind the increased bioavailability of this wafer presentation compared to the tablet.
	tablet	200 microgram	For cranial diabetes insipidus and primary nocturnal enuresis as per the PBS indications
	eye drops	0.1%	Specialist Ophthalmologists for discharge and outpatient use as per the PBS indications.
	tablet	700 microgram	<i>See above</i>
dexamethasone phosphate	injection	4 mg/mL	For special circumstances when prednisolone is not suitable
		8 mg/2 mL	<i>See above</i>
dexamethasone phosphate	oral liquid solution	1mg per mL 50mL	For use in accordance with croup protocol
			<i>See above</i>
dexamfetamine	tablet	5 mg	Schedule 8 substance restricted to treatment of narcolepsy and attention deficit hyperactivity disorder in children * CONTROLLED DRUG *
			<i>See above</i>
dexchlorpheniramine	tablet	2 mg	<i>See above</i>
dexmedetomidine	injection	200 microgram/2 mL	a) Intensive care specialists and anaesthetists for use not exceeding 24 hours; b) Paediatric intensive care specialists for managing sedation of critically ill neonatal and paediatric patients.
		200 microgram/50 mL	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		400 microgram/100 mL	Intensive care specialists and anaesthetists for use not exceeding 24 hours. <i>See above</i>
dexrazoxane (SAS)	injection	500mg	a) Specialist paediatric oncology staff for use in patients prior to anthracycline treatment. b) Treatment of anthracycline extravasation under the direction of a paediatric oncologist.
			* For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
dextran-1	injection	3 g/20 mL	
dextran-70 + hypromellose	eye drops	0.1% + 0.3%	

Drug	Form	Strength	Restriction
dextranomer in hyaluronic acid		with polyquaternium 0.1% + 0.3% + 0.001%	Specialist Ophthalmologists for patients unable to tolerate alternative preparations
	pre-filled syringe	50mg in 1mL	Specialist paediatric surgeons, or in consultation with a specialist paediatric surgeon, for treatment of children with vesicoureteral reflux (VUR) grades II-IV. <i>See above</i> <i>See above</i>
diazepam	injection	10 mg/2 mL	
	oral liquid	10 mg/10 mL	
	tablet	2 mg	
		5 mg	Patients unable to swallow tablets
diazoxide	injection	300 mg/20 mL	
diclofenac	eye drops	0.1%	Specialist Ophthalmologists
	suppository	12.5 mg	For use in children over 12 months of age.
		25 mg	<i>See above</i>
		50 mg	<i>See above</i>
		100 mg	
dicloxacillin	capsule	250 mg	For treatment of Staphylococcal infections
		500 mg	<i>See above</i>
			<i>See above</i>
dicobalt edetate	injection		Cyanide poisoning
		300 mg/20 mL	<i>See above</i> <i>See above</i>
digoxin	injection	50 microgram/2 mL	
		500 microgram/2 mL	Note: The time to effect for intravenous digoxin is not significantly faster than the oral route. Use oral digoxin where suitable.
	oral liquid	50 microgram/mL	
	tablet	62.5 microgram	Children too young to swallow tablets or capsules
250 microgram			
digoxin-specific antibody fragment F(Ab)	injection		For the treatment of cardiac glycoside intoxication resulting in life-threatening cardiac arrhythmias; cardiac arrest; cardiac decompensation with hypotension; serum potassium >5.5mmol/L with cardiovascular instability or compromise. In the absence of these recognised indications of cardiac glycoside toxicity, digoxin immune Fab is not indicated based solely on a serum digoxin concentration.
		40 mg	<i>See above</i>
diltiazem	modified release capsule		

Drug	Form	Strength	Restriction
	tablet	180 mg 240 mg 360 mg	For angina where treatment with verapamil or nifedipine has failed
dimercaprol		60 mg	See above
	injection	10% 2mL	
dimethylether "Medi Freeze Tick Off"	spray		
dimeticone (Hedrin)		38mL	
	gel, 100mL	dimeticone 4%	
dinoprost	injection	5 mg/mL	Specialist Obstetricians and Gynaecologists and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology, for second line management of severe life-threatening primary postpartum haemorrhage within the guidance of the Queensland Maternity and Neonatal Clinical Guideline "Primary Postpartum Haemorrhage". Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained.
dinoprostone			Specialist Obstetricians and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology for patients with unripe cervix (Bishop score 4 or less).
	pessary	10 mg	See above
	vaginal gel		See above
		1 mg/3 g	See above
		2 mg/3 g	See above
diphenoxylate + atropine sulfate	tablet		
		2.5 mg + 25 microgram	
diphtheria + tetanus + pertussis + poliomyelitis vaccine "Boostrix-IPV"	injection		For haematopoietic stem cell transplant recipients aged >10 years who are not eligible for National Immunisation Program (NIP) funded vaccines.
		0.5 mL	See above
diphtheria + tetanus + pertussis acellular vaccine "Boostrix"	injection		
		0.5 mL	(a) For use in accord with QH policy for staff immunisation. (b) For patients ≥10 years of age who require tetanus prophylaxis and are not eligible for National Immunisation Program (NIP) funded vaccines. For children and adolescents, refer to Children's Health Queensland "Tetanus Prophylaxis in Wound Management" guideline Note: National Immunisation Program (NIP) funded vaccines should be used for all eligible patients. If using NIP vaccines ensure adherence to eligibility criteria and any documentation requirements.
diphtheria + tetanus vaccine	injection		For patients >10 years who are not eligible for National Immunisation Program (NIP) funded vaccines and pertussis immunisation is not indicated.
		0.5 mL	See above
			See above



Drug	Form	Strength	Restriction
diphtheria antitoxin	injection	10,000 units	* For use in accord with Special Access Scheme (SAS) arrangements *
dipyridamole	injection	10 mg/2 mL	For use with nuclear medicine thallium scans <i>See above</i>
dipyridamole + aspirin	modified release capsule	200 mg + 25 mg	For the secondary prevention of ischaemic stroke or transient cerebral ischaemic events <i>See above</i> <i>See above</i>
disodium edetate	eye drops	3% 10mL	
disopyramide	injection	50mg in 5mL	
disopyramide	capsule	100 mg 150 mg	
disulfiram	effervescent tablet	200 mg	
dithranol and salicylic acid in soft paraffin	ointment	1%-2% 100g 2%-2% 100g	
dithranol in soft paraffin	ointment	0.1% 100g	
dobutamine	injection	250 mg	Intensive Care and Coronary Care Units only <i>See above</i> <i>See above</i>
docetaxel	injection	20 mg/2 mL 80 mg/4 mL 80 mg/8 mL 160 mg/8 mL 160 mg/16 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
docusate	tablet	50 mg 120 mg	
docusate + sennoside B	tablet	50 mg + 8 mg	
dolutegravir	tablet	50 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
dolutegravir + abacavir + lamivudine	tablet	50 mg + 600 mg + 300 mg	* For use in accord with PBS Section 100 indications *  <i>See above</i> <i>See above</i>
dolutegravir + lamivudine	tablet	50 mg + 300 mg	* For use in accord with PBS Section 100 indications *
dolutegravir + rilpivirine	tablet	50 mg + 25 mg	* For use in accord with PBS Section 100 indications *  <i>See above</i> <i>See above</i>
domperidone	tablet	10 mg	
dopamine	injection	200 mg/5 mL	
dornase alfa	inhalation solution	2.5 mg/2.5 mL	* For use in accord with PBS Section 100 indications *  <i>See above</i> <i>See above</i>
dorzolamide	eye drops	2%	Where other treatments are ineffective or inappropriate  <i>See above</i> <i>See above</i>
dorzolamide + timolol	eye drops	2% + 0.5%	For reduction of elevated intra-ocular pressure in patients with open-angle glaucoma and ocular hypertension who are not adequately controlled with timolol maleate (0.5%) eye drops or latanoprost eye drops.  <i>See above</i> <i>See above</i>
dosulepin (dothiepin)	capsule	25 mg	
	tablet	75 mg	
doxepin	capsule	10 mg 25 mg	
	tablet	50 mg	
doxorubicin	injection	50 mg/25 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		200 mg/100 mL	<i>See above</i>
doxorubicin hydrochloride (as pegylated liposomal)	injection	20 mg/10 mL	* For use in accord with PBS Section 100 indications * or For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS
		50 mg/25 mL	Maximum amount 100mg * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *

Drug	Form	Strength	Restriction
doxycycline	tablet	50 mg 100 mg	
doxycycline	injection	100mg	For the treatment of severe infections in patients unable to take oral doxycycline on the advice of an infectious diseases physician or clinical microbiologist. Physicians trained in interventional radiology and with proper skills in sclerotherapy - for use in sclerotherapy for treatment of lymphatic malformations in paediatric patients. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i> <i>See above</i>
doxylamine	tablet	25 mg	For use in pregnant women for the treatment of nausea, vomiting and hyperemesis <i>See above</i> <i>See above</i>
droperidol	injection	2.5 mg/mL	(a) patients with post-operative nausea and vomiting which is not responsive to metoclopramide; and (b) for use by emergency physicians or psychiatrists to sedate severely agitated patients in the emergency setting. <i>See above</i> <i>See above</i>
droperidol	injection	10mg in 2mL	For use by emergency physicians or psychiatrists to sedate severely agitated patients in the emergency setting. <i>See above</i> <i>See above</i>
dulaglutide	injection	1.5 mg/0.5 mL	* For use as per the PBS indications *
duloxetine	enteric capsule	30 mg 60 mg	Specialist Staff and Country Medical Superintendents for major depressive disorders <i>See above</i> <i>See above</i>
dupilumab	injection	200 mg/1.14 mL 300 mg/2 mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications <i>See above</i> <i>See above</i>
durvalumab	injection	120 mg/2.4 mL 500 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i>
dutasteride + tamsulosin	modified release capsule	500 microgram + 400 microgram	Urologists for use as per the PBS indications. Caution - prior to prescribing, confirm whether the patient has a prior history of cataract surgery or impending cataract surgery. <i>See above</i> <i>See above</i>
eculizumab			(a) For inpatient, discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications for the treatment of atypical haemolytic uraemic syndrome (aHUS). Note: access to PBS-subsidised eculizumab under the National Health (Highly Specialised Drugs Program) Special Arrangement 2021, will still be available to public hospital inpatients, but only for the treatment of aHUS. See (b) below for restrictions relating

Drug	Form	Strength	Restriction
			to paroxysmal nocturnal haemoglobinuria. (b) For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).
	injection	300 mg/30 mL	See above See above
edrophonium	injection	10mg in 1mL	Restricted by availability from manufacturer See above See above
electrolyte replacement oral (contains sodium chloride, potassium chloride, sodium citrate, citric acid, sucrose, glucose) "Gluco-lyte"	powder for oral liquid	40g sachet "Gluco-lyte"	
elexacaftor + tezacaftor + ivacaftor tablet (&) ivacaftor	combination pack	50 mg + 25 mg + 37.5 mg (&) 75 mg 100 mg + 50 mg + 75 mg (&) 150 mg	* For use in accord with PBS Section 100 indications * See above
elosulfase alfa	injection	5 mg/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
elotuzumab	injection	300 mg 400 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
eltrombopag	tablet	25 mg 50 mg	* For use in accord with PBS Section 100 indications * See above
emicizumab	injection	30 mg/mL 60 mg/0.4 mL 105 mg/0.7 mL 150 mg/mL	Specialist Haematologists or Haemophilia Nurse Practitioners prescribing under the oversight of a Queensland Haemophilia Centre Director or delegate, for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with moderate or severe congenital haemophilia A or congenital haemophilia A with inhibitors. See above See above See above See above
emollient	cream	100g	
empagliflozin	tablet	10 mg 25 mg	* For use as per the PBS indications * See above See above See above
emtricitabine + rilpivirine + tenofovir alafenamide			* For use in accord with PBS Section 100 indications *

Drug	Form	Strength	Restriction
emtricitabine + tenofovir alafenamide	tablet	200 mg + 25 mg + 25 mg	See above See above * For use in accord with PBS Section 100 indications *
	tablet	200 mg + 10 mg	See above
		200 mg + 25 mg	See above
emulsifying ointment	ointment	100g	
encorafenib	capsule	50 mg	Specialist oncologists for discharge and outpatient use as per the PBS indications
		75 mg	See above
enoxaparin sodium	injection	20 mg/0.2 mL	For use in line with TGA approved indications; QHMAC also endorses 'off-label' use of enoxaparin in children - refer to relevant QH guidelines: Guideline for the Prevention of Venous Thromboembolism (VTE) in Adult Hospitalised Patients Venous thromboembolism (VTE) prophylaxis in pregnancy and the puerperium Enoxaparin - Paediatric Medication Guideline * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		40 mg/0.4 mL	See above
		60 mg/0.6 mL	See above
		80 mg/0.8 mL	See above
		100 mg/mL	See above
entacapone	tablet	200 mg	Neurologists for treatment of Parkinson's Disease as adjunctive therapy in combination with levodopa-decarboxylase inhibitor combinations in patients experiencing motor fluctuations
entecavir	tablet	1 mg	* For use in accord with PBS Section 100 indications *
		500 microgram	(a) For use in accord with PBS Section 100 indications; (b) For use by specialist staff for the prevention of Hepatitis B reactivation in patients with serological evidence of prior infection who are receiving immunosuppressive therapy. Therapy should be in consultation with or managed by a Hepatology or Infectious Diseases Service and follow established protocols for treatment duration, monitoring whilst on therapy and follow up. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
enteral nutrition products and food supplements	(various formulations)	see link below for specific products available	Please see LAM attachment Enteral Nutrition and Food Supplements list to view which specific products. This list includes products, forms and packs sizes that are available on the list of approved medicines. <a href="https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/medicines/approved-">https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/medicines/approved-</a>

Drug	Form	Strength	Restriction
enzalutamide	capsule	40 mg	list/nutrition-and-food Medical Oncologists for discharge and outpatient use as per the PBS indications <i>See above</i> <i>See above</i>
ephedrine	hydrochloride injection	30 mg/mL	Ephedrine Hydrochloride Note: Preference the more cost-effective ephedrine hydrochloride 30mg/mL injection over ephedrine sulfate 30mg/mL injection if clinically appropriate. Note: Consider their different TGA approved indications and routes of administration.
	sulfate injection	30 mg/10 mL 30 mg/mL	Ephedrine Hydrochloride 10mL pre-filled syringe  Ephedrine Sulfate Note: Preference the more cost-effective ephedrine hydrochloride 30mg/mL injection over ephedrine sulfate 30mg/mL injection if clinically appropriate. Note: Consider their different TGA approved indications and routes of administration.
ephedrine and potassium iodide	mixture A.P.F.	1mg-25mg per mL 200mL	
epirubicin	injection	50 mg/25 mL 100 mg/50 mL 200 mg/100 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
epoetin alfa	injection	10 000 units/mL 20 000 units/0.5 mL 40 000 units/mL 1000 units/0.5 mL 2000 units/0.5 mL 3000 units/0.3 mL 4000 units/0.4 mL 5000 units/0.5 mL 6000 units/0.6 mL 8000 units/0.8 mL	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
epoprostenol	injection	1.5 mg 500 microgram	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
eptifibatide	injection	20 mg/10 mL 75 mg/100 mL	For use commencing immediately prior to percutaneous intervention with intracoronary stenting and not to exceed 24 hours infusion. <i>See above</i> <i>See above</i> <i>See above</i>
ergometrine	injection	500 microgram/mL	

Drug	Form	Strength	Restriction
eribulin	injection	1 mg/2 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
ertapenem	injection	1 g	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. <i>See above</i> <i>See above</i>
erythromycin	enteric capsule	250 mg	
	injection	1 g	
erythromycin ethylsuccinate	powder for oral liquid	200 mg/5 mL	Children too young to swallow tablets or capsules
escitalopram	tablet	10 mg	* For use as per the PBS indications *
		20 mg	<i>See above</i>
esmolol	injection	100 mg/10 mL	Specialists in Anaesthetics, Cardiology or Intensive Care
esomeprazole	enteric coated granules	10 mg	For use in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 – 6 months.
	injection	40 mg	For use in children aged 1 to 18 years (a) in ICU; (b) after endoscopy with high risk stigmata of re-bleeding; or (c) in major upper gastrointestinal haemorrhage
esomeprazole (&) amoxicillin (&) clarithromycin	combination pack	20 mg (&) 500 mg (&) 500 mg	For eradication of Helicobacter pylori in newly diagnosed or past duodenal or gastric ulcers <i>See above</i> <i>See above</i>
estradiol	gel	0.1% (1 mg/g)	For use when oral oestrogen therapy cannot be tolerated or is contraindicated
	modified release pessary "Vagifem Low"	10 microgram	
	patch	25 microgram/24 hours	For use when oral oestrogen therapy cannot be tolerated or is contraindicated
	tablet	1 mg	
		2 mg	
estradiol (&) estradiol + norethisterone acetate (&) estradiol	combination pack	2 mg (&) 2 mg + 1 mg (&) 1 mg	

Drug	Form	Strength	Restriction
estradiol + norethisterone acetate	tablet	1 mg + 500 microgram 2 mg + 1 mg	
	cream	0.1% (1 mg/g)	
etanercept	injection	25 mg	For use in accord with PBS Section 100 indications (paediatric use) (for patients under 18 years who have severe active polyarticular course juvenile chronic arthritis)
		50mg (pre-filled syringe and auto-injector)	For use in accord with PBS Section 100 indications (Continuing therapy in patients 18 years and older who were diagnosed with active polyarticular course juvenile chronic arthritis in childhood).
ethambutol	tablet	100 mg	
		400 mg	
ethosuximide	capsule	250 mg	
	oral liquid	250 mg/5 mL	Children too young to swallow tablets or capsules <i>See above</i>
etonogestrel	implant	68 mg	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. <i>See above</i> <i>See above</i>
etoposide	capsule	50 mg 100 mg	
	injection	1.136 g (etoposide 1 g)	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
	injection	100 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
etravirine	tablet	200 mg	* For use in accord with PBS Section 100 indications *
everolimus	tablet	1 mg	* For use in accord with PBS Section 100 indications *
		5 mg	Outpatient use for breast cancer only, as per the PBS indication. All other use must be on an Individual Patient Approval basis.
		10 mg	<i>See above</i>
		250 microgram	* For use in accord with PBS Section 100 indications *
		500 microgram	<i>See above</i>
		750 microgram	<i>See above</i>
evolocumab	injection		* For discharge and outpatient use as per the PBS indications *



Drug	Form	Strength	Restriction
exemestane	tablet	140 mg/mL	See above
		25 mg	For treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate and a non-steroidal aromatase inhibitor. See above
ezetimibe	tablet	10 mg	* For use as per the PBS indications * See above
		250 mg	See above
famciclovir	tablet	125 mg	Treatment of immunocompetent patients with herpes zoster in whom the duration of rash is less than 72 hours Intermittent treatment of moderate to severe recurrent genital herpes Herpes zoster in immunocompromised patients Ophthalmic herpes zoster
		250 mg	See above
famotidine	tablet	20 mg	
famotidine (SAS)	injection	10mg/mL	* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * See above
			See above
faricimab	intraocular injection	6 mg/0.05 mL, vial	* For discharge and outpatient use as per the PBS indications * See above
fat emulsion - olive oil and soya oil (eg 'Clinoleic')	injection	80 g/500 mL + 20 g/500 mL	For intravenous therapy when 'SMOFlipid' cannot be used and oral or enteral feeding is not possible.
felodipine	modified release tablet	2.5 mg	
		5 mg	
		10 mg	
fenofibrate	tablet	48 mg	
		145 mg	
fentanyl	injection	100 microgram/2 mL	For severe disabling pain not responsive to non-narcotic analgesics. For intranasal use in paediatric patients in the Emergency Department. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
		500 microgram/10 mL	Specialist Staff for severe disabling pain not responsive to non-narcotic analgesics. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	patch		

Drug	Form	Strength	Restriction
		12 microgram/hour	a) For use in persistent pain clinics and cancer pain or on the advice of a persistent pain specialist, for patients with chronic severe disabling pain requiring daily, continuous, long term therapy which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care for patients with chronic severe disabling pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. Patient must not be opioid naïve. * CONTROLLED DRUG *
		25 microgram/hour	See above
		50 microgram/hour	See above
		75 microgram/hour	See above
		100 microgram/hour	See above
	sublingual tablet	100 microgram	Palliative Care Physicians and Radiation Oncology Staff for use as per the PBS indications. * CONTROLLED DRUG *
		200 microgram	See above
		300 microgram	See above
		400 microgram	See above
		600 microgram	See above
		800 microgram	See above
fentanyl	intravenous infusion injection	10 micrograms/mL 100mL	* CONTROLLED DRUG * See above See above
ferric carboxymaltose	injection		For discharge and outpatient use for patients from two years of age. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
		1 g/20 mL	See above
		500 mg/10 mL	See above
ferrous fumarate + folic acid	tablet	310 mg (iron 100 mg) + 350 microgram	
ferrous sulfate	modified release tablet	325 mg (iron 105 mg)	
	oral liquid	30 mg/mL (iron 6 mg/mL)	250mL: Children too young to swallow tablets or capsules See above
fexofenadine	tablet	60 mg	Where other antihistamines are inappropriate
filgrastim (Neupogen)	injection, vial		Neupogen vials for use ONLY in paediatric patients for doses less than 120 microgram or when prefilled syringe graduations do not allow accurate measurement of dosing. This use must also be in accord with PBS Section 100 indications. For use of filgrastim outside of the above restriction, refer to Zarzio (filgrastim) injection, prefilled syringe.
		300 microgram/mL	See above
		480 microgram/1.6 mL	See above

Drug	Form	Strength	Restriction
filgrastim (Zarzio)	injection, prefilled syringe		* For use in accord with PBS Section 100 indications *
		300 microgram/0.5 mL	If vials are required for use in paediatrics, refer to Neupogen (filgrastim) injection, vial <i>See above</i>
		480 microgram/0.5 mL	<i>See above</i>
fingolimod	capsule		* For discharge and outpatient use as per the PBS indications *
		500 microgram	<i>See above</i> <i>See above</i>
flecainide	injection	150 mg/15 mL	
	tablet	50 mg	
		100 mg	
flecainide acetate "rosemont"	oral liquid solution		Paediatric cardiac specialists for use in accord with Special Access Scheme (SAS) arrangements * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		5mg per mL 300mL	<i>See above</i> <i>See above</i>
flucloxacillin	injection	250mg	All preparations restricted to treatment of Staphylococcal infections <i>See above</i> <i>See above</i>
flucloxacillin	capsule		All preparations restricted to treatment of Staphylococcal infections
		250 mg	<i>See above</i>
		500 mg	<i>See above</i>
	injection	1 g	<i>See above</i>
		500 mg	<i>See above</i>
	powder for oral liquid	125 mg/5 mL	<i>See above</i>
		250 mg/5 mL	<i>See above</i>
fluconazole	capsule	50 mg	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy (g) inpatient use as part of a single 150mg oral dose for the acute treatment of uncomplicated vaginal candidiasis; (h) for use by Sexual Health Services as part of a single 150mg oral fluconazole dose for the acute treatment of microbiologically confirmed uncomplicated vaginal candidiasis.
		100 mg	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients

Drug	Form	Strength	Restriction
			receiving a bone marrow transplant for haematological malignancy (g) inpatient use as part of a single 150mg oral dose for the acute treatment of uncomplicated vaginal candidiasis; (h) for use by Sexual Health Services as part of a single 150mg oral fluconazole dose for the acute treatment of microbiologically confirmed uncomplicated vaginal candidiasis.
		200 mg	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy
	injection	100 mg/50 mL	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy
		200 mg/100 mL	<i>See above</i>
	powder for oral liquid	50 mg/5 mL	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy But only for: Patients who cannot swallow capsules and meet one of the above criteria
flucytosine			For use in accord with Special Access Scheme (SAS) arrangements
	capsule	500mg	<i>See above</i> <i>See above</i>
flucytosine			For systemic yeast infections and subcutaneous mycoses (Prescribers please note: Danger of drug resistance - laboratory monitoring recommended)
	injection	2.5 g/250 mL	<i>See above</i> <i>See above</i>
fludarabine			
	injection	50 mg	For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS Intermediate or high risk chronic lymphocytic leukaemia where first line treatment (including either cyclo-phosphamide or chlorambucil) has proven ineffective or is contraindicated OR For Specialist Haematologists for use in induction and consolidation in relapsed and/or refractory acute myeloid leukaemia, or in patients with contraindication to anthracyclines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		50 mg/2 mL	<i>See above</i>
	tablet	10 mg	General use for TGA approved indications; and

Drug	Form	Strength	Restriction
			Specialist Haematologists for the treatment of relapsed and/or refractory low grade lymphoma in patients who have received at least 2 alternate prior therapies. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
fludrocortisone	tablet	100 microgram	
flumazenil	injection	500 microgram/5 mL	For inpatient use only.
flumetasone pivalate + clioquinol	ear drops	0.02% + 1%	
fluorescein	diagnostic strip	1 mg	
	eye drops	2%	Inpatient: 0.5mL: For inpatient use only
	injection	500 mg/5 mL	
fluorometholone in polyvinyl alcohol	eye drops	0.1%-1.4% 5mL	Specialist Ophthalmologists <i>See above</i> <i>See above</i>
fluorouracil	cream	5%	50g <i>See above</i>
	injection	1 g/20 mL 2.5 g/50 mL 5 g/100 mL 500 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
fluoxetine	capsule	20 mg	For major depressive disorders or obsessive compulsive disorder.
	tablet	20 mg	For major depressive disorders or obsessive compulsive disorder.
flupentixol decanoate	injection	20 mg/mL 40 mg/2 mL 100 mg/mL	Specialist Psychiatrists where other antipsychotic agents are ineffective or contraindicated <i>See above</i> <i>See above</i> <i>See above</i>
flutamide	tablet	250 mg	For use in conjunction with LHRH agonists for treatment of advanced prostatic carcinoma <i>See above</i> <i>See above</i>
fluticasone propionate	inhalation	50 microgram/actuation	For patients experiencing side effects on alternative inhaled corticosteroids <i>See above</i>

Drug	Form	Strength	Restriction
		125 microgram/actuation	See above
		250 microgram/actuation	See above
	powder for inhalation		See above
		100 microgram/actuation	See above
		250 microgram/actuation	See above
fluticasone propionate + salmeterol	inhalation	50 microgram/actuation + 25 microgram/actuation	* For use as per the PBS indications *
		125 microgram/actuation + 25 microgram/actuation	See above
		250 microgram/actuation + 25 microgram/actuation	(a) For initiation by specialist physicians in patients with severe asthma in line with PBS asthma criteria; (b) For continuation of therapy in existing patients, but consider reducing dose of fluticasone.
	powder for inhalation		
		100 microgram/actuation + 50 microgram/actuation	* For use as per the PBS indications *
		250 microgram/actuation + 50 microgram/actuation	See above
flvoxamine	tablet		For major depressive disorders or obsessive compulsive disorder.
		50 mg	See above
		100 mg	See above
folic acid	injection		
	tablet	15 mg/mL	
		5 mg	
		500 microgram	
folinic acid	injection		
		1 g/100 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
		15 mg/2 mL	
		50 mg/5 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
		100 mg/10 mL	See above
		300 mg/30 mL	See above
	tablet		
		15 mg	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
fondaparinux	injection		
		2.5 mg/0.5 mL	a) Patients with NSTEMI/ACS undergoing invasive or medical management (except for those going directly for emergency (less than 120 min) invasive management [PCI]); or b) For use as VTE prophylaxis in patients with a history of heparin-induced thrombocytopenia (HIT) where rivaroxaban is inappropriate; c) For use as an alternative anticoagulant therapy for management of HIT in patients with a calculated GFR greater than 30 mL/min where rivaroxaban is inappropriate. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *

Drug	Form	Strength	Restriction
formaldehyde	solution	4% 2 litre 37% 2 litre	
formoterol	powder for inhalation	6 microgram/actuation 12 microgram/actuation	For patients with frequent episodes of asthma who are concurrently being treated with inhaled corticosteroids See above
fosamprenavir	tablet	700 mg	* For use in accord with PBS Section 100 indications *
fosaprepitant	injection	150 mg	For use where the enteral route is not suitable, providing use is in line with the following: For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
fosfomycin	granules	3 g	For treatment of urinary tract infections with isolates resistant to all other appropriate antibiotics, or in patients intolerant to all other oral options * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * See above See above
framycetin sulfate + gramicidin + dexamethasone	ear drops	0.5% + 0.005% + 0.05%	
fulvestrant	injection	250 mg/5 mL	* For discharge and outpatient use as per the PBS indications *
funnel web spider antivenom	injection	125 units, vial	
furosemide	injection	20 mg/2 mL 250 mg/25 mL	
	oral liquid	10 mg/mL	30mL
	tablet	20 mg 40 mg 500 mg	
fusidate	tablet	250 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
gabapentin	capsule		a) partial epilepsy not controlled by other drugs as per the PBS indications; b) continuation of existing patients being treated for neuropathic pain; c) pain management in paediatric patients under the acute and/or persistent pain service. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label

Drug	Form	Strength	Restriction
			medicines (www.catag.org.au) * Note: Initiate pregabalin in preference to gabapentin for neuropathic pain where clinically appropriate. Caution: Consider potential for abuse or diversion with this medicine.
		100 mg	<i>See above</i>
		300 mg	<i>See above</i>
		400 mg	<i>See above</i>
galsulfase	injection	5 mg/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
ganciclovir	injection	500 mg	Preferably on the advice of an Infectious Diseases Physician or a Clinical Microbiologist; and In accord with PBS Section 100 indications. <i>See above</i> <i>See above</i>
gelatin + pectin + carmellose sodium	paste	16.7% + 16.7% + 16.7% - 5g and 15g	
gemcitabine	injection	1 g/26.3 mL 2 g/52.6 mL 200 mg/5.3 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i>
gemeprost	pessary	1 mg	Specialist Obstetricians with approval of Medical Superintendent Note: Special storage requirement of below -10 degrees centigrade <i>See above</i> <i>See above</i>
gemfibrozil	tablet	600 mg	
gentuzumab ozogamicin	injection	5 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i>
gentamicin	eye drops	0.3%	
	injection	80 mg/2 mL	For short term treatment (up to 72 hrs maximum); ongoing treatment on the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
gentamicin	eye drops	1.5% 10mL	Ophthalmologists <i>See above</i> <i>See above</i>
gentian alkaline	(A.P.F. 14) 200mL	200mL	
glecaprevir + pibrentasvir	tablet	100 mg + 40 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications



Drug	Form	Strength	Restriction
gliclazide	modified release tablet	30 mg	
		60 mg	
	tablet	80 mg	
glimepiride	tablet	1 mg	
		2 mg	
		3 mg	
		4 mg	
glucagon hydrochloride	injection	1 mg	
glucose	injection	50% 50mL	
		50% 50mL minijet	
	intravenous infusion	5% (200 Cal per litre) 1 Litre	
		5% (200 Cal per litre) 100mL (Double Pack)	
		5% (200 Cal per litre) 100mL (Single Pack)	
		5% (200 Cal per litre) 250mL	
		5% (200 Cal per litre) 250mL (non-PVC)	
		5% (200 Cal per litre) 500mL	
		10% (400 Cal per litre) 500mL	
		25% (1000 Cal per litre) 1 Litre	
50% (2000 Cal per litre) 500mL			
glucose	oral gel	40% (15g glucose in 37.5g tube) - Glucose 15®	Paediatric Use - for initial supply; for newly diagnosed diabetics; and Paediatricians and registered midwives for newborn hypoglycaemia - for buccal use only. <i>See above</i>
			(a) For diabetic clinic (b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet. <i>See above</i>
glucose and ketone indicator urine	diagnostic strip	1 diagnostic strip	<i>See above</i>
			Hospital use "FreeStyle Optium Neo H" (a) For use in hospitals and clinics. (b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet. "StatStrip" For use in neonates. Community use "FreeStyle Optium" For use in remote area aboriginal health services - Stock can be ordered through "Healthy Living NT", in accord with National Diabetes Services Scheme (NDSS) supply arrangements. <i>See above</i>
glucose indicator blood	diagnostic strip	1 diagnostic strip	<i>See above</i>
glucose indicator urine			

Drug	Form	Strength	Restriction
glutaral (glutaraldehyde)	diagnostic strip	1 diagnostic strip	
	buffered solution	2% 5 litre	For specific instrument decontamination (eg Endoscopes) in a controlled environment
glycerol	ear drops	7mL	
	liquid	sterile 14mL 200mL	
glycerol	suppository	1.4 g 2.8 g 700 mg	
glycerol + magnesium sulfate dried	paste	44% + 48%	
glyceryl trinitrate	injection	50 mg/10 mL	Note: Special giving sets are required for the administration of this preparation <i>See above</i>
	ointment	0.2%	
	patch	5 mg/24 hours 10 mg/24 hours	
	spray	400 microgram/actuation	* For discharge and outpatient use as per the PBS indications * <i>See above</i>
	sublingual tablet	600 microgram	As of August 2020: QHMAC endorses use of the S19A 300microgram glyceryl trinitrate sublingual tablet while supplies of the 600microgram tablet are not available <i>See above</i>
glycine	solution	1.5% (30 g/2 L)	Bladder irrigation during transurethral resection
glycopyrronium bromide	injection	200 microgram/mL	
glycopyrronium bromide (glycopyrrolate) (QH-CP)			For oral or enteral administration for the management of respiratory secretions and/or hypersalivation in patients receiving palliative care or with complex neurological conditions. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	oral liquid suspension	0.5mg/mL, 100mL	<i>See above</i> <i>See above</i>
Glycopyrronium bromide (glycopyrrolate) (SAS)			For oral or enteral administration for the management of respiratory secretions and/or hypersalivation in patients receiving palliative care or with complex neurological conditions. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	tablet	1mg	<i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
glycopyrronium bromide + neostigmine	injection	500 microgram/mL + 2.5 mg/mL	
golimumab	injection	50 mg/0.5 mL 100 mg/mL	* For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i>
goserelin	implant	3.6 mg  10.8 mg	For (a) advanced carcinoma of the prostate - for outpatient use only (b) Short term treatment (up to 6 months) of visually proven endometriosis for patients who cannot tolerate intranasal nafarelin (c) Hormone dependent breast cancer in line with the PBS indications a) For discharge and outpatient use as per the PBS indications. b) Paediatric oncology staff for use in paediatric patients receiving chemotherapy and/or radiation that has a high risk of premature ovarian failure. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
granisetron	injection	3 mg/3 mL	For patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications
	tablet	2 mg	For paediatric patients on cytotoxic chemotherapy or radiotherapy for whom ondansetron is ineffective.
griseofulvin	tablet	125 mg 500 mg	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists in a shared care arrangement for use in recalcitrant laboratory proven tinea infections. <i>See above</i> <i>See above</i> <i>See above</i>
guanfacine	modified release tablet	1 mg 2 mg 3 mg 4 mg	* For discharge and outpatient use as per the PBS indications (ADHD) * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
haemodiafiltration fluid (containing 1.2mmol/L phosphate) "Phoxilium"	intravenous infusion injection	5000mL	Intensive care staff for use in ICU patients who require continuous renal replacement therapy  <i>See above</i> <i>See above</i>
haemofiltration citrate replacement fluid (calcium free) "PrismOcal"	fluid	5000mL	Intensive Care Staff for use in ICU patients who require haemofiltration and where systemic anticoagulation is contraindicated.  <i>See above</i> <i>See above</i>
haemofiltration citrate replacement fluid (citrate 18, citric acid 0, sodium 140,			Intensive Care Staff for use in ICU patients who are critically ill with acute kidney injury/ kidney failure requiring haemofiltration and who are not able to receive systemic anticoagulation without significant risk of bleeding and death.

Drug	Form	Strength	Restriction
chloride 86 mmol/L) "Prismocitrate 18/0"	fluid	5000mL	See above See above
haemofiltration replacement fluid "Hemosol B0"	fluid	5000mL	
Haemophilus B influenza vaccine	injection	0.5 mL	At risk patients See above See above
haloperidol	injection	5 mg/mL	
	oral liquid	2 mg/mL	For inpatient use only.
	tablet	1.5 mg 5 mg 500 microgram	Caution: Avoid use for behavioural disturbance in dementia.
haloperidol decanoate	injection	50 mg/mL 150 mg/3 mL	
heparin	intravenous infusion	25 000 units in 50mL pre-filled syringe 1000 units in 0.9% sodium chloride 500mL	
heparin	injection	25 000 units/5 mL 1000 units/mL 5000 units/mL 5000 units/0.2 mL 5000 units/5 mL	
hepatitis B vaccine	injection	10 microgram/0.5 mL, Paediatric Formulation 20 microgram/1mL 40 microgram/1mL, Dialysis Formulation	For use in chronic kidney disease Stage 4 and 5 patients likely to progress to renal replacement therapy, dialysis patients, haematopoietic stem cell transplant recipients, and people with HIV infection.
homatropine	eye drops	1% 5mL 2% 15mL	
homatropine	eye drops	2% 0.5mL	For inpatient use only. See above
human chorionic gonadotrophin	injection	1500 units 5000 units	

Drug	Form	Strength	Restriction
human papillomavirus quadrivalent vaccine	injection	0.5 mL vial	For suitable haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock
hyaluronidase	injection	1500 units	
hydralazine	injection	20 mg	
	tablet	25 mg 50 mg	
hydrochlorothiazide	tablet	25 mg	
hydrochlorothiazide + triamterene	tablet	25 mg + 50 mg	
hydrocortisone	tablet	4 mg 20 mg	For adrenal hyperplasia <i>See above</i> <i>See above</i>
hydrocortisone acetate	cream	1%	30g
	enema	10%	
	eye ointment	1%	
	ointment	1%	30g
hydrocortisone sodium succinate	injection	100 mg	
hydrogen peroxide	solution	sterile 3% (10 vol) 30mL 6% 175mL	For use in neurosurgery.
hydrogen peroxide	mouthwash	3% 200mL	
hydromorphone	injection	2 mg/mL	Not to be held on imprest except in stand-alone palliative care units and areas where nursing staff are familiar with use. a) For use in pain clinics and cancer pain for patients with severe pain which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated; b) For use in palliative care for patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high.

Drug	Form	Strength	Restriction
		10 mg/mL	* CONTROLLED DRUG * Not to be held on imprest except in stand-alone palliative care units and areas where nursing staff are familiar with use. a) For use in pain clinics and cancer pain for patients with severe pain which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated; b) For use in palliative care for patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: This is a high potency injection. The risk of drug dependence is high. * CONTROLLED DRUG *
	oral liquid	1 mg/mL	Not to be held on imprest except in stand-alone palliative care units and areas where nursing staff are familiar with use. a) For use in pain clinics and cancer pain for patients with severe pain which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated; b) For use in palliative care for patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	tablet	2 mg	Not to be held on imprest except in stand-alone palliative care units and areas where nursing staff are familiar with use. a) For use in pain clinics and cancer pain for patients with severe pain which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated; b) For use in palliative care for patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * Caution: TGA advises that the S19A brands (Rhodes and Hikma /West-Ward) contain sulfites
		4 mg	<i>See above</i>
		8 mg	<i>See above</i>
hydroxocobalamin	injection	1 mg/mL	
hydroxocobalamin "cyanokit"	injection	2.5g x 2	For cyanide poisoning
hydroxycarbamide (hydroxyurea)	capsule	500 mg	
hydroxycarbamide (hydroxyurea) (SAS)	oral liquid	100mg/mL	On the advice of a paediatric haematologist, for the treatment of paediatric patients with sickle cell disease. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i>
hydroxychloroquine			For use by an authorised prescriber in accordance with the Medicines and Poisons (Medicines) Regulation 2021. Prescribers are authorised to prescribe hydroxychloroquine if: (a) they are one of the following specialist practitioners: dermatologist, emergency medicine physician, haematologist, immunologist, infectious disease physician, intensive care physician,

Drug	Form	Strength	Restriction
			nephrologist, paediatrician, rheumatologist, specialist physician in general medicine, a dentist who is a specialist registrant in oral medicine; or (b) they are a medical practitioner or nurse practitioner who is continuing treatment with hydroxychloroquine that was initiated by one of these specialist practitioners. Medical practitioners and nurse practitioners who are continuing treatment with hydroxychloroquine must mark the prescription with the words 'Continuing treatment'.
	tablet	200 mg	See above See above
hydroxypropylmethyl-cellulose	injection	20mg per mL 1mL	Ophthalmologists See above See above
hyoscine butylbromide	injection	20 mg/mL	
	tablet	10 mg	For inpatient use only
hyoscine hydrobromide	chewable tablet	300 microgram	On the advice of a Psychiatrist for clozapine induced hypersalivation. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	injection	400 microgram/mL	
hypromellose	eye drops	0.5%	
hypromellose + carbomer-980	eye gel	0.3% + 0.2%	
ibandronate	injection	6 mg/6 mL	* For use in accord with PBS Section 100 indications * See above
ibrutinib	capsule	140 mg	Specialist haematologists for discharge and outpatient use as per the PBS indications See above
ibuprofen	chewable tablet	100 mg	For patients who are unable to swallow tablets whole or for whom the 200mg tablets are unsuitable. Note: The Advil 100mg chewable tablets are scored, which allows doses in 50mg increments to be administered.
	oral liquid	100 mg/5 mL	Paediatric inpatient use.
	tablet	200 mg 400 mg	
icatibant	injection - pre-filled syringe	30 mg/3 mL	For outpatient use, as per the PBS indications. See above

Drug	Form	Strength	Restriction
icodextrin + sodium chloride + sodium lactate + calcium chloride + magnesium chloride	peritoneal dialysis solution		For peritoneal dialysis patients with refractory fluid retention despite fluid restriction, the use of high percentage glucose dialysates and high doses of loop diuretics.
		187.5 g/2.5 L + 13.5 g/2.5 L + 11.25 g/2.5 L + ...	See above See above
idarubicin	capsule	5 mg	For acute myelogenous leukaemia (AML). See above
		10 mg	See above
	injection	5 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		10 mg/10 mL	See above See above
idarucizumab	injection		Specialist Staff or rural senior medical officers for management of serious bleeding in patients anticoagulated with dabigatran or for reversal of dabigatran when emergency invasive procedures are required that cannot await restoration of normal haemostasis expected on withholding dabigatran. Note: Dose is 5 g (two x 2.5 g vials).
		2.5 g/50 mL	See above See above
idursulfase	injection		
		6 mg/3 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
ifosfamide	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		1 g	See above
		2 g	See above
iloprost	inhalation solution		* For use in accord with PBS Section 100 indications *
		20 microgram/2 mL	See above See above
imatinib	tablet		* For use as per the PBS indications *
		100 mg	See above
		400 mg	See above
imiglucerase	injection	200 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
		400 units	See above
imipenem + cilastatin	injection		On the advice of an infectious diseases physician for use in atypical mycobacteria or nocardia.
		500 mg + 500 mg	See above See above
imipramine	tablet	10 mg	
		25 mg	
imiquimod	cream	5% 250mg Sachet (12)	For use as per the PBS indications (for superficial basal cell carcinoma); Sexual Health Physicians, Infectious Disease Physicians or Gynaecologists - where other therapy



Drug	Form	Strength	Restriction
incobotulinumtoxinA	injection	100 units	has failed. For use in outpatients, day admitted patients or inpatients admitted for less than 24 hours duration in accord with PBS Section 100 indications.
indapamide	modified release tablet	1.5 mg	
indigo carmine	injection	40mg in 5mL (0.8%)	
indocyanine green	powder for injection	25mg in 5mL	Surgical consultants, hepatologists and registrars for patients undergoing pre-operative assessment for liver resection; Gynaecological oncologists for intraoperative mapping of suspected cervical or endometrial cancer and biopsy of sentinel lymph nodes. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i> <i>See above</i>
indometacin	capsule	25 mg	
	injection	1 mg	
	suppository	100 mg	
infliximab (Remsima)	injection (subcutaneous)	120 mg/mL	* For use as per the PBS indications * <i>See above</i>
infliximab (Renflexis)	powder for injection	100 mg	a) For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications. b) For first dose inpatient use for acute severe ulcerative colitis in accordance with PBS Section 100 criteria. In children under 14 years with Crohn disease or ulcerative colitis, it is recommended a paediatric gastroenterologist is consulted prior to initiation of infliximab.
influenza virus polyvalent vaccine	injection	0.5mL	FOR STOCK PURCHASED FROM CENTRAL PHARMACY: At risk patients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and hospital staff FOR NIP FUNDED VIVAS STOCK: High risk persons who meet NIP eligibility criteria and would benefit from opportunistic vaccination. NOTE: If using VIVAS stock ensure adherence to eligibility criteria and any documentation requirements Refer: <a href="https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/service-providers/influenza">https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/service-providers/influenza</a> <i>See above</i> <i>See above</i>
insulin aspart (Novorapid Flexpen)	injection	100 units/mL	
insulin aspart (Novorapid Penfill)	injection		

Drug	Form	Strength	Restriction
insulin aspart (Novorapid)	injection	100 units/mL	
insulin aspart + insulin aspart protamine (Novomix 30 Flexpen)	injection	100 units/mL	For paediatric use only.
insulin aspart + insulin aspart protamine (Novomix 30 Penfill)	injection	30 units/mL + 70 units/mL pen device	
insulin degludec + insulin aspart (Ryzodeg 70/30 Flextouch)	injection	30 units/mL + 70 units/mL	
insulin degludec + insulin aspart (Ryzodeg 70/30 Penfill)	injection	70 units/mL + 30 units/mL, 3 mL pen device	
insulin detemir (Levemir Flexpen)	injection	70 units/mL + 30 units/mL, 3 mL cartridge	
insulin detemir (Levemir Penfill)	injection	100 units/mL	Type 1 diabetes
insulin glargine (Optisulin Solostar)	injection	100 units/mL	Type 1 diabetes
insulin glargine (Optisulin)	injection	100 units/mL	Note: Optisulin is an alternative brand to Lantus. Note: From 1 July 2020, Lantus brand will be removed from the PBS.
insulin glargine (Toujeo Solostar)	injection	300 units/mL	* For discharge and outpatient use as per the PBS indications * For continuing therapy in inpatients already established on this high-concentration insulin who are able to self-administer or in conjunction with a local facility prescribing protocol. Initiation in inpatients requires IPA approval. Caution: High-concentration insulin. The insulin is NOT to be withdrawn from the prefill device using a needle and syringe. A dose adjustment may be required when converting between glargine 100 units/mL and glargine 300 units/mL — seek advice from an endocrinologist if required.
insulin glulisine (Apidra Solostar)	injection	100 units/mL	
insulin isophane human (Protaphane Innolet)	injection	100 units/mL	
insulin isophane human (Protaphane Penfill)			

Drug	Form	Strength	Restriction
	injection	100 units/mL	
insulin isophane human (Protaphane)	injection	100 units/mL	For paediatric use only.
insulin lispro (Humalog Kwikpen)	injection	100 units/mL	
insulin lispro (Humalog)	injection	100 units/mL	
insulin lispro + insulin lispro protamine (Humalog Mix25 Kwikpen)	injection	25 units/mL + 75 units/mL	
insulin lispro + insulin lispro protamine (Humalog Mix25)	injection	25 units/mL + 75 units/mL	
insulin lispro + insulin lispro protamine (Humalog Mix50 Kwikpen)	injection	50 units/mL + 50 units/mL	
insulin lispro + insulin lispro protamine (Humalog Mix50)	injection	50 units/mL + 50 units/mL	
insulin neutral human (Actrapid Penfill)	injection	100 units/mL	
insulin neutral human + insulin isophane human (Mixtard 30/70 Innolet)	injection	70 units/mL + 30 units/mL	
insulin neutral human + insulin isophane human (Mixtard 30/70 Penfill)	injection	70 units/mL + 30 units/mL	
insulin neutral human + insulin isophane human (Mixtard 50/50 Penfill)	injection	50 units/mL + 50 units/mL	
interferon alfa-2b	injection	10 million units/mL	Clinical Haematologists and Oncologists for treatment of hairy cell leukaemia
interferon gamma-1b	injection	2 million units/0.5 mL	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
intraocular staining solution "membrane blue"	intraocular solution for injection	0.5mL	Specialist Ophthalmologists
iodine and boric acid	powder for insufflation	Iodine 0.75% Potassium Iodide 0.75% Boric Acid 98.5% - 10g	
iodine and lactose	powder for insufflation	Iodine 0.8% Potassium Iodide 0.4% Lactose 98.8% - 10g	
iodine and potassium	solution alcoholic	2.5% -2.5%, 500mL	
	solution aqueous (Lugol's)	5% - 10%, 100mL	
	solution sterile	5% - 10%, 50mL	
ipecacuanha	emetic syrup (A.P.F.)	100mL	
ipilimumab	injection	50 mg/10 mL 200 mg/40 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i>
ipratropium	inhalation	21 microgram/actuation	
	inhalation solution	250 microgram/mL 500 microgram/mL	For use where treatment with this drug delivered from an oral pressurised inhalation device via a large volume spacer is inappropriate. <i>See above</i>
irbesartan	tablet	75 mg 150 mg 300 mg	For patients unable to tolerate ACE inhibitors because of cough or angioedema, or patients intolerant of other antihypertensive therapy. <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
irinotecan	injection	40 mg/2 mL 100 mg/5 mL 500 mg/25 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
iron polymaltose	injection	100 mg/2 mL	For treatment of iron deficiency when oral iron preparations are ineffective or cannot be used.
iron sucrose			For treatment of iron deficiency when oral iron preparations are ineffective or cannot be used; or Gastroenterologists and Renal Physicians for use in patients less than 14 years of age for: a) Persistent iron deficiency anaemia despite oral supplementation; and

Drug	Form	Strength	Restriction
	injection	100 mg/5 mL	b) iron deficiency of such severity that resolution with oral supplementation is not practical or is detrimental to patient wellbeing. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) * <i>See above</i> <i>See above</i>
isoflurane	inhalation solution	1 mL/mL	
isoniazid	solution	20mg per mL 100mL	For children who cannot swallow tablets. <i>See above</i> <i>See above</i>
isoniazid	tablet	100 mg	
isoprenaline	injection	1 in 5000 (1 mg/5 mL) 1 in 5000 (200 microgram/mL)	
isosorbide mononitrate	modified release tablet	60 mg 120 mg	
isotretinoin	capsule	10 mg 20 mg	Specialist Dermatologists and Specialist Physicians for severe cystic acne only. Caution: This drug causes birth defects. Isotretinoin has been reported to cause other frequent and potentially serious toxicity <i>See above</i> <i>See above</i>
itraconazole	oral liquid	10 mg/mL	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for patients who cannot swallow capsules and meet one of the following criteria; (a) aspergillosis, sporotrichosis or histoplasmosis infections (b) treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients NOTE: This preparation is not interchangeable with other itraconazole preparations.
itraconazole (Itranox)	capsule	100 mg	For paediatric patients only, on the advice of an Infectious Diseases Physician or a Clinical Microbiologist for: aspergillosis, sporotrichosis or histoplasmosis infections. NOTE: This preparation is not interchangeable with other itraconazole preparations. <i>See above</i> <i>See above</i>
itraconazole (Lozanoc)	capsule	50 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for (a) aspergillosis, sporotrichosis or histoplasmosis infections (b) treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients. NOTE: This preparation is not interchangeable with other itraconazole preparations.
ivabradine			

Drug	Form	Strength	Restriction
ivacaftor	tablet	5 mg	Cardiologists and Radiologists to reduce heart rate in patients in sinus rhythm undergoing CT coronary angiography who do not respond to maximal doses of betablockers or are unable to tolerate beta blockers (or when a beta blocker is contraindicated); For use in chronic heart failure, as per the PBS indications.
		7.5 mg	For use in chronic heart failure, as per the PBS indications.
	granules	50 mg	* For use in accord with PBS Section 100 indications *
		75 mg	<i>See above</i>
		150 mg	<i>See above</i>
tablet		<i>See above</i>	
		<i>See above</i>	
ivermectin	tablet	3 mg	Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with <i>Strongyloides stercoralis</i> or <i>Sarcoptes scabiei</i> (Crusted scabies).
ketamine	injection	200 mg/2 mL	(a) For use as a general anaesthetic agent in areas where anaesthesia is delivered; (b) For use as an analgesic adjuvant under the supervision of an acute pain service, or in emergency departments, where standard analgesics in appropriate doses are insufficient to control pain; (c) For use as an analgesic adjuvant in the treatment of persistent pain under the supervision of specialists in pain medicine and palliative care; (d) For use in the field by practitioners trained to administer ketamine in emergency situations where standard anaesthetic and analgesic agents are contraindicated. The above restrictions apply to the parenteral route. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
			<i>See above</i>
ketoconazole	shampoo	2%	<i>See above</i>
			For immunologically compromised patients; For use as per the PBS indications
ketone indicator - blood	diagnostic strip	test strips	"FreeStyle Optium H" (a) For diagnosis and management of diabetic ketoacidosis (b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet. "StatStrip" For use in neonates.
ketoprofen	modified release capsule	100 mg	
		200 mg	
ketorolac	injection	10 mg/mL	For postoperative pain where commonly indicated opioids are best avoided * Where a medicine is not TGA approved, patients should be made fully aware of the status of the

Drug	Form	Strength	Restriction
		30 mg/mL	medicine and appropriate consent obtained * (a) postoperative pain where commonly indicated opioids are best avoided; and (b) management of migraine or ureteric colic, as a single dose, when oral NSAID therapy is not tolerated or is considered inappropriate. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
king brown snake antivenom	injection	18 000 units, vial	
labetalol	injection	50 mg/10 mL	The emergency treatment of severe hypertension when prompt and urgent reduction of blood pressure is essential
	tablet	100 mg 200 mg	
lacosamide	injection	200 mg/20 mL	Specialist Neurology Staff as an adjunctive treatment for epilepsy when oral lacosamide has already been established but is temporarily not feasible.
	oral liquid	10 mg/mL	For initiation by a Specialist Neurologist or Paediatrician as an adjunctive treatment for epilepsy in paediatric patients as per the PBS indications. For continuing use in paediatric patients established on therapy as per PBS indications where tablets are unsuitable.
	tablet	50 mg 100 mg 150 mg 200 mg	Specialist Neurology Staff as an adjunctive treatment for epilepsy as per the PBS indications. See above See above See above
lactulose	oral liquid	3.34 g/5 mL	
lamivudine	oral liquid	10 mg/mL	* For use in accord with PBS Section 100 indications *
	tablet	100 mg 150 mg 300 mg	* For use in accord with PBS Section 100 indications * See above See above
lamivudine + zidovudine	tablet	150 mg + 300 mg	* For use in accord with PBS Section 100 indications * See above See above
lamotrigine	tablet	5 mg 25 mg 50 mg 100 mg	For epilepsy not controlled by other drugs See above See above See above

Drug	Form	Strength	Restriction
lanadelumab	injection	200 mg	See above
		300 mg/2 mL	Specialist Immunology Staff for outpatient use only as per the PBS indications in the routine prevention of recurrent attacks of hereditary angioedema (C1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older. Not for inpatient use. See above
lanreotide	injection	60 mg/0.5 mL	* For use in accord with PBS Section 100 indications * See above
		90 mg/0.5 mL	See above
		120 mg/0.5 mL	See above
lansoprazole	orally disintegrating tablet	15 mg	For use in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 – 6 months. See above
		30 mg	See above
lanthanum	chewable tablet	1 g	For use in accord with PBS Section 100 indications (for initiation and stabilisation of treatment); For use as per the PBS indications (for maintenance therapy). See above
		500 mg	See above
		750 mg	See above
			See above
lapatinib	tablet	250 mg	* For use as per the PBS indications * See above
			See above
laronidase	injection	500 units/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
latanoprost	eye drops		Specialist Ophthalmologists as monotherapy for the reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are intolerant of or insufficiently responsive to other intraocular pressure medication. See above
		0.005%	See above
latanoprost + timolol	eye drops		For reduction of elevated intra-ocular pressure as per the PBS indications. See above
		0.005% + 0.5%	See above
leflunomide	tablet	10 mg	Specialist Rheumatologist Staff for use when other disease modifying drugs are inappropriate See above
		20 mg	See above
		Pack > 100 mg x3 + 20mg x30	See above
			See above
lenalidomide	capsule	5 mg	* For use in accord with PBS Section 100 indications * See above
		10 mg	See above
		15 mg	See above
		25 mg	See above
			See above



Drug	Form	Strength	Restriction
lenvatinib	capsule	4 mg	Specialist oncologists and hepatologists for discharge and outpatient use as per the PBS indications.
		10 mg	Specialist oncologists for discharge and outpatient use as per the PBS indications.
lercanidipine	tablet	10 mg	
		20 mg	
letrozole	tablet		* For use as per the PBS indications *
		2.5 mg	See above
leuprorelin	modified release injection	7.5 mg intramuscular depot and subcutaneous depot	* For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines.
		22.5 mg intramuscular depot and subcutaneous depot	INTRAMUSCULAR DEPOT 22.5 mg (a) For discharge and outpatient use as per the PBS indications. (b) For pubertal suppression in children and adolescents (less than 18 years of age) with persistent gender dysphoria. Treatment must only be initiated: By specialists who have a credentialled scope of clinical practice that includes assessment and treatment of gender diverse children and adolescents AND In accordance with the current version of Australian Standards of Care and Treatment Guidelines for trans and gender diverse children and adolescents where care is coordinated by a multidisciplinary service. Treatment may be continued: By a specialist medical prescriber if care continues to be coordinated by a multi-disciplinary service in accordance with the current version of the Australian Standards of Care and Treatment Guidelines for trans and gender diverse children and adolescents. When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au). SUBCUTANEOUS DEPOT 22.5 mg * For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines.
		30 mg intramuscular depot and subcutaneous depot and intramuscular paediatric depot	* For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines.
		45 mg subcutaneous depot	See above
levamisole	tablet	50mg (SAS)	Nephrologists for use in paediatric patients with steroid dependent nephrotic syndrome or frequently relapsing nephrotic syndrome. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
levetiracetam	injection	500 mg/5 mL	Note: For use in Status Epilepticus in children, refer to the statewide paediatric guideline. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *

Drug	Form	Strength	Restriction
	oral liquid		
	tablet	100 mg/mL	For partial epilepsy not controlled by other drugs when other oral dosage forms are inappropriate.
		1 g	For partial epilepsy not controlled by other drugs
		250 mg	See above
		500 mg	See above
levocarnitine	capsule		
		500 mg	For use on the advice of a metabolic physician or gastroenterologist.
levocarnitine	injection		
		1g in 5mL	For use on the advice of a metabolic physician or gastroenterologist.
	liquid		
		100mg per mL	For use on the advice of a metabolic physician or gastroenterologist.
levodopa + benserazide	capsule		
		50 mg + 12.5 mg	
		100 mg + 25 mg	
		200 mg + 50 mg	
	dispersible tablet		
		50 mg + 12.5 mg	For use in Parkinson disease for patients who have difficulty swallowing tablets or who require administration of medications via an enteral feeding tube
	modified release capsule		
		100 mg + 25 mg	Patients not adequately controlled by other levodopa/decarboxylase inhibitors
	tablet		
		100 mg + 25 mg	
		200 mg + 50 mg	
levodopa + carbidopa	intestinal gel		
		20 mg/mL + 5 mg/mL	* For use as per the PBS indications *
	modified release tablet		
		200 mg + 50 mg	Patients not adequately controlled by other levodopa/decarboxylase inhibitors
	tablet		
		100 mg + 25 mg	
		250 mg + 25 mg	
levodopa + carbidopa + entacapone	tablet		
		50 mg + 12.5 mg + 200 mg	Neurologists for Parkinson's disease in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-dose effect; Parkinson's disease in patients stabilised on concomitant treatment with levodopa-decarboxylase inhibitor combinations and entacapone.
		100 mg + 25 mg + 200 mg	See above
		150 mg + 37.5 mg + 200 mg	See above
levonorgestrel	intrauterine drug delivery system		
		19.5 mg	Specialist Staff, Nurse Practitioners and authorised nursing staff who are trained in IUD/IUS insertion and removal. This device is indicated for contraception only.
		52 mg	Specialist Staff, Nurse Practitioners and authorised nursing staff who are trained in IUD/IUS insertion and removal. This device is indicated for contraception, menorrhagia and endometrial protection with menopausal hormone therapy (MHT).

Drug	Form	Strength	Restriction
	tablet	1.5 mg 30 microgram	For use as an emergency oral contraceptive within 72 hours of unprotected intercourse Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. Suitable choice for women unable to use oestrogen hormonal methods of contraception.
levonorgestrel + ethinylestradiol	tablet	125 microgram + 50 microgram 150 microgram + 30 microgram	
levosimendan	injection	2.5 mg/mL (SAS)	a) Paediatric Cardiac Intensivists for use when other inotropes have failed or are inappropriate; b) Specialist Cardiology or Intensive Care Staff for use up to 24 hours for the management of patients with acute decompensated heart failure to facilitate weaning from continuous inotropic and/or mechanical circulatory support. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
levothyroxine	tablet	50 microgram 75 microgram 100 microgram 200 microgram	
lidocaine	cream	4%	
	gel	2%	
	injection	0.5% (25 mg/5 mL) 1% (50 mg/5 mL) 1% (200 mg/20 mL) 2% (40 mg/2 mL) 2% (100 mg/5 mL) 2% (400 mg/20 mL) 10% (500 mg/5 mL)	Cardiac arrhythmias
	lotion	4%	
	ointment	5% 10%	For dental use
	oral liquid	2%	
	spray	10%	For inpatient use only
lidocaine (lignocaine), tetracaine (amethocaine), epinephrine (adrenaline) "Laceraine"	sterile topical solution	4.2%-0.5%-0.2%, 4mL	For topical anaesthesia during suturing of uncomplicated lacerations on the face and scalp in children. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
lidocaine + adrenaline (epinephrine)			

Drug	Form	Strength	Restriction
	injection	0.5% (100 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL) 1% (50 mg/5 mL) + 1 in 100 000 (50 microgram/5 mL) 1% (200 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL) 2% (44 mg/2.2 mL) + 1 in 80 000 (27.5 microgram/2.2 mL) 2% (400 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL)	
lidocaine + cetrimide	injection		
	dressings	5% + 0.15%	For dental use
lidocaine + chlorhexidine	injection		
	gel	50mg + 0.15%	For dental use
lidocaine + fluorescein	injection	2% + 0.05%	Ophthalmologists
	eye drops	4% + 0.25%	See above See above
lidocaine + glucose	injection		
	injection	0.4% (2 g/500 mL) + 5% (25 g/500 mL)	
lidocaine + phenylephrine	injection		
	nasal spray	5% + 0.5%	
lidocaine + prilocaine	injection		
	cream	2.5% + 2.5%	
	gel	2.5% + 2.5%	For dental use
	patch	25 mg/g + 2.5%	
lincomycin	injection	600 mg/2 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	injection		
linezolid	injection		
	tablet	600 mg	(a) On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol; (b) For treatment after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available here. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
liothyronine	injection		
	injection		

Drug	Form	Strength	Restriction
liothyronine	tablet	20mcg	For use according to Special Access Scheme (SAS) requirements.
lipegfilgrastim	injection	20 microgram	
lisinopril	tablet	6 mg/0.6 mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
		5 mg	Paediatric cardiac specialists
		10 mg	See above
		20 mg	See above
lisinopril	oral liquid suspension	1mg per mL, 100mL	Paediatric cardiac specialists
lithium carbonate	modified release tablet		
	tablet	450 mg	
		250 mg	
lomustine	capsule		
		10 mg	
		40 mg	
		100 mg	
loperamide	capsule		
		2 mg	
lopinavir + ritonavir	oral liquid		
	tablet	400 mg/5 mL + 100 mg/5 mL	* For use in accord with PBS Section 100 indications *
		100 mg + 25 mg	* For use in accord with PBS Section 100 indications *
		200 mg + 50 mg	See above
loratadine	tablet		Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists where other antihistamines are inappropriate.
		10 mg	See above
lorazepam	injection	4 mg/mL, ampoule	(a) For management of acute behavioural disturbance where de-escalation attempts have failed and oral medications have failed or are impossible to administer to the patient. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) (b) Treatment of catatonia where oral formulations are not appropriate.
	tablet	1 mg	(a) use with cancer chemotherapy; (b) use with anaesthetics; (c) use in ICU; (d) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) (e) Specialist Palliative Care practitioners for sublingual use when swallowing is not possible

Drug	Form	Strength	Restriction
lorazepam (SAS)	injection	2mg in 1mL	(a) For management of acute behavioural disturbance where de-escalation attempts have failed and oral medications have failed or are impossible to administer to the patient. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) (b) Treatment of catatonia where oral formulations are not appropriate. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
lorlatinib	tablet	25 mg 100 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
lubricating gel sterile	prefilled syringe sachet tube	6mL and 11mL prefilled syringe 2.7g sachet 42g tube	For use in operating theatres for patients under general anaesthetic.
lumacaftor + ivacaftor	granules tablet	100 mg + 125 mg 150 mg + 188 mg 100 mg + 125 mg 200 mg + 125 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> * For use in accord with PBS Section 100 indications * <i>See above</i>
lurasidone	tablet	40 mg 80 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
macitentan	tablet	10 mg	* For use in accord with PBS Section 100 indications *
macrogol-3350	powder for oral liquid	1 g/g	For use in patients who are: (a) unresponsive to, or unable to tolerate, existing combinations of laxatives; or (b) on large doses of opioid analgesics.
macrogol-3350 + sodium chloride + bicarbonate + potassium chloride	powder for oral liquid	13.125 g + 350.7 mg + 178.5 mg + ...	For use in patients who are (a) unresponsive to existing combinations of laxatives; or (b) on large doses of opioid analgesics.
magnesium	aspartate tablet chloride injection	500mg (each tablet contains 1.55 mmol of magnesium) 480 mg/5 mL (each 5 mL ampoule contains 5 mmol of magnesium)	
magnesium + zinc			

Drug	Form	Strength	Restriction
Magnesium compound	capsule	magnesium oxide heavy 564.2 mg + magnesium phosphate pentahydrate 175 mg + magnesium amino acid chelate 135 mg + zinc oxide 2.49 mg (each capsule contains 16.45 mmol magnesium + 0.03 mmol zinc)	For patients with high dose magnesium requirements.
	oral liquid	50mg/mL (each mL contains 2mmol of magnesium)	For use in paediatrics and neonates for the enteral management of hypomagnesaemia, where LAM listed solid dose forms are not appropriate.
magnesium sulfate	injection	2.5 g/5 mL (each 5mL vial contains 10 mmol of magnesium)	
	powder "epsom salts"	1 g/g	
malathion	lotion	0.5%	Organophosphate head lice preparation
mannitol	injection	20% (100 g/500 mL)	
	powder for inhalation	pack containing 40mg capsules x 280 and 2 inhalers "bronchitol"	* For use in accord with PBS Section 100 indications *
mannitol "Aridol"	diagnostic kit	including capsules plus inhalation device	For bronchial provocation tests in respiratory laboratories
maraviroc	tablet	150 mg	* For use in accord with PBS Section 100 indications *
		300 mg	<i>See above</i>
measles + mumps + rubella live vaccine	injection		(a) For use in accord with QH policy for staff immunisation; (b) For haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded vaccines; (c) For patients planned for solid-organ transplantation who are not eligible for National Immunisation Program (NIP) funded vaccines. Seek expert opinion if vaccination is required within four weeks of the scheduled date of transplant.
		1 vial	<i>See above</i>
		1 vial	<i>See above</i>
mebendazole	oral liquid	100 mg/5 mL	Alternative treatment of adults and children with <i>Ancylostoma caninum</i> (Eosinophilic enterocolitis), <i>Ancylostoma duodenale</i> / <i>Necator americanus</i> (Hookworm), <i>Ascaris lumbricoides</i> (Roundworm), <i>Trichuris trichiuria</i> (Whipworm) or <i>Enterobius vermicularis</i> (Pinworm).
	tablet	100 mg	Alternative treatment of adults and children with <i>Ancylostoma caninum</i> (Eosinophilic enterocolitis), <i>Ancylostoma duodenale</i> / <i>Necator americanus</i> (Hookworm), <i>Ascaris lumbricoides</i> (Roundworm), <i>Trichuris trichiuria</i> (Whipworm) or <i>Enterobius vermicularis</i> (Pinworm).
mecasermin			

Drug	Form	Strength	Restriction
	injection	10 mg/mL, 4 mL vial	* For use in accord with PBS Section 100 indications * <i>See above</i>
medroxyprogesterone	injection	150 mg/mL	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception.
	tablet	2.5 mg 5 mg 10 mg 100 mg 200 mg 500 mg	
mefenamic acid	capsule	250 mg	
mefloquine	tablet	250 mg	For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
melphalan	injection	50 mg	
	tablet	2 mg 5 mg	
meningococcal A + meningococcal C + meningococcal W135 + meningococcal Y conjugate vaccine	injection		For use in persons with anatomical or functional asplenia, haematopoietic stem cell transplant recipients, or requiring treatment with eculizumab.  <i>See above</i>
meningococcal B 4 component vaccine	injection		For use in persons with anatomical or functional asplenia or requiring treatment with eculizumab.  <i>See above</i>
mepivacaine	injection	0.5 mL syringe 3% (66 mg/2.2 mL)	<i>See above</i>  For dental use
mepivacaine + adrenaline (epinephrine)	injection	2% (44 mg/2.2 mL) + 1 in 100 000 (22 microgram/2.2 mL)	For dental use
mepivacaine caudal	injection	1.5% 20mL	
mepolizumab	injection	100 mg	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
mercaptopurine	oral liquid	20 mg/mL	Oncology consultants and paediatricians for paediatric patients where the solid dose form is unsuitable



Drug	Form	Strength	Restriction
meropenem	tablet	50 mg	
	injection	1 g 500 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. <i>See above</i> <i>See above</i>
mesalazine	enema	1 g/100 mL	For the treatment of acute distal inflammatory bowel disease with a maximum ONE month supply for any single exacerbation. Caution: These items may not be linking to the correct MIMs dosing information. Refer to brand specific dosing information - the different brands are NOT interchangeable. <i>See above</i>
		1 g/application 2 g/60 mL	<i>See above</i>
	enteric tablet	500 mg	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate.
	modified release granules	1 g	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate. Caution: These items may not be linking to the correct MIMs dosing information. Refer to brand specific dosing information - the different brands are NOT interchangeable. <i>See above</i>
		2 g 500 mg	<i>See above</i>
	modified release tablet	1 g	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate.
	suppository	1.2 g	Gastroenterologists for use in ulcerative colitis as per the PBS indications.
		1 g	For the treatment of acute distal inflammatory bowel disease with a maximum ONE month supply for any single exacerbation.
mesna	injection	1 g/10 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. * <i>See above</i>
		400 mg/4 mL	<i>See above</i>
	tablet	400 mg	Specialist Oncology / Haematology Staff
mesterolone	tablet	25 mg	
metaraminol	injection	3 mg/6 mL	Note: The 5mg/10mL presentation is available as a vial and a pre-filled syringe <i>See above</i>
		5 mg/10 mL	<i>See above</i>
		10 mg/mL	<i>See above</i>
metformin	modified release tablet	1 g	For discharge and outpatient use only
		500 mg	

Drug	Form	Strength	Restriction
methacholine	tablet	1 g 500 mg 850 mg	
	broncho provocation test set of 6x10mL	0.25, 0.5, 1, 2, 4 and 8mg/mL	Specialist Staff for diagnostic use
methadone	injection	10 mg/mL	a) For use in persistent pain clinics and cancer pain for patients with chronic severe disabling pain requiring daily, continuous, long term therapy which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care for patients with chronic severe disabling pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. Patient must not be opioid naïve. * CONTROLLED DRUG *
	syrup and oral solution not containing sorbitol, sugar, preservatives or alcohol	5 mg/mL	a) For use in accord with PBS S100 indications; b) For patients in burns units; c) For patients in Specialist pain clinics. * CONTROLLED DRUG *
	tablet	10 mg	a) For use in persistent pain clinics and cancer pain for patients with chronic severe disabling pain requiring daily, continuous, long term therapy which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care for patients with chronic severe disabling pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. Patient must not be opioid naïve. * CONTROLLED DRUG *
methenamine hippurate (hexamine hippurate)	tablet	1 g	Prescribers Note Acidification of urine not necessary with use
methionine	tablet	500mg	For treatment of paracetamol overdose <i>See above</i> <i>See above</i>
methotrexate	injection	1 g/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		5 mg/2 mL	<i>See above</i>
		5 g/50 mL	<i>See above</i>
		7.5 mg/0.15 mL	(a) For discharge and outpatient use as per the PBS indications; (b) For use by, or in consultation with, a paediatric rheumatologist for children with juvenile idiopathic arthritis or non-infectious (inflammatory) uveitis. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's

Drug	Form	Strength	Restriction
		10 mg/0.2 mL 15 mg/0.3 mL 20 mg/0.4 mL 50 mg/2 mL	advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * Caution: This item is not linking to the correct MIMs dosing information. Please refer to other reference sources. <i>See above</i> <i>See above</i> <i>See above</i>
	tablet	500 mg/20 mL  2.5 mg 10 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * or Specialist Rheumatologists; Specialist Staff for pharmacological management of ectopic pregnancy. When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
methoxsalen	injection	200 microgram/10 mL	* For use in accord with PBS Section 100 indications * Caution: This drug is for ex vivo administration and must not be injected directly into the patient.
methoxsalen	injection (SAS)	100 microgram/5 mL (SAS)	Specialist oncology staff, for paediatric patients receiving extracorporeal photopheresis at the Queensland Children's Hospital managed by the Bone Marrow Transplant team. Caution: This drug is for ex vivo administration and must not be injected directly into the patient. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
methoxy polyethylene glycol-epoetin beta (Mircera)	injection	30 microgram/0.3 mL 50 microgram/0.3 mL 75 microgram/0.3 mL 100 microgram/0.3 mL 120 microgram/0.3 mL 200 microgram/0.3 mL 360 microgram/0.6 mL	For use in accord with PBS Section 100 indications for patients who reside in remote areas. Mircera® is — methoxy polyethylene glycol-epoetin beta <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
methoxyflurane	inhalation solution	99.9% (999 mg/g)	(a) Specialist staff and registrars in the haematology unit for analgesia during bone marrow biopsy procedures; (b) Specialist staff, registrars, and registered nurses with extended scope in gynaecology, for the relief of pain in patients requiring gynaecology procedures. (c) For use by clinicians in rural and remote locations to provide short-term pain relief to patients with acute pain in the pre-hospital and facility setting, in line with authorisation requirements and the Medicines and Poisons (Medicines) Regulation 2021.

Drug	Form	Strength	Restriction
NOTE: Not to be used in combination with other sedating agents.			
methyl salicylate	liniment	25%	
methyl dopa	tablet	250 mg	
methyl dopa	tablet	125mg	
methylene blue	injection	50 mg/5 mL	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
methylphenidate	modified release capsule	10 mg	For use as per the PBS indications (ADHD) * CONTROLLED DRUG *
		20 mg	See above
		30 mg	See above
		40 mg	See above
		60 mg	See above
	modified release tablet	18 mg	For use as per the PBS indications (ADHD) * CONTROLLED DRUG *
		27 mg	See above
		36 mg	See above
	54 mg	See above	
tablet	10 mg	a) The treatment of narcolepsy; b) Use as per the PBS indications (ADHD) and in accordance with State/Territory law. * CONTROLLED DRUG *	
methylprednisolone	sodium succinate injection	1 g	
		40 mg	
		500 mg	
methylprednisolone acetate	modified release injection	40 mg/mL	For intralesional; intra-articular use See above See above
methylrosanilinium chloride (crystal violet C14255) and brilliant green (bonneys blue)	paint	0.5%-0.5% in 45% Ethanol, 100mL	
metoclopramide	injection	10 mg/2 mL	
	tablet	10 mg	
metoprolol	injection		

Drug	Form	Strength	Restriction
	modified release tablet	5 mg/5 mL	
		23.75 mg	* For use as per the PBS indications *
		47.5 mg	See above
		95 mg	See above
	tablet	190 mg	See above
		50 mg	
		100 mg	
metoprolol	oral liquid		Paediatric cardiac specialists
		10mg per mL, 100mL	See above
			See above
metronidazole	injection	500 mg/100 mL	
	oral liquid	200 mg/5 mL	
	suppository	500 mg	
	tablet	200 mg	
		400 mg	
mexiletine	capsule		
		150mg	* For use in accord with Special Access Scheme (SAS) arrangements *
		250mg	See above
mianserin	tablet		For severe depression.
		10 mg	See above
		20 mg	See above
micafungin	injection	50 mg	For paediatric use on the advice of an Infectious Diseases Physician or a Clinical Microbiologist for prophylaxis or treatment of severe systemic candida infections that are resistant to fluconazole therapy, or where fluconazole is strongly contraindicated; or in accord with an infectious diseases approved protocol.
miconazole	cream 25g	2%	Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	cream 30g	2%	For use as per the PBS indications for the treatment of a fungal or a yeast infection in an Aboriginal or Torres Strait Islander person. Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	oral gel	2%	For systemic fungal infections susceptible to this agent
midazolam	injection	5 mg/mL	Glass ampoule 5mg/mL Specialist Staff for use in procedures, palliative care patients, emergency departments and mental health facilities

Drug	Form	Strength	Restriction
			Plastic ampoule 5mg/mL Intranasal, sublingual or sub-buccal administration for: a) The emergency treatment of acute seizures in both adults and children; and b) Specialist Paediatricians for outpatient management of prolonged seizures in children. Limit of 10 ampoules per supply. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		5 mg/5 mL 15 mg/3 mL 50 mg/10 mL	For use in intensive care units See above
midostaurin	capsule	25 mg	* For use in accord with PBS Section 100 indications * Note: Contact Central Pharmacy for advice on the required process to order inpatient stock.
mifepristone	tablet	200 mg	Specialist obstetrics and gynaecology staff who are registered with the MS-2 Step Prescribing Program for use in the termination of an intra-uterine pregnancy, in sequential combination with misoprostol, as per the Queensland Maternity and Neonatal Clinical Guideline for therapeutic termination of pregnancy. Specialist obstetrics and gynaecology staff who are registered with the MS-2 Step Prescribing Program for use in the medical management of second trimester pregnancy loss, in sequential combination with misoprostol, as per the Queensland Maternity and Neonatal Clinical Guideline for early pregnancy loss.
mifepristone (&) misoprostol	combination pack	200 mg (&) 200 microgram	Specialist obstetrics and gynaecology staff who are registered with the MS-2 Step Prescribing Program for use in the termination of an intra-uterine pregnancy, as per the Queensland Maternity and Neonatal Clinical Guideline for therapeutic termination of pregnancy. Refer to separate LAM listings of mifepristone tablet 200mg and misoprostol tablet 200 microgram if required for use in the medical management of second trimester pregnancy loss. <i>See above</i> <i>See above</i>
migalastat	capsule	123 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
miglustat	capsule	100 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program <i>See above</i> <i>See above</i>
milrinone	injection	10 mg/10 mL	Specialist Physicians where other positive inotropes have been shown to be ineffective
minocycline	tablet	50 mg	
minoxidil	tablet	10 mg	
mirtazapine	orally disintegrating tablet	15 mg	For patients with major depressive disorders who have swallowing difficulties or require monitoring for compliance <i>See above</i>

Drug	Form	Strength	Restriction
		30 mg	See above
	tablet		For major depressive disorders
		15 mg	See above
		30 mg	See above
		45 mg	See above
misoprostol	tablet	200 microgram	(a) For reduction in the incidence of gastrointestinal complications in patients who have a history of peptic ulcer disease and in whom NSAID therapy is essential; (b) For second line management of primary post partum haemorrhage; (c) Specialist Staff for the therapeutic termination of pregnancy as per the Queensland Maternity and Neonatal Clinical Guideline for therapeutic termination of pregnancy (d) Specialist Staff for the management of missed abortion, as per the Queensland Maternity and Neonatal Clinical Guideline for early pregnancy loss. (e) Specialist obstetrics and gynaecology staff for cervical dilation prior to intrauterine surgical intervention. [Note: not for routine use prior to IUD insertion] * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
mitomycin	injection	2 mg 10 mg 20 mg	
mitozantrone	injection	20 mg/10 mL 25 mg/12.5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above
mivacurium	injection	20 mg/10 mL	Specialist Anaesthetists for short duration procedures in Day Surgery Units
moclobemide	tablet	150 mg 300 mg	For major depressive disorders See above See above
molnupiravir	capsule	200 mg	* For use as per the PBS indications * OR For the treatment of COVID-19 in accordance with recommendations in the National Clinical Evidence Taskforce COVID-19 Guidelines See above
mometasone	cream	0.1% 15g and 50g	
	lotion	0.1%	
	ointment	0.1% 15g and 50g	
monobasic sodium phosphate + dibasic sodium phosphate	enema	19 g/118 mL + 7 g/118 mL	a) Adult patients for bowel preparation for colonoscopy;

Drug	Form	Strength	Restriction
	oral liquid	417.8 mg/mL + 95.6 mg/mL	b) For the treatment of severe constipation/impaction which is unresponsive to, or inappropriate for, treatment with oral laxatives; c) For palliative care patients on long term opioid analgesia resulting in an ongoing problem with faecal impaction, after trying first line oral and rectal laxatives; d) For addition to dialysate to increase phosphate levels in haemodialysis patients, particularly those who dialyse for extended times. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
monsel's ferric subsulfate	gel	21%, 15mL	Adult patients for bowel preparation for colonoscopy Gynaecologists and their registrars for gynaecological procedures <i>See above</i> <i>See above</i>
morphine	intravenous infusion injection	1mg/1mL 100mL	
morphine	injection	120 mg/1.5 mL	Use in syringe pumps only for severe disabling pain not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	injection	5 mg/mL 30 mg/mL	For use in neonates and paediatric patients only * CONTROLLED DRUG * * CONTROLLED DRUG *
	injection	10 mg/mL	* CONTROLLED DRUG *
	intrathecal injection	500 microgram/mL	Anaesthetists for intrathecal postoperative analgesia. * CONTROLLED DRUG ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	modified release capsule	10 mg  20 mg 50 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first-line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. c) For use in chronic breathlessness, as per the PBS indications. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i>
	modified release tablet	100 mg  5 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first-line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i>  a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first-line opioid analgesics or where these agents are inappropriate or not tolerated.



Drug	Form	Strength	Restriction
			b) For use in severe pain which is not responding to non-opioid analgesics in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	oral liquid	10 mg	See above
		15 mg	See above
		30 mg	See above
		60 mg	See above
		100 mg	See above
	tablet	1 mg/mL	Specialist paediatricians for use in neonates with neonatal abstinence syndrome. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) * * CONTROLLED DRUG *
		2 mg/mL	For use in patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		5 mg/mL	For use in patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		10 mg/mL	See above
		10 mg	a) For use in cancer pain for patients with severe disabling pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care for patients with severe disabling pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		20 mg	See above
moxifloxacin			For use after approval by an Infectious Diseases Physician or a Clinical Microbiologist or in accord with an Infectious Diseases approved protocol: a) For empirical therapy of patients with community acquired pneumonia or acute bacterial meningitis who have immediate hypersensitivity to penicillin and cannot be given cephalosporin; b) For patients with an infection caused by an organism with proven resistance to antibiotic agents apart from moxifloxacin, or who have severe allergy to standard agents where moxifloxacin is the most appropriate therapy available; OR For treatment after approval by the Medical Advisory Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: <a href="mailto:NDPC@health.qld.gov.au">NDPC@health.qld.gov.au</a> Contact information for Regional TB Control Units is available here. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
	injection		See above
		400 mg/250 mL	See above
	tablet		See above
		400 mg	See above

moxonidine

Drug	Form	Strength	Restriction
	tablet	200 microgram 400 microgram	As add-on therapy for severe refractory hypertension except in congestive heart failure <i>See above</i> <i>See above</i>
multi-test urine strips (for pH, Protein, Glucose, Ketone, Bilirubin and Urobilinogen)	diagnostic strip	strip	
mupirocin	ointment	ointment 15g and nasal ointment 3g	Mupirocin 2% ointment 15g - unrestricted Mupirocin 2% nasal ointment 3g - For decolonisation of MRSA following approval by Infectious Diseases Physicians, Clinical Microbiologists or infection control practitioners or in accord with recommended practices for the prevention and control of infections in dialysis settings; and on the advice of Infectious Diseases Physicians or Clinical Microbiologists to assist in preventing recurrent furunculosis.
Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish strain	injection	30 mg	For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. * <i>See above</i>
Mycobacterium bovis (BCG) live vaccine	injection	1.5 mg vial	For vaccination after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9722 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available at: <a href="https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/diseases/tuberculosis/contact-a-service">https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/diseases/tuberculosis/contact-a-service</a> <i>See above</i> <i>See above</i>
Mycobacterium bovis BCG Connaught strain	injection	81 mg	Specialist Urologists for bladder cancer <i>See above</i> <i>See above</i>
Mycobacterium bovis BCG Tice strain	injection	500 million CFU	Specialist Urologists for bladder cancer; * For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. * <i>See above</i> <i>See above</i>
mycophenolate	enteric tablet	180 mg 360 mg	(a) for patients with lupus nephritis as per the PBS Section 100 indications; (b) for continuation of therapy in existing transplant patients. <i>See above</i>
	mofetil powder for oral liquid	1 g/5 mL	For use in accord with PBS Section 100 indications only; and for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine.
mycophenolate (Cellcept (mycophenolate mofetil))			

Drug	Form	Strength	Restriction
	capsule	250 mg	For use in accord with PBS Section 100 indications for existing transplant patients who have been stabilised on solid oral dosage forms of CellCept®; and for existing liver transplant patients who are intolerant of, or unsuitable for, treatment with azathioprine.
	tablet	500 mg	For use in accord with PBS Section 100 indications for existing transplant patients who have been stabilised on solid oral dosage forms of CellCept®; and for existing liver transplant patients who are intolerant of, or unsuitable for, treatment with azathioprine.
mycophenolate (Mycophenolate mofetil (Pharmacor))	capsule	250 mg	For use in accord with PBS Section 100 indications only; and for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine; and on an individual patient basis for other indications approved by local medicines committees.
	tablet	500 mg	For use in accord with PBS Section 100 indications only; and for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine; and on an individual patient basis for other indications approved by local medicines committees.
nadolol	tablet	40mg	For use in patients under cardiac specialist care, for the treatment of congenital long QT syndrome and other hereditary malignant arrhythmic conditions. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		80mg	See above
nafarelin	nasal spray	200 microgram/actuation	For treatment of visually proven endometriosis
naloxone	injection	1 mg/mL 400 microgram/mL	For discharge and outpatient use.
	nasal spray	1.8 mg/actuation	For use in discharge and outpatients.
naltrexone	tablet	50 mg	Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.
nanoparticle albumin-bound paclitaxel	injection	100 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
naproxen	tablet	250 mg 500 mg	
natalizumab	injection		

Drug	Form	Strength	Restriction
		300 mg/15 mL	For use in accord with PBS Section 100 indications (for multiple sclerosis) Note: There are additional mandatory requirements regarding this medication. Full details are available from the manufacturer.
neomycin sulfate	tablet		
		500 mg	
neostigmine	injection		
		2.5 mg/mL	
		500 microgram/mL	
netupitant + palonosetron	capsule		
		300 mg + 500 microgram	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
nevirapine	modified release tablet		* For use in accord with PBS Section 100 indications *
			<i>See above</i>
		400 mg	<i>See above</i>
	oral liquid		<i>See above</i>
		10 mg/mL	<i>See above</i>
	tablet		<i>See above</i>
		200 mg	<i>See above</i>
nicorandil	tablet		As a second line agent when conventional antianginal therapy is ineffective
			<i>See above</i>
		10 mg	<i>See above</i>
		20 mg	<i>See above</i>
nicotine	chewing gum		
		4 mg	For management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway
	inhalation		
		15 mg	Inpatient: For short term use in mental health inpatients in high dependency units or psychiatric intensive care units.
	lozenge		
		4 mg	For use in patients who cannot use or tolerate nicotine chewing gum 4mg for management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway.
	oral spray		
		1 mg/actuation	For short term use in mental health inpatients in secure mental health rehabilitation units, high dependency units or psychiatric intensive care units. For supervised administration only.
	patch		
		7 mg/24 hours	For management of nicotine withdrawal in adolescents and pregnant patients
		14 mg/24 hours	<i>See above</i>
		21 mg/24 hours	Inpatient: For management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway. Outpatient: For discharge and outpatient use as per the PBS indications where the patient has committed to quit and has entered, or is entering, the necessary counselling and support program.
nicotinic acid	tablet		
		250 mg	
nifedipine	modified release tablet		

Drug	Form	Strength	Restriction	
nilotinib	tablet / capsule	20 mg	For use in tocolysis. 10mg tablet: Inpatient management of acute hypertension in paediatric patients where other antihypertensive medications are contraindicated or not tolerated. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *	
		30 mg		
		60 mg		
		10 mg		
nilotinib	capsule	20 mg	See above	
		150 mg	Specialist Haematologists for use as per the PBS indications.	
nimodipine	injection	200 mg	See above	
		10 mg/50 mL	Specialist Neurosurgeons	
		30 mg	Specialist Neurosurgeons	
nirmatrelvir + ritonavir (Paxlovid) tablet 150 mg + 100 mg	tablet	150 mg + 100 mg	* For use as per the PBS indications * OR For the treatment of COVID-19 in accordance with recommendations in the National Clinical Evidence Taskforce COVID-19 Guidelines See above	
			For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program See above	
nitisinone	capsule	2 mg	See above	
		5 mg	See above	
		10 mg	See above	
		20 mg	See above	
	nitisinone	oral liquid		See above
		tablet	4 mg/mL	See above
	nitisinone	tablet	2 mg	See above
			5 mg	See above
10 mg			See above	
nitrazepam	tablet	5 mg		
nitrofurantoin	capsule	50 mg		
		100 mg		
nitroprusside	injection	50 mg		
nivolumab	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *	

Drug	Form	Strength	Restriction
noradrenaline (norepinephrine)	injection	40 mg/4 mL	See above
		100 mg/10 mL	See above
norethisterone	injection	1 in 1000 (2 mg/2 mL)	
norethisterone + mestranol	tablet	5 mg	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. Suitable choice for women unable to use oestrogen hormonal methods of contraception.
		350 microgram	
norfloxacin	tablet	1 mg + 50 microgram	
		400 mg	For serious bacterial urinary tract infections unresponsive to other agents wherever possible on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
normal immunoglobulin	injection	5 g/100 mL	
		10 g/200 mL	
		320 mg/2 mL	
		800 mg/5 mL	
nortriptyline	tablet	10 mg	
		25 mg	
nusinersen	intrathecal injection	12 mg/5 mL	* For use in accord with PBS Section 100 indications *
nystatin	cream	100 000 units/g	15g
	oral liquid	100 000 units/mL	24mL: For children and Specialist Staff for adults
	tablet	500 000 units	
	vaginal cream	20 000 units/g	75g. Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment
oatmeal colloidal.	application	100% 1kg	For use with children with burns
obinutuzumab	injection	1 g/40 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
ocrelizumab	injection	300 mg/10 mL	* For use in accord with PBS Section 100 indications *
ocriplasmin	intraocular injection		

Drug	Form	Strength	Restriction
octreotide	injection	375 microgram/0.3 mL	Specialist ophthalmologists for outpatient use as per the PBS indications
		50 microgram/mL	(a) For use in accord with PBS Section 100 indications; (b) For the treatment of suspected variceal haemorrhage. Endoscopy to prove variceal haemorrhage must be performed within 24 hours or therapy should be ceased. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		100 microgram/mL	(a) For use in accord with PBS Section 100 indications; (b) For the treatment of suspected variceal haemorrhage. Endoscopy to prove variceal haemorrhage must be performed within 24 hours or therapy should be ceased. (c) For use in chyle leaks post surgery. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	modified release injection	500 microgram/mL	(a) For use in accord with PBS Section 100 indications; (b) For the treatment of suspected variceal haemorrhage. Endoscopy to prove variceal haemorrhage must be performed within 24 hours or therapy should be ceased. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		10 mg	For use in accord with PBS Section 100 indications only to treat vasoactive intestinal peptide secreting tumour (VIPoma) and for continuation of therapy in existing patients.
		20 mg 30 mg	<i>See above</i> <i>See above</i>
ofloxacin	eye drops	0.3%	For the treatment of severe conjunctivitis or keratitis where first line antibacterial therapy has failed or is inappropriate
olanzapine	injection	10 mg	For management of acute behavioural disturbance where de-escalation attempts have failed and oral medications have failed or are impossible to administer to the patient. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) For use in delirium, refer to statewide guidance
	orally disintegrating tablet	5 mg	(a) For use as per the PBS indications; (b) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents); For use in delirium, refer to statewide guidance (c) For use in alcohol and drug withdrawal in line with statewide guidelines. (d) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines

Drug	Form	Strength	Restriction
			(www.catag.org.au) * [NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
		10 mg	<i>See above</i>
		20 mg	* For use as per the PBS indications * [NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
	tablet	2.5 mg	* For use as per the PBS indications *
		5 mg	(a) For use as per the PBS indications; (b) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		7.5 mg	* For use as per the PBS indications *
		10 mg	(a) For use as per the PBS indications; (b) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	wafer	5 mg	(a) For use as per the PBS indications; (b) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) For use in delirium, refer to statewide guidance (c) For use in alcohol and drug withdrawal in line with statewide guidelines. (d) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * [NOTE]Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
		10 mg	<i>See above</i>
		20 mg	* For use as per the PBS indications * [NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
olanzapine pamoate			Specialist Psychiatrists for schizophrenia in patients who have been prescribed oral olanzapine (as a second or third line antipsychotic) and have responded to this therapy, but are non-compliant. Patients must consent to remain on site for at least two hours after each injection for physical



Drug	Form	Strength	Restriction
			observations.
	modified release injection	210 mg 300 mg 405 mg	See above See above See above See above
olaparib	tablet	100 mg 150 mg	For discharge and outpatient use as per the PBS indications. See above See above
omalizumab	injection	75 mg/0.5 mL 150 mg/mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications See above See above
omeprazole	enteric capsule	20 mg	Only for compounding suspension if Central Pharmacy supply is unavailable. Caution - need for ongoing therapy/dose to be reviewed every 3 - 6 months.
	enteric tablet	10 mg	For use in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 to 6 months. Note: Losec contains enteric-coated pellets which can be dispersed.
	injection	40 mg	For use in children less than 1 year (a) in ICU; (b) after endoscopy with high risk stigmata of re-bleeding; or (c) in major upper gastrointestinal haemorrhage
omeprazole QH-CP	oral liquid suspension	2mg per mL, 100mL	For use in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 – 6 months.
onasemnogene abeparvovec	injection	20 trillion vector genomes/mL, 8.3 mL vial (in varying quantities)	* For use in accord with PBS Section 100 indications *
onasemnogene abeparvovec (& onasemnogene abeparvovec	combination pack	20 trillion vector genomes/mL, 5.5 mL vial (&) 20 trillion vector genomes/mL, 8.3 mL vial (in varying quantities)	* For use in accord with PBS Section 100 indications *
ondansetron	injection	4 mg/2 mL  8 mg/4 mL	General use for TGA approved indications; and for (a) nonspecific nausea and vomiting and (b) second line therapy in hyperemesis gravidarum. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * (a) Patients on cytotoxic chemotherapy or radiotherapy; (b) Use for postoperative nausea and vomiting (PONV).
	oral liquid	4 mg/5 mL	50mL: For use in children who cannot use any other forms of ondansetron.

Drug	Form	Strength	Restriction
	orally disintegrating tablet	4 mg	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *  (a) For use as per the PBS indications; (b) use in postoperative nausea and vomiting (PONV) in (i) adult patients not responsive to alternative oral antiemetic therapy and who cannot use other forms of ondansetron; and (ii) children; (c) Use within Emergency Departments for acute gastroenteritis in children up to age sixteen years when frequent vomiting is interfering with oral rehydration therapy. It is recommended that the Children's Health Queensland Flowchart - Gastroenteritis - Emergency Management of Children be consulted and followed. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * * For use as per the PBS indications *
	tablet	8 mg 4 mg 8 mg	* For use as per the PBS indications *
ornipressin	injection	5 units/mL	
orphenadrine	modified release tablet	100 mg	
ortho-phthalaldehyde chemical disinfectant	solution	0.5%, 5 litre	
oseltamivir	capsule	30 mg	(1) On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases / Clinical Microbiology approved protocol for: a) Treatment of inpatients who have clinically suspected or laboratory proven influenza who are at high risk of severe disease (not for general use in Emergency Departments unless admission is intended); b) Prophylaxis of inpatients who are close contacts of inpatients with laboratory proven influenza on the advice of an infectious diseases physician, clinical microbiologist or infection control practitioner. Oseltamivir therapy should be ceased if influenza polymerase chain reaction (PCR) test of a nasopharyngeal swab or aspirate is negative. OR (2) In accord with a QH pandemic influenza protocol. <i>See above</i>
		45 mg 75 mg	<i>See above</i>
	powder for oral liquid	6 mg/mL	(1) On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases / Clinical Microbiology approved protocol for: a) Treatment of inpatients who have clinically suspected or laboratory proven influenza who are at high risk of severe disease (not for general use in Emergency Departments unless admission is intended); b) Prophylaxis of inpatients who are close contacts of inpatients with laboratory proven influenza on the advice of an infectious diseases physician, clinical microbiologist or infection control practitioner.

Drug	Form	Strength	Restriction
			Osetamivir therapy should be ceased if influenza polymerase chain reaction (PCR) test of a nasopharyngeal swab or aspirate is negative. OR (2) In accord with a QH pandemic influenza protocol.
osimertinib	tablet	40 mg 80 mg	Specialist oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
oxaliplatin	injection	100 mg/20 mL 200 mg/40 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i>
oxazepam	tablet	15 mg 30 mg	
oxcarbazepine	oral liquid tablet	60 mg/mL 150 mg 300 mg 600 mg	250mL: For epilepsy not controlled by other drugs For epilepsy not controlled by other drugs <i>See above</i> <i>See above</i>
oxybuprocaine	eye drops	0.4%	Inpatient: 0.5mL: For inpatient use only
oxybutynin	tablet	5 mg	Treatment of detrusor overactivity where conservative measures have failed
oxycodone	capsule injection modified release tablet	10 mg 20 mg 10 mg/mL 20 mg/2 mL 10 mg	For use on the advice of a palliative care physician, for patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. All other use requires individual patient approval. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i> For use by Pain or Palliative Medicine Specialists and Oncologists where (a) morphine or hydromorphone is contraindicated or provides inadequate analgesia; or (b) transdermal opioids provide inadequate analgesia. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i> a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated.  b) For use in severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated, in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states.

Drug	Form	Strength	Restriction
			Caution: The risk of drug dependence is high. * CONTROLLED DRUG*
		15 mg	See above
		20 mg	See above
		30 mg	See above
		40 mg	See above
		80 mg	For use on the advice of a palliative care physician in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG*
	oral liquid	1 mg/mL 20mL and 250mL	20mL pack size For paediatric use - for severe pain not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated, in patients who: a) cannot swallow tablets or capsules and b) are intolerant to morphine or for whom morphine is thought to be inappropriate. Caution: The risk of drug dependence is high. 250mL pack size For severe pain not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated, in patients who: a) cannot swallow tablets or capsules or b) are intolerant to morphine or for whom morphine is thought to be inappropriate. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	tablet	5 mg	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *  For use in patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. A maximum quantity of 10 tablets for discharge and outpatient use, except for palliative care patients. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
oxycodone + naloxone	modified release tablet	2.5 mg + 1.25 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics, in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		5 mg + 2.5 mg	See above
		10 mg + 5 mg	See above
		15 mg + 7.5 mg	See above
		20 mg + 10 mg	See above
		30 mg + 15 mg	See above
		40 mg + 20 mg	See above
		60 mg + 30 mg	For discharge and outpatient use on the advice of a palliative care physician in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or

Drug	Form	Strength	Restriction
		80 mg + 40 mg	first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
oxyquinoline sulfate, acetic acid and ricinoleic acidIc "Aci-gel"	jelly	0.025%-0.94%-0.75%, 100g	See above
oxytocin	injection	5 units/mL 10 units/mL	
oxytocin + ergometrine	injection	5 units/mL + 500 microgram/mL	
ozanimod	combination pack	230 microgram (&) 460 microgram	For discharge and outpatient use for relapsing-remitting multiple sclerosis only, as per the PBS indication. <i>See above</i> <i>See above</i>
ozanimod	capsule	920 microgram	For discharge and outpatient use for relapsing-remitting multiple sclerosis only, as per the PBS indication. <i>See above</i>
paclitaxel	injection	30 mg/5 mL 100 mg/16.67 mL 100 mg/16.7 mL 150 mg/25 mL 300 mg/50 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
palbociclib	tablet	75 mg 100 mg 125 mg	For discharge and outpatient use as per the PBS indications where ribociclib is not suitable or not tolerated. Usual individual patient approval (IPA) process applies for continuation of therapy in admitted patients. Caution: For patients admitted to hospital on palbociclib, seek advice from a medical oncologist before continuing therapy. <i>See above</i> <i>See above</i> <i>See above</i>
paliperidone	modified release injection	1 g/5 mL, syringe	Specialist Psychiatrists for the treatment of schizophrenia. Caution: Note different dosing intervals between products and ensure appropriate product selection. Invega Sustenna, a once-monthly long-acting injection – paliperidone modified release injection 25 mg, 50 mg, 75 mg, 100 mg, 150 mg Invega Trinza, a 3-monthly long-acting injection – paliperidone modified release injection 175 mg/0.875 mL, 263 mg/1.315 mL, 350 mg/1.75 mL, 525 mg/2.625 mL. Invega Hafyera, a 6-monthly long-acting injection – paliperidone modified release injection 700 mg/3.5 mL, 1 g/5 mL. <i>See above</i>

Drug	Form	Strength	Restriction
		25 mg	See above
		50 mg	See above
		75 mg	See above
		100 mg	See above
		150 mg	See above
		175 mg/0.875 mL	See above
		263 mg/1.315 mL	See above
		350 mg/1.75 mL	See above
		525 mg/2.625 mL	See above
		700 mg/3.5 mL, syringe	See above
palonosetron	injection	250 microgram/5 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
pamidronate disodium	injection	15 mg/5 mL	(a) treatment of Paget's Disease; (b) severe hypercalcaemia where zoledronic acid is inappropriate or not tolerated; (c) in accord with PBS Section 100 indications * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		30 mg/10 mL	See above
		90 mg/10 mL	(a) severe hypercalcaemia where zoledronic acid is inappropriate or not tolerated; (b) use in accord with PBS Section 100 indications * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Pancreatic extract (Creon) lipase + amylase + protease	enteric coated granules "Creon Micro"	5000 units/100 mg + 3600 units/100 mg + 200 units/100 mg	
	modified release capsule	"Creon 10,000" 10 000 units + 8000 units + 600 units "Creon 25,000" 25 000 units + 18 000 units + 1000 units "Creon 35,000" 35 000 units + 25 200 units + 1400 units	
pancuronium	injection	4 mg/2 mL	Specialist Anaesthetists and Country Medical Superintendents
panitumumab	injection	100 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		400 mg/20 mL	See above
pantoprazole	enteric tablet		See above

Drug	Form	Strength	Restriction
		20 mg	For use in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 – 6 months.
	injection	40 mg	See above
		40 mg	For use (a) in ICU; (b) after endoscopy with high risk stigmata of re-bleeding; or (c) in major upper gastrointestinal haemorrhage
papaverine	injection	30 mg/mL 120 mg/10 mL	
para-aminosalicylic acid	powder for oral liquid	4g	For treatment after approval by the Medical Advisory Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available here. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
paracetamol	effervescent tablet	500 mg	For patients with cancer therapy associated mucositis; patients unable to swallow tablets; and in pre-operative areas for use in preference to IV paracetamol.
	injection	1 g/100 mL	For a maximum of 48 hours for patients unable to take paracetamol by the oral or nasogastric route.
	oral liquid	24 mg/mL	Children too young to swallow tablets or capsules Care should be taken to avoid accidental overdosage. Caution: - This item is not linking to the correct MIMs dosing information. Please refer to other reference sources. - There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19). Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
		50 mg/mL	Care should be taken to avoid accidental overdosage. Caution: - This item is not linking to the correct MIMs dosing information. Please refer to other reference sources. - There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19). Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
		100 mg/mL	Care should be taken to avoid accidental overdosage. Caution: There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19). Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
	suppository	125 mg	

Drug	Form	Strength	Restriction
paracetamol + codeine	tablet	250 mg 500 mg	
	tablet	500 mg	
	tablet	500 mg + 30 mg	For use in patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. In view of safety concerns, codeine is not recommended for use in breastfeeding women, in children under 12 years of age or in children up to 18 years of age after tonsillectomy and/or adenoidectomy.
paraffin	cream	100g and 500g	
	eye drops	7.5mL	
	liquid	5g tube 200mL	
	oral liquid emulsion	33% 200mL and 500mL 50% 450mL	
paraffin	eye ointment	1 g/g	
paraffin white soft	application	5g sterile tube, 100g, 470g/500g	
paraffin white soft and paraffin liquid	ointment	50%-50%, 500g	Epidermolysis Bullosa patients only.  <i>See above</i> <i>See above</i>
paraffin yellow soft	application	100g	
paraldehyde	injection	5 mL/5 mL	(Do not use with plastic syringe - only glass)
parecoxib	injection	40 mg	For use as a single peri-operative dose for the management of post-operative pain.
PARENTERAL NUTRITION ADULT SOLUTION WITH ELECTROLYTES: amino acids 25.3g/L, glucose 82.5g/L, clinoleic, electrolytes mmol/L (Na 21.0, K 16.0, Ca 2.0, Mg 2.2, PO4 8.5), 700kcal/L (eg 'PeriOlimel N4-600E')	intravenous infusion	2L	For use by a Parenteral Nutrition team (or local equivalent) in adult patients unable to maintain nutrition orally or enterally and in whom central parenteral nutrition is either not readily available (i.e. no central access) or the presumed duration of parenteral nutrition is between 3 to 7 days.



Drug	Form	Strength	Restriction
PARENTERAL NUTRITION STANDARD ADULT SOLUTION - alternate lipid source, higher protein - with electrolytes; Amino acids 50-60g/L, glucose 100-125g/L, electrolytes mmol/L (Na 35-40, K 30, Ca 2-4, Mg 4-5, PO4 10-15), 1000-1200kcal/L (eg 'Olimel N9')	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible and when patients require a higher kcal:g nitrogen ratio (eg burns, neurosurgery, BMT) or when a product containing fish oil is not suitable.
PARENTERAL NUTRITION STANDARD ADULT SOLUTION - alternate lipid source, higher protein - without electrolytes; Amino acids 50-60g/L, glucose 100-125g/L, 1000-1200kcal/L (eg 'Olimel N9 electrolyte free')	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible and when patients require a higher kcal:g nitrogen ratio (eg burns, neurosurgery, BMT) or when a product containing fish oil is not suitable.
PARENTERAL NUTRITION STANDARD ADULT SOLUTION WITH ELECTROLYTES: Fat emulsion with amino acids 40-50g/L, glucose 100-125g/L, electrolytes mmol/L (Na 35-40, K 30, Ca 2-4, Mg 4-5, PO4 10-15), 1000-1200kcal/L (eg 'SMOFKabiven')	intravenous infusion	1L 2L	For intravenous therapy when oral or enteral feeding is not possible. See above
PARENTERAL NUTRITION STANDARD ADULT SOLUTION WITHOUT ELECTROLYTES: Fat emulsion with amino acids 40-50g/L, glucose 100-125g/L, 1000-1200kcal/L (eg 'SMOFKabiven electrolyte free')	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, high energy density, high protein, high glucose, with electrolytes (30/200): Amino Acids 30g/L, Glucose 200g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 59.2, Acet 58.5) 917kcal/L			

Drug	Form	Strength	Restriction
	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, low energy density, low protein, low glucose, with electrolytes (20/100): Amino acids 20g/L, Glucose 100g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 47.4, Acet 50.4) 479kcal/L	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, medium energy density, medium protein, medium glucose, with electrolytes (25/150): Amino acids 25g/L, Glucose 150g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 57.2, Acet 54.5) 699kcal/L	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
paroxetine	tablet	20 mg	For major depressive disorders or obsessive-compulsive disorder or panic disorder
pasireotide embonate	modified release injection	20 mg 40 mg 60 mg	* For use in accord with PBS Section 100 indications * See above See above
Patent blue V	injection	125mg in 5mL (2.5%)	Lymphangiography. See above See above
pazopanib	tablet	200 mg 400 mg	* For discharge and outpatient use as per the PBS indications * See above See above
pegaspargase	injection	3750 units/5 mL	Haematologists, for the treatment of Acute Lymphoblastic Leukaemia.
pegcetacoplan	injection	1.08 g/20 mL, vial	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). See above See above
pegfilgrastim	injection		

Drug	Form	Strength	Restriction
peginterferon alfa-2a	injection	6 mg/0.6 mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications
		135 microgram/0.5 mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications
		180 microgram/0.5 mL	See above
pegvisomant	injection		* For use in accord with PBS Section 100 indications *
			See above
		10 mg	See above
		15 mg	See above
pembrolizumab	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
			See above
		100 mg/4 mL	See above
pemetrexed	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
			See above
		1 g	See above
		100 mg	See above
penicillamine	tablet		
		125 mg	
		250 mg	
pentamidine	injection		
		300 mg	On the advice of an infectious diseases physician or a clinical microbiologist as second line therapy for treatment of severe Pneumocystis jirovecii pneumonia or prophylaxis
PEP starter pack A	tablet		For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
			See above
		Kit containing 3 x tenofovir with emtricitabine tablet 300mg-200mg	See above
PEP starter pack B	tablet		For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		Kit containing 3 x tenofovir with emtricitabine tablet 300mg-200mg PLUS 6 x raltegravir tablet 400mg	See above
perhexiline	tablet	100 mg	

Drug	Form	Strength	Restriction
periciazine	tablet	2.5 mg	Specialist Psychiatrists See above
		10 mg	
perindopril	tablet	2.5 mg	
		5 mg	
		10 mg	
perindopril + indapamide	tablet	5 mg + 1.25 mg	Hypertension in patients who are not adequately controlled with either indapamide or perindopril monotherapy.
permethrin	cream	5%	
	lotion	5%	
pertuzumab	injection	420 mg/14 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
pethidine	injection	50 mg/mL	Anaesthetists, Obstetricians and Country Medical Superintendents. Use in general ward areas and Emergency Departments is discouraged. * CONTROLLED DRUG * See above
		100 mg/2 mL	
pheniramine	oral liquid	15 mg/5 mL	
	tablet	45.3 mg	
phenobarbital	injection	200 mg/mL	Note: For use in Status Epilepticus in children, refer to the statewide paediatric guideline. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	oral liquid	15 mg/5 mL	
	tablet	30 mg	
phenol	injection	5% in Oil 5mL	Anaesthetists
		6%, 5mL (aqueous)	
		10% in Meglumine lothalamate 60%,10mL	
phenoxybenzamine	capsule	10 mg	For treatment of severe vasospastic disorders
phenoxymethylpenicillin	capsule		

Drug	Form	Strength	Restriction
		250 mg 500 mg	
	oral liquid		
		125 mg/5 mL 250 mg/5 mL	Children too young to swallow tablets or capsules See above
phentolamine	injection	10 mg/mL	* For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
phenylephrine	eye drops	2.5% 10%	For inpatient use only. See above
	injection	10 mg/mL (1%)	For anaesthetics
phenylephrine	nasal drops	0.25% 15mL	
phenytoin	capsule	30 mg 100 mg	
	chewable tablet	50 mg	
	injection	100 mg/2 mL 250 mg/5 mL	Note: For use in Status Epilepticus in children, refer to the statewide paediatric guideline See above
	oral liquid	30 mg/5 mL	Children too young to swallow tablets or capsules
phosphate	injection	sodium dihydrogen phosphate (No K Phos) - (10mL vial contains - phosphate 10mmol, sodium 10mmol)	
phosphate (Elemental Phosphorus 436mg per 50mL, Na 434 mmol/L, PO4 280 mmol/L) Parfitt's Mixture	mixture	50mL	
phosphorus	effervescent tablet	500 mg	
physostigmine	injection	1mg in 2mL	
phytomenadione	capsule	10 mg	
	injection	2 mg/0.2 mL 10 mg/mL	
picosulfate	oral liquid		

Drug	Form	Strength	Restriction
		7.5 mg/mL	For constipation in palliative care patients where other agents are not tolerated.
picosulfate + magnesium oxide + citric acid	powder for oral liquid	10 mg + 3.5 g + 12 g	On the advice of a paediatric gastroenterologist for use in paediatric patients requiring bowel cleansing prior to bowel examination by endoscopy, radiography or surgery.
pilocarpine	eye drops	1% 2% 3% 4%	
	eye drops minims	2%	For inpatient use only.
pilocarpine	eye drops	0.125% 15mL	
pimecrolimus	cream	1%	Dermatologists and ophthalmologists for discharge and outpatient use as per the PBS indications .
pindolol	tablet	5 mg 15 mg	
pioglitazone	tablet	15 mg 30 mg 45 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
piperacillin + tazobactam	injection	4 g + 500 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
pirfenidone	capsule	267 mg	* For discharge and outpatient use as per the PBS indications *
pizotifen	tablet	500 microgram	
plague vaccine	injection	1.5 x 1,000,000,000 organisms in 0.5mL	
plastic wound dressing	spray	aerosol	
plerixafor	injection	24 mg/1.2 mL	* For use in accord with PBS Section 100 indications *
pneumococcal 13 valent conjugate vaccine			Patients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and are at highest increased risk of invasive pneumococcal disease due to (i) functional or anatomical asplenia, (ii) cochlear implant, (iii) unreparable cerebrospinal fluid leak,

Drug	Form	Strength	Restriction
			(iv) stem cell transplant, (v) HIV with CD4 count <200, (vi) solid organ transplant - to be given pre-transplant in cardiac, lung and high-risk (ABO-incompatible or paired kidney exchange program) renal patients.
	injection	0.5 mL syringe	See above See above
pneumococcal 23 valent vaccine			For persons who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and are at high risk of pneumococcal infections.
	injection	0.5 mL vial	See above See above
podophyllotoxin	application	0.5%, paint 3.5mL	
poloxamer	oral liquid	100 mg/mL	Children too young to swallow tablets or capsules
polyvalent Australian snake antivenom	injection	1 vial	
polyvinyl alcohol	eye drops	1.4%	
polyvinyl alcohol with povidone	eye drops	1.4% with 0.6%, 0.4mL	Where other ocular lubricants are inappropriate
pomalidomide	capsule	3 mg 4 mg	* For use in accord with PBS Section 100 indications * See above
ponatinib	tablet	15 mg 45 mg	* For discharge and outpatient use as per the PBS indications * See above
poractant alfa	intratracheal suspension	120 mg/1.5 mL 240 mg/3 mL	For use in respiratory distress in neonates on the advice of a neonatologist (which can be retrospective) See above See above
posaconazole	injection	300 mg/16.7 mL	After advice on each individual case by an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy and where oral therapy is unsuitable or gastrointestinal disease causes impaired absorption. Patients should be transitioned to oral posaconazole as soon as feasible.
	modified release tablet	100 mg	(a) After advice on each individual case by an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy; or (b) As part of an infectious diseases approved protocol for prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients who are at high risk of developing these infections,

Drug	Form	Strength	Restriction
			<p>defined as follows:</p> <p>(i) Neutropenic patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome.</p> <p>(ii) Graft versus host disease (GVHD) patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant for up to 6 months. Extension past this time requires individual patient approval.</p> <p>NOTE: This preparation is not interchangeable with other posaconazole preparations.</p>
	oral liquid	40 mg/mL	<p>For paediatric patients who are unable to swallow posaconazole tablets</p> <p>(a) on the advice of an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy; or</p> <p>(b) as part of an infectious diseases approved protocol for prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients who are at high risk of developing these infections, defined as follows:</p> <p>(i) Neutropenic patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome.</p> <p>(ii) Graft versus host disease (GVHD) patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant for up to 6 months. Extension past this time requires individual patient approval.</p> <p>NOTE: This preparation is not interchangeable with other posaconazole preparations.</p>
potassium acetate	injection	2.45 g/5 mL	
potassium chloride	injection	750 mg/10 mL	For use only in critical care, oncology/haematology and paediatric high dependency units for the replacement of potassium when an intravenous potassium premix preparation does not fulfil the needs of the patient.
	modified release tablet	600 mg (potassium 8 mmol)	
potassium chloride	intravenous infusion in glucose and sodium chloride	<p>20mmol/L (0.15%) in Glucose 3.3% and Sodium Chloride 0.3% (125 Cal per litre) (Potassium 20, Sodium 51, Chloride 71 mmol per litre)</p> <p>20mmol/L (0.15%) in Glucose 5% Sodium Chloride 0.45% (200 Cal per litre) (Potassium 20, Sodium 77, Chloride 97mmol per litre)</p> <p>20mmol/L (0.15%) in Glucose 5% and Sodium Chloride 0.9%</p> <p>40mmol/L (0.298%) in in Glucose 3.3% and Sodium Chloride 0.3% (125 Cal per litre) (Sodium 50, Potassium 40, Chloride 90 mmol per litre)</p>	
	intravenous infusion in sodium chloride	<p>20mmol/L (0.15%) in Sodium Chloride 0.9% (Potassium 20, Sodium 154, Chloride 174 mmol per litre)</p> <p>40mmol/L (0.298%) in Sodium Chloride 0.9% (Sodium 150, Potassium 40, Chloride 190 mmol per litre)</p>	



Drug	Form	Strength	Restriction
	intravenous infusion in sodium chloride "mini bag"	10mmol/100mL in Sodium Chloride 0.29% (Potassium 10, Sodium 5, Chloride 15 mmol per 100mL bag) 40mmol/100mL (2.98%) in Sodium Chloride 0.9% (Sodium 15, Potassium 40, Chloride 55 mmol per 100mL)	For use only via a central line in critical care or in oncology/haematology units or under the authorisation of a consultant if the patient is in a non-critical care environment, for severe hypokalaemia (serum potassium equal to or less than 2.5mmol/L). Appropriate monitoring is required.
	oral liquid solution	10% (20mmol potassium in 15mL), 500mL	For potassium supplementation via tube feeding
potassium chloride + potassium bicarbonate + potassium carbonate	effervescent tablet	595 mg + 384 mg + 152 mg (total potassium 14 mmol)	
potassium citrate	modified release tablet	1.08 g (potassium 10 mmol)	For the prevention of renal calculi in patients with hypocitraturia.
potassium citrate	oral liquid solution	2g/10mL	Carbohydrate Containing Formula (APF) (2g/10mL, 200mL): For the prevention of renal calculi in patients with hypocitraturia. Carbohydrate Free Formula (QH-CP) (2g/10mL, 200mL): Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of the QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet.
potassium permanganate	powder	1 g/g	
povidone-iodine	alcoholic solution	10% in 70% Ethanol, 500mL	
	aqueous solution	5%, 100mL [*STERILE*] 10% tube (30mL) or sachet (22.5mL)	Procedures where sterile povidone-iodine is clinically indicated in the health facility's perioperative unit and procedural areas. Use alternative products if sterile povidone-iodine is not clinically required.
	aqueous swab	10%, 500mL	
	ointment sachet	pack 100 10%	
	surgical hand wash	10%, 1.5g 10%, 25g	
	swab stick	7.5%, 1.5L 7.5%, 500mL	
pralatrexate	injection	20 mg/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
pralidoxime iodide			

Drug	Form	Strength	Restriction
pramipexole	injection	2.5% (500 mg/20 mL)	
	modified release tablet	1.5 mg	For the treatment of Parkinson disease as per the PBS indications.
		3 mg	See above
		4.5 mg	See above
		375 microgram	See above
		750 microgram	See above
tablet	1 mg	For the treatment of Parkinson Disease as per the PBS indications	
	125 microgram	For the treatment of Parkinson Disease and severe primary restless legs as per the PBS indications	
	250 microgram	See above	
pravastatin	tablet	20 mg	* For use as per the PBS indications *
		40 mg	See above
praziquantel	tablet	600 mg	Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with Schistosomiasis, Hymenolepis nana (Dwarf tapeworm), Taenia saginata, Opisthorchis viverrine or Clonorchis sinensis or as an adjunct to surgical therapy of hydatid disease.
prazosin	tablet	1 mg	
		2 mg	
		5 mg	
prednisolone	tablet	1 mg	
		5 mg	
		25 mg	
prednisolone acetate + phenylephrine	eye drops	1% + 0.12%	Specialist Ophthalmologists
prednisolone sodium phosphate	enema	20 mg/100 mL	
	eye drops	0.5%	Specialist Ophthalmologists
	oral liquid	5 mg/mL	
	suppository	5 mg	
pregabalin	capsule	25 mg	* For use as per the PBS indications * Note: Initiate pregabalin in preference to gabapentin for neuropathic pain where clinically appropriate. Caution: Consider potential for abuse or diversion with this medicine.

Drug	Form	Strength	Restriction
prilocaine	injection	75 mg	See above
		150 mg	See above
		300 mg	See above
prilocaine + felypressin	injection	0.5% (250 mg/50 mL)	
primaquine	injection	3% (66 mg/2.2 mL) + 0.066 units/2.2 mL	For dental use
primidone	tablet	7.5 mg	
	tablet	250 mg	
probenecid	tablet	500 mg	
procaine benzylpenicillin	injection	1.5 g/3.4 mL	
procarbazine	capsule	50 mg	
prochlorperazine	injection	12.5 mg/mL	
	suppository	25 mg	
	tablet	5 mg	
	tablet	5 mg	
progesterone	pessary	200 mg	Obstetricians for prevention of preterm birth in women with shortened cervix and those with short cervixes in singleton pregnancies.
promethazine	injection	50 mg/2 mL	Caution - Administration of promethazine hydrochloride injection, regardless of the route, can cause severe chemical irritation and tissue damage due to extravasation or unintentional intra-arterial injection. Adverse reactions include burning, pain, thrombophlebitis, tissue necrosis and gangrene. Due to the risks of intravenous injection, the preferred route of administration of promethazine is orally unless a central venous line is used. Deep intramuscular injection could be used in exceptional circumstances. Subcutaneous injection is contraindicated. Caution - not to be used for anaphylaxis.
		5 mg/5 mL	Patients over two years of age unable to swallow tablets or capsules.
	oral liquid	5 mg/5 mL	
	tablet	10 mg 25 mg	
propantheline	tablet	15 mg	
propofol	injection		

Drug	Form	Strength	Restriction
propranolol	oral liquid	1 g/100 mL 200 mg/20 mL 500 mg/50 mL	For paediatric use only.
		10mg in 5mL, 100mL	
propranolol	tablet	10 mg 40 mg 160 mg	
		50 mg	
propylthiouracil	tablet	50 mg	For use in adult patients only, second line to carbimazole except for the following cases: (a) patients who are in their first trimester of pregnancy; (b) patients who are allergic to or intolerant of carbimazole; (c) thyroid storm
protamine sulfate	injection	50 mg/5 mL	
prothionamide	tablet	250mg	For treatment after approval by the Medical Advisory Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available here. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
pseudoephedrine	tablet	60 mg	Patients with autonomic insufficiency
psyllium husk powder	powder for oral liquid		
psyllium husk powder	powder for oral liquid sachet	5g	
pyrantel	tablet	125 mg	Alternative treatment of adults and children with Enterobius vermicularis (Pinworm), Ancylostoma caninum (Eosinophilic enterocolitis), Ancylostoma duodenale/Necator americanus (Hookworm) or Ascaris lumbricoides (Roundworm). See above
		250 mg	
		500 mg	
pyrazinamide	tablet		
pyridostigmine	modified release tablet	180 mg	
		10 mg 60 mg	
pyridoxine			

Drug	Form	Strength	Restriction
pyrimethamine	tablet	25 mg	
	tablet	25 mg	
quetiapine	modified release tablet		For use in schizophrenia following failure of aripiprazole, risperidone, olanzapine, amisulpride or lurasidone; For use in bipolar disorder as per the PBS indications and for bipolar depression as per the TGA indications.
		50 mg	See above
		150 mg	See above
		200 mg	See above
		300 mg	See above
	tablet	400 mg	See above
		25 mg	See above
		100 mg	See above
200 mg	See above		
quinine	injection		For the treatment of malaria.
		600 mg/10 mL (6%)	See above
	tablet	300 mg	See above
raltegravir	chewable tablet	25 mg	* For use in accord with PBS Section 100 indications *
		100 mg	See above
	tablet	400 mg	For use in accord with PBS Section 100 indications For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		600 mg	* For use in accord with PBS Section 100 indications *
raltitrexed	injection	2 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
ramipril	tablet	1.25 mg	
		2.5 mg	
		5 mg	
		10 mg	
ranibizumab	injection	1.65 mg/0.165 mL	* For use as per the PBS indications *

Drug	Form	Strength	Restriction
rasagiline	tablet	1 mg	For Parkinson disease as per the PBS indications
rasburicase	injection	1.5 mg	For use in paediatric patients on the advice of a haematologist or paediatric oncologist, to prevent and treat hyperuricaemia manifestations of tumour lysis syndrome. For use in adult patients, this medicine is not LAM listed - individual patient approval is required. QHMAC guidance on rasburicase use in children and adults is provided below - see 'Guidelines and Other Resources' section.
ravulizumab	injection	1.1 g/11 mL 300 mg/3 mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). <i>See above</i> <i>See above</i>
red back spider antivenom	injection	500 units, vial	
remdesivir	injection	100 mg/20 mL	On the advice of a specialist physician for the treatment of COVID-19 in accordance with recommendations in the National Clinical Evidence Taskforce COVID-19 Guidelines
remifentanyl	injection	1 mg 2 mg 5 mg	Specialist Anaesthetists for use during induction and/or maintenance of general anaesthesia when endotracheal intubation and controlled ventilation are anticipated * CONTROLLED DRUG * <i>See above</i> <i>See above</i> <i>See above</i>
Resorcinol	cream	15% in antioxidant base (QH-CP)	Dermatologists for use in the treatment of hidradenitis suppurativa. <i>See above</i>
rh immunoglobulin	injection	250mg in 1mL	Rh(D)-negative mother without anti-D antibodies with an Rh(D)-positive baby; a) Following abortion or threatened abortion after 8 weeks gestation b) After manipulations during pregnancy; or c) After (Rh) mismatched transfusions especially in premenopausal females
ribavirin	tablet	200 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications. <i>See above</i>
ribociclib	tablet	200 mg	* For discharge and outpatient use as per the PBS indications * Usual individual patient approval (IPA) process applies for continuation of therapy in admitted patients. Caution: For patients admitted to hospital on ribociclib, seek advice from a medical oncologist before continuing therapy.
rifabutin	capsule	150 mg	For use in accord with PBS Section 100 indications; For use as part of combination therapy for Helicobacter Pylori when first-line therapy has failed or for proven resistance to Helicobacter Pylori combination therapy; or * On the advice of an infectious diseases physician, clinical microbiologist

Drug	Form	Strength	Restriction
			or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
rifampicin	capsule	150 mg	a) Treatment of TB and leprosy b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults; c) all other infections on the advice of an infectious diseases physician, clinical microbiologist, or in conjunction with an antimicrobial stewardship (AMS) team protocol
		300 mg	a) Treatment of TB and leprosy [available as a component of the leprosy WHO calendar packs]; b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults; c) all other infections on the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol
	injection	600 mg	For treatment of infections on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
	oral liquid	100 mg/5 mL	a) Children too young to swallow tablets or capsules * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults.
rifaximin	tablet	550 mg	* For discharge and outpatient use as per the PBS indications *
rilpivirine	tablet	25 mg	* For use in accord with PBS Section 100 indications *
ringers solution (compound sodium chloride)	injection sterile irrigation solution	500mL Pour bottle	
riociguat	tablet	1 mg 1.5 mg 2 mg 2.5 mg 500 microgram	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
risdiplam	powder for oral liquid	750 microgram/mL	* For use in accord with PBS Section 100 indications * <i>See above</i>
risedronate	tablet	35 mg	* For use as per the PBS indications *
risperidone	modified release injection	25 mg	Specialist Psychiatrists for: a) Schizophrenia for continuation therapy in inpatients, for initiation in inpatients when paliperidone is not clinically suitable, and for outpatient use b) Maintenance treatment, in combination with lithium or sodium valproate, of treatment refractory

Drug	Form	Strength	Restriction	
	oral liquid	37.5 mg	bipolar I disorder. <i>See above</i>	
		50 mg	<i>See above</i>	
		1 mg/mL	100mL: For use as per the PBS indications 30mL: Specialist psychiatrists and paediatricians for (a) behavioural disturbances; (b) schizophrenia; (c) bipolar disorder; and (d) autism spectrum disorder. The PBS indications of risperidone oral solution 1mg per mL, 100mL should be consulted and followed.	
	tablet	1 mg	* For use as per the PBS indications *	
		2 mg	<i>See above</i>	
		3 mg	<i>See above</i>	
		4 mg	<i>See above</i>	
		500 microgram	(a) For use as per the PBS indications; (b) For the symptomatic management of severe behavioural disturbance secondary to delirium when non-pharmacological strategies have been unsuccessful and in consultation with a geriatrician or psychiatrist. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *	
	ritonavir	oral liquid		
		tablet	600 mg/7.5 mL	* For use in accord with PBS Section 100 indications *
rituximab (Riximyo)	injection	100 mg	* For use in accord with PBS Section 100 indications *	
		100 mg/10 mL	Outpatient and day admitted patient use: Specialist physicians for a condition in which rituximab is considered clinically appropriate, as per the PBS S100 HSD and S100 EFC listings. Inpatient use: via individual patient approval (IPA) / other local approval mechanism, except if used for the following indications: (i) On the advice of a haematologist for thrombotic thrombocytopenia purpura (TTP) in patients with suboptimal response to standard treatment (e.g. plasma exchange and high-dose steroids) or with relapsed disease; (ii) Specialist oncologists or haematologists for chemotherapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *	
		500 mg/50 mL	<i>See above</i>	
rivaroxaban	tablet	2.5 mg	(a) For use as per the PBS indications (b) On the advice of paediatric Haematologists for the treatment of venous thromboembolism (lower or upper limb extremity DVT), right atrial thrombosis, pulmonary embolism, catheter related thrombosis, cerebral venous sinus thrombosis, portal vein thrombosis or renal vein thrombosis in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product	



Drug	Form	Strength	Restriction
		10 mg	information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * (a) For use as per the PBS indications; or (b) Venous thromboembolism (VTE) prophylaxis for inpatients previously diagnosed with heparin induced thrombocytopenia (HIT) (c) On the advice of paediatric Haematologists for the treatment of venous thromboembolism (lower or upper limb extremity DVT), right atrial thrombosis, pulmonary embolism, catheter related thrombosis, cerebral venous sinus thrombosis, portal vein thrombosis or renal vein thrombosis in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		15 mg	(a) For use as per the PBS indications; or (b) For use as an alternative anticoagulant therapy for management of heparin induced thrombocytopenia (HIT) in patients with a calculated GFR greater than 15 mL/min. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation. (c) On the advice of paediatric Haematologists for the treatment of venous thromboembolism (lower or upper limb extremity DVT), right atrial thrombosis, pulmonary embolism, catheter related thrombosis, cerebral venous sinus thrombosis, portal vein thrombosis or renal vein thrombosis in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		20 mg	<i>See above</i>
rivaroxaban granules for oral suspension (SAS)	granules	1mg/mL	On the advice of paediatric Haematologists for the treatment of venous thromboembolism (lower or upper limb extremity DVT), right atrial thrombosis, pulmonary embolism, catheter related thrombosis, cerebral venous sinus thrombosis, portal vein thrombosis or renal vein thrombosis in paediatric patients. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
rocuronium	injection	50 mg/5 mL 100 mg/10 mL	Emergency Specialists, Specialist Anaesthetists and Country Medical Superintendents. Specialist Anaesthetists and Country Medical Superintendents.
romiplostim	injection	250 microgram 500 microgram	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications <i>See above</i> <i>See above</i>
ropivacaine	injection	0.2% (20 mg/10 mL) 0.2% (40 mg/20 mL) 0.2% (200 mg/100 mL) 0.2% (400 mg/200 mL) 0.75% (75 mg/10 mL) 0.75% (150 mg/20 mL)	

Drug	Form	Strength	Restriction
ropivacaine (Baxter)	infusion	1% (100 mg/10 mL)	
		1% (200 mg/20 mL)	
ropivacaine + fentanyl	epidural infusion	(0.1%) 200mg in 200mL	
		200 mg/100 mL + 200 microgram/100 mL	For use in epidural anaesthesia. * CONTROLLED DRUG *
		400 mg/200 mL + 400 microgram/200 mL	See above
		400 mg/200 mL + 800 microgram/200 mL	See above
ropivacaine + fentanyl (Baxter)	epidural infusion	(0.1%) 200mg + 400 microgram/200mL, 200mL	* CONTROLLED DRUG *
rosuvastatin	tablet		* For use as per the PBS indications *
		5 mg	See above
		10 mg	See above
		20 mg	See above
		40 mg	See above
rotigotine	patch		(a) For discharge and outpatient use as per the PBS indications; (b) For inpatient use, on the advice of a neurologist or geriatrician, where oral or nasogastric therapy is not possible/suitable.
		2 mg/24 hours	See above
		4 mg/24 hours	See above
		6 mg/24 hours	See above
		8 mg/24 hours	See above
roxithromycin	dispersible tablet		
	tablet	50 mg	
		150 mg 300 mg	
rufinamide	tablet		Neurologists for use as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut Syndrome in patients 4 years of age or older, such patients having had appropriate trials of standard antiepileptic therapies for this condition (valproate, lamotrigine, topiramate, clobazam) unless intolerable side effects or contraindicated.
		200 mg	See above
		400 mg	See above
ruxolitinib	tablet	5 mg	(a) For discharge and outpatient use for myelofibrosis, as per the PBS indications; (b) For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
		10 mg	See above
		15 mg	For discharge and outpatient use for myelofibrosis, as per the PBS indications.
		20 mg	See above
sacituzumab govitecan	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *

Drug	Form	Strength	Restriction
sacubitril + valsartan	tablet	180 mg	See above
			* For use as per the PBS indications *
			See above
		24.3 mg + 25.7 mg	See above
		48.6 mg + 51.4 mg	See above
salbutamol	inhalation	100 microgram/actuation	
	inhalation solution	2.5 mg/2.5 mL	For use where treatment with this drug delivered from an oral pressurised inhalation device via a large volume spacer is inappropriate.
	injection	5 mg/2.5 mL	See above
		5 mg/5 mL	Obstetric use only
oral liquid	500 microgram/mL		
salicylic acid	ointment	2 mg/5 mL	Children too young to swallow tablets or capsules
	paste	(in Soft Paraffin) 3%, 100g (in Soft Paraffin) 5%, 100g (in Soft Paraffin) 12%, 50g (in Soft Paraffin) 20%, 50g	
(in Paraffin Base) 2% in Zinc Oxide Co Paste, 100g		Lassar's Paste	
salicylic acid	oral gel	8.7%	15g
salicylic acid and lactic acid (A.P.F.)	application	paint 20%-20%, 15mL	
salmeterol	powder for inhalation		For patients with frequent episodes of asthma who are concurrently being treated with inhaled corticosteroids
		50 microgram/actuation	See above See above
sapropterin	powder for oral liquid	500 mg	a) * For use as per the PBS indications * b) For use in infants (under 1 month of age) who have been identified by the Queensland Newborn Screening Program with an elevated phenylalanine level likely related to hyperphenylalaninaemia due to BH4 deficiency or Phenylketonuria (PKU)
		soluble tablet	100 mg
saquinavir	tablet	500 mg	* For use in accord with PBS Section 100 indications *
sea snake antivenom			

Drug	Form	Strength	Restriction
	injection	1000 units, vial	
secukinumab	injection	150 mg/mL	* For discharge and outpatient use as per the PBS indications *
selexipag	tablet	1 mg 1.2 mg 1.4 mg 1.6 mg 200 microgram 400 microgram 600 microgram 800 microgram	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
selinexor	tablet	20 mg	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications. <i>See above</i>
semaglutide	injection	1.34 mg/mL, 2mg/1.5mL (0.25mg or 0.5mg per dose prefilled pen) 1.34 mg/mL, 4mg/3mL (1mg per dose prefilled pen)	* For use as per the PBS indications * <i>See above</i>
senna leaf powder + fig + date	bar	1 g/10 g + 3 g/10 g + 3 g/10 g	For inpatient use only.
sennoside B	tablet	7.5 mg	
sertraline	tablet	50 mg 100 mg	For major depressive disorders or obsessive-compulsive disorder or panic disorder where other treatments have failed or are inappropriate. <i>See above</i> <i>See above</i>
sesame oil	nasal spray	1 mL/mL	Patients undergoing radiotherapy to nose and sinuses; for postoperative use following sinus surgery; and for use in inpatients only for the relief of nasal symptoms associated with continuous positive airway pressure (CPAP) therapy. <i>See above</i>
sevelamer	tablet	800 mg	For use in accord with PBS Section 100 indications (for initiation and stabilisation of treatment); For use as per the PBS indications (for maintenance therapy).
sevoflurane	inhalation solution	1 mL/mL	For use down to a minimum fresh gas flow of one litre per minute. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
sildenafil	oral liquid suspension		

Drug	Form	Strength	Restriction
sildenafil		2mg per mL, 200mL	Paediatric cardiac specialists
	tablet	20 mg	(a) For use in accord with PBS Section 100 indications; (b) For use under the guidance of paediatric cardiac specialists.
silicone	cream	2.5% 500mL	For back rubbing
siltuximab	injection	100 mg	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications <i>See above</i>
		400 mg	<i>See above</i>
silver nitrate	stick		
silver sulfadiazine	cream	1% 50g, 500g	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
simethicone	oral liquid	100 mg/mL	Specialist radiological and endoscopic procedures
	powder	125 mg	Specialist radiological and endoscopic procedures
simvastatin	tablet	20 mg	* For use as per the PBS indications * <i>See above</i>
		40 mg	<i>See above</i>
sirolimus	oral liquid	1 mg/mL	* For use in accord with PBS Section 100 indications *
	tablet	1 mg	* For use in accord with PBS Section 100 indications *
		2 mg	<i>See above</i>
		500 microgram	<i>See above</i>
sirolimus in white soft paraffin QH-CP	ointment	0.1% 50g	(a) For use in therapy initiated by Tuberous Sclerosis Complex Clinic specialists (paediatric neurologists, renal physicians and dermatologists) in patients with tuberous sclerosis for topical treatment of facial angiofibroma and other dermatological manifestations. (b) Renal physicians and dermatologists for use in adult patients with tuberous sclerosis for topical treatment of facial angiofibroma and other dermatological manifestations. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		0.5% 50g	<i>See above</i> <i>See above</i>
sitagliptin	tablet		For initiation, only when used in combination with insulin, in line with PBS criteria. For continuing use in established patients as per the PBS indications. Note: Initiate alogliptin in preference to sitagliptin for patients requiring a DPP-4 inhibitor who are not using insulin
		25 mg	<i>See above</i>
		50 mg	<i>See above</i>

Drug	Form	Strength	Restriction
sodium acetate		100 mg	See above
	injection		
sodium alginate + bicarbonate + calcium carbonate		1.64 g/10 mL	
	oral liquid		For infant use only
		500 mg/10 mL + 213 mg/10 mL + 325 mg/10 mL 500 mg/10 mL + 267 mg/10 mL + 160 mg/10 mL	See above See above
sodium aurothiomalate	injection		
		10 mg/0.5 mL 20 mg/0.5 mL 50 mg/0.5 mL	
sodium bicarbonate	ear drops		
	mouthwash	3% in 75% Glycerol, 15mL	
	oral liquid	1% 500mL	
		8.4%, 200mL	
sodium calcium edetate	injection		
		200mg/mL, 5mL	
sodium chloride	eye drops		
		5% 10mL	Specialist Ophthalmologists
	inhalation solution		
		sterile 6% solution for nebulisation 10mL sachet	For use in patients with cystic fibrosis, infants with acute bronchiolitis and for sputum induction as required.
	injection		
		0.9% (154 mmol per /litre) Injection in glass 50mL 0.9% (154 mmol per /litre) in glass 100mL 0.9% (154 mmol per /litre) in plastic 100mL	For use in Eye Wards; Eye Outpatients and Eye Casualty
	intravenous infusion injection		
		0.9% (154 mmol per litre) 1 Litre 0.9% (154 mmol per litre) 50mL 0.9% (154 mmol per litre) 250mL 0.9% (154 mmol per litre) 500mL 3% (510 mmol per litre) 250mL	For use only in emergency departments, critical care and high dependency units.
irrigation solution			
	sterile 0.9% 1 Litre pour bottle sterile uromatic 0.9% 2 Litre sterile uromatic 0.9% 3 Litre sterile 0.9% 100mL sterile 0.9% 500mL		
	pre-filled syringe "PosiFlush" 5mL		
		0.9%, 5mL	
sodium chloride	injection		
		0.9% (45 mg/5 mL) 0.9% (90 mg/10 mL) 0.9% (900 mg/100 mL)	For use in Eye Wards; Eye Outpatients and Eye Casualty

Drug	Form	Strength	Restriction
	soluble tablet	23.4% (40mmol/10 mL) 600 mg	For use only in emergency departments, critical care and high dependency units.
sodium chloride "auspman brand"	oral liquid	2mmol/mL, 100mL	For treatment of hyponatraemia in paediatric patients who are unable to swallow tablets when intravenous therapy is not indicated <i>See above</i> <i>See above</i>
sodium chloride + potassium chloride + calcium chloride + magnesium chloride + acetate + citric acid	solution	6.4 mg/mL + 750 microgram/mL + 480 microgram/mL +30mL: ...	Eye casualty only 120mL: Ophthalmologists
sodium chloride + potassium citrate monohydrate + glucose + citric acid	oral liquid	156.2 mg/62.5 mL + 137.5 mg/62.5 mL + 1 g/62.5 mL + ...	Paediatric Use
	powder for oral liquid	530 mg + 440 mg (potassium 4 mmol) + 2.91 g + ...	
sodium chloride + sodium gluconate + sodium acetate trihydrate + potassium chloride + magnesium chloride	injection	5.26 g/L + 5.02 g/L + 3.68 g/L + ...	
sodium chloride + sodium gluconate + sodium acetate trihydrate + potassium chloride + magnesium chloride + glucose	injection	5.26 g/L + 5.02 g/L + 3.68 g/L + ...	On the advice of paediatric intensivists.
sodium chloride with electrolytes - Sodium Chloride 0.64%, Potassium Chloride 0.075%, Magnesium Chloride 0.03%, Calcium Chloride 0.048%, Sodium Acetate 0.39%, Sodium Citrate 0.17% (Balanced Sterile Salt Solution) (Single use only)	irrigation solution	Sodium Chloride 0.64%, Potassium Chloride 0.075%, Magnesium Chloride 0.03%, Calcium Chloride 0.048%, Sodium Acetate 0.39%, Sodium Citrate 0.17% (Balanced Sterile Salt Solution) (Single use only)	15mL: Eye Casualty 250mL and 500mL: Ophthalmologists  <i>See above</i> <i>See above</i>
sodium chloride with glucose	intravenous infusion injection	sodium chloride 0.3% and glucose 3.3% (125 Cal per litre) (Sodium 51, Chloride 51 mmol per litre) 1 Litre sodium chloride 0.3% and glucose 3.3% (125 Cal per litre) (Sodium 51, Chloride 51 mmol per litre) 500mL	

Drug	Form	Strength	Restriction
		sodium chloride 0.45% and glucose 5% (200 Cal per litre) (Sodium 154, Chloride 154 mmol per litre) 1 Litre sodium chloride 0.9% and glucose 1% 1 Litre sodium 0.9% chloride and glucose 5% (200 Cal per litre) (Sodium 154, Chloride 154 mmol per litre)	For paediatric perioperative use only.
sodium hyaluronate	intraocular injection	(M.W.=5,000,000) "Healon GV" 14mg/mL, 0.55mL "Healon" 10mg/mL, 0.4mL "Healon" 10mg/mL, 0.85mL "Amvisc Plus" 16mg/mL, 0.8mL	Specialist Ophthalmologists where alternatives are inappropriate Specialist Ophthalmologists See above See above
sodium hyaluronate - chondroitin	intraocular injection	3% - 4%, 0.5mL	Specialist Ophthalmologists
sodium hyaluronate - sodium chondroitin sulfate and sodium hyaluronate "Duovisc Viscoelastic System"	intraocular injection	3%-4%, 0.35mL and 1%, 0.4mL 3%-4%, 0.5mL and 1%, 0.55mL	Specialist Ophthalmologists See above
sodium hypochlorite	solution	2% 500mL, 5 Litres	
	tablet for disinfectant solution	tablet for Disinfectant Solution	Patients with spinal cord injury
sodium lactate compound solution (Hartmann's Solution) and glucose 5% (200 Cal per litre) (Sodium 131, Potassium 5, Calcium 2, Chloride 111, Lactate 29 mmol per litre)	intravenous infusion injection	1 Litre	
sodium lactate compound solution (Sodium 131, Potassium 5, Calcium 2, Chloride 111, Lactate 29 mmol per Litre) "Hartmann's Solution"	intravenous infusion injection	1 Litre 500mL	
sodium polystyrene sulfonate	powder	999.3 mg/g	
sodium tetradecyl sulfate	injection	3% (60 mg/2 mL)	
sodium thiosulfate	injection	25% (2.5 g/10 mL)	As second line treatment for cyanide poisoning.
sodium thiosulfate	lotion	20%, 100mL	





Drug	Form	Strength	Restriction
	injection	500mg/8mL	On the advice of an infectious diseases physician for the treatment of COVID-19 in accordance with recommendations in the National Clinical Evidence Taskforce COVID-19 Guidelines <i>See above</i>
soya oil	fat emulsion (eg 'intralipid')	20% (100 g/500 mL)	Anaesthetists and Emergency Department Specialists for the management of severe local anaesthetic toxicity.
soya oil + medium chain triglycerides + olive oil + fish oil natural	injection	6 g/100 mL + 6 g/100 mL + 5 g/100 mL + ... 30 g/500 mL + 30 g/500 mL + 25 g/500 mL + ...	For intravenous therapy when oral or enteral feeding is not possible. Note: 100mL is to be used in neonates only For intravenous therapy when oral or enteral feeding is not possible.
spacer device inhalation	spacer device inhalation	airflow space chamber with child mask airflow space chamber with infant mask breath-a-tech adult mask breath-a-tech child mask breath-a-tech for use with asthma inhalers la petite e-chamber volumatic For Ventolin and Becotide Aerosols	
spironolactone	oral liquid suspension	2.5mg per mL, 50mL	Patients unable to swallow tablets
spironolactone	tablet	25 mg 100 mg	
sterculia	granules	620 mg/g	
stonefish antivenom	injection	2000 units, vial	
streptokinase	injection	250 000 units	
streptomycin sulfate	injection	1g	* For use in accord with Special Access Scheme (SAS) arrangements *
succinylated gelatin	injection	20 g/500 mL	Plasma substitute as an alternative to plasma protein
sucralfate	tablet	1 g	
sucroferric oxyhydroxide	chewable tablet	2.5 g (iron 500 mg)	* For use in accord with PBS Section 100 indications *
sucrose	oral liquid solution	24% 2mL	

Drug	Form	Strength	Restriction
sufentanil	injection	250microgram in 5mL	Palliative Care Specialists and Medical Oncologists for the control of severe disabling pain when other opioids are inappropriate or not tolerated. Caution: The risk of drug dependence is high. CONTROLLED DRUG Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained.
sugammadex	injection	200 mg/2 mL  500 mg/5 mL	For paediatric use by credentialed anaesthetists and Emergency Physicians for emergency reversal of rocuronium in patients who cannot be intubated and cannot be oxygenated. All other use of sugammadex must be on an Individual Patient Approval basis, with approval by the Director of Anaesthetics, the Director of Emergency Medicine or nominated representative, and in line with the SWAPNET guideline. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) * Note: Only limited stock may be held outside pharmacy - on the difficult intubation trolley. For use by credentialed anaesthetists and Emergency Physicians for emergency reversal of rocuronium in patients who cannot be intubated and cannot be oxygenated. All other use of sugammadex must be on an Individual Patient Approval basis, with approval by the Director of Anaesthetics, the Director of Emergency Medicine or nominated representative, and in line with the SWAPNET guideline. Note: Only limited stock may be held outside pharmacy - on the difficult intubation trolley.
sulfadiazine	tablet	500 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
sulfasalazine	enteric tablet tablet	500 mg 500 mg	
sulthiame	tablet	50 mg 200 mg	
sumatriptan	injection nasal spray tablet	6 mg/0.5 mL 20 mg/actuation 50 mg	For use in hospital under medical supervision  For migraine attacks in patients aged 12 years and older, where oral treatment with a triptan is not tolerated.  Treatment of migraine attacks in patients failing other therapy.
sunitinib	capsule	12.5 mg 25 mg 50 mg	For discharge and outpatient use in patients with pancreatic neuroendocrine tumours or gastrointestinal stromal tumours, as per the PBS indications. See above See above

Drug	Form	Strength	Restriction
sunscreen (SPF 50+) cream and lotion	cream	75g	
	lotion	500mL	
suxamethonium	injection	100 mg/2 mL	
tacrolimus	capsule	1 mg 5 mg 500 microgram	
	modified release capsule	1 mg 3 mg 5 mg 500 microgram	
tacrolimus "ACS"	oral liquid suspension (QH-CP)	1mg in 1mL, 100mL	For use in paediatric patients.
tadalafil	tablet	20 mg	* For use in accord with PBS Section 100 indications *
	injection	12 000 units, vial	
talc	powder	3g aerosol 4g	
	injection	200 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
tamoxifen	tablet	10 mg 20 mg	
	modified release tablet	50 mg 100 mg 150 mg 200 mg 250 mg	Persistent pain specialists for use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
taurolidine + citrate 4% (TauroLock)	catheter lock solution		For use as a line lock for the prevention of blood stream infections and to maintain patency in: a) haemodialysis patients

Drug	Form	Strength	Restriction
		3mL & 5mL	b) patients on home parenteral nutrition who have experienced a central venous catheter line infection <i>See above</i>
taurolidine + citrate 4% + heparin 500 units (TauroLock Hep500)	catheter lock solution	5mL	For use as a line lock for the prevention of blood stream infections and to maintain patency in: a) haemodialysis patients b) patients on home parenteral nutrition who have experienced a central venous catheter line infection.
teduglutide	injection	5 mg	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications
teicoplanin	injection	400 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
telmisartan	tablet	40 mg 80 mg	For patients unable to tolerate ACE inhibitors because of cough or angioedema, or patients intolerant of other antihypertensive therapy. <i>See above</i> <i>See above</i> <i>See above</i>
temazepam	tablet	10 mg	
temozolomide	capsule	5 mg 20 mg 100 mg 140 mg 250 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
tenecteplase	injection	40 mg	Note: Due to the current shortage of tenecteplase injection, this LAM listing has been amended. Usage of this product should be in line with the ADDG memorandum (dated 19/09/22) attached. a) pre-hospital treatment of acute ST elevation myocardial infarction; b) treatment of acute ST elevation myocardial infarction in smaller regional centres and rural and remote facilities/hospitals, including Aboriginal health services; c) second line treatment (when alteplase cannot be used) of acute ischaemic stroke with large arterial obstruction documented by angiography prior to emergency endovascular clot retrieval. Dose 0.25mg/kg to maximum 25mg; d) treatment of acute ischaemic stroke in rural hospitals (when alteplase is not available as a first line treatment) under telehealth consultation with a physician (including Emergency Department physicians) trained and experienced in acute stroke management. Thrombolysis may be initiated within four and a half hours after the onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques. Dose 0.25mg/kg to maximum 25mg. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *

Drug	Form	Strength	Restriction
		50 mg	Note: Due to the current shortage of tenecteplase injection, this LAM listing has been amended. Usage of this product should be in line with the ADDG memorandum (dated 19/09/22) attached. a) pre-hospital treatment of acute ST elevation myocardial infarction; b) treatment of acute ST elevation myocardial infarction in smaller regional centres and rural and remote facilities/hospitals, including Aboriginal health services.
teniposide	injection		
		50 mg/5 mL	
tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat	tablet	10 mg + 200 mg + 150 mg + ...	* For use in accord with PBS Section 100 indications *
tenofovir disoproxil	tablet		
		291 mg	* For use in accord with PBS Section 100 indications *
tenofovir disoproxil + emtricitabine	tablet		
		291 mg + 200 mg	For use in accord with PBS Section 100 indications; For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
tenofovir disoproxil + emtricitabine + efavirenz	tablet		* For use in accord with PBS Section 100 indications *
		300 mg + 200 mg + 600 mg	See above See above
terbinafine	cream		
		1%	* For use as per the PBS indications *
	tablet		
		250 mg	Specialist Staff and Endorsed Podiatrists in a shared care arrangement for (i) microbiologically proven chronic onychomycosis; (ii) extensive tinea unresponsive to griseofulvin or in patients intolerant of griseofulvin
terbutaline	injection		
		500 microgram/mL	General use for TGA approved indications; and for treatment of uterine hyperstimulation / tachysystole. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	powder for inhalation		
		500 microgram/actuation	
teriparatide	injection		
		250 microgram/mL	For discharge and outpatient use as per the PBS indications. Patients must be made fully aware of the 18 month maximum length of PBS subsidised treatment.
terlipressin	injection		

Drug	Form	Strength	Restriction
		850 microgram/5 mL	Under the direction of a transplant hepatologist for treatment of patients with hepatorenal syndrome (HRS) Type 1 who are actively being considered for liver transplant.
testosterone	gel	1% (12.5 mg/actuation) 1% (50 mg/5 g)	* For use as per the PBS indications * See above
testosterone enantate	injection	250 mg/mL	(a) For use in confirmed testosterone deficiency. (b) Paediatric endocrinologists, and paediatricians under the supervision of a paediatric endocrinologist, for use in adolescents with persistent gender dysphoria. (Note that therapy MUST have been initiated by the Statewide CHQ Gender Service.) (c) Adult endocrinologists, and adult physicians under the supervision of an adult endocrinologist, for the treatment of persistent gender dysphoria. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
tetanus immunoglobulin	injection	250 units 4000 units	
tetrabenazine	tablet	25 mg	
tetracaine (amethocaine)	eye drops	1%	Specialist Ophthalmologists
tetracosactide	injection	250 microgram/mL	
	modified release injection	1 mg/mL	
tetracycline	capsule	250 mg	
tezacaftor + ivacaftor (& ivacaftor	combination pack	100 mg + 150 mg (&) 150 mg	* For use in accord with PBS Section 100 indications *
thalidomide	capsule	50 mg 100 mg	* For use in accord with PBS Section 100 indications * See above See above
theophylline	modified release tablet	250 mg 300 mg	
	oral liquid	133.3 mg/25 mL	To be used where tablets are unsuitable
thiabendazole (tiabendazole)	tablet	500mg	
thiamine			

Drug	Form	Strength	Restriction
	injection 300mg/3mL	300mg/3mL	
thiamine	injection 100mg/1mL	100 mg/mL	For use only in paediatric patients
	tablet	100 mg	
thiopental	injection	470 mg (equiv 500mg thiopental sodium and sodium carbonate)	Note: The amount of active ingredient differs between brands of thiopental sodium. Refer to Queensland Health memorandum dated 25/11/19
thrombin "Aspen"	application	5000 units	Requires SAS category A approval
thymol + benzoic acid + bicarbonate	mouthwash	1.5 mg/mL + 8 mg/mL + 3 mg/mL	
tiagabine	tablet	5 mg 10 mg 15 mg	For partial epilepsy not controlled by other drugs See above See above
ticagrelor	dispersible tablet	90 mg	(a) For inpatient use in combination with aspirin for treatment of STEMI and high risk non-ST elevation acute coronary syndrome; (b) Use by the Queensland Ambulance Service (QAS) in accordance with the QAS Ticagrelor Drug Therapy Protocol; (c) Interventional radiologists or neurosurgical specialists for inpatient use in proven clopidogrel non-responders identified by the multiplate / VerifyNow P2Y12 assay post neuro-endovascular stent insertion. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet	90 mg	(a) To be used in combination with aspirin for treatment of STEMI and high risk non-ST elevation acute coronary syndrome; (b) Interventional radiologists or neurosurgical specialists for use in proven clopidogrel non-responders identified by the multiplate / VerifyNow P2Y12 assay post neuro-endovascular stent insertion. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
tiger snake antivenom	injection	3000 units, vial	
timolol	eye drops	0.25% 0.5%	
tinidazole			



Drug	Form	Strength	Restriction
tioguanine	tablet	500 mg	* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	tablet	40 mg	For treatment of leukaemia
tirofiban	injection	12.5 mg/50 mL	<p>Patients with high-risk acute coronary syndromes (as defined by new transient or persistent ST or T-wave ECG changes and ischaemic pain lasting at least 20 minutes within the previous 12 hours) who are either:</p> <p>1) undergoing percutaneous coronary intervention (PCI); or</p> <p>2) continuing to experience repeated episodes of ischaemic chest pain despite maximal medical therapy including combination anti-platelet therapy and therapeutic dose heparin.</p>
tobramycin	eye drops	0.3%	Ophthalmologists
	eye ointment	0.3%	Ophthalmologists
	inhalation solution	300 mg/5 mL	Specialist respiratory staff or physicians in regional centres with approval from the specialist cystic fibrosis physician for discharge and outpatient use (including use for training purposes in outpatient clinics) for the management of cystic fibrosis patients with Pseudomonas aeruginosa infections as per the PBS indications.
	injection	80 mg/2 mL	<p>Preservative Free</p> <p>Specialist respiratory staff for nebulised use as treatment of pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis in situations where patients are intolerant to other tobramycin products;</p> <p>and on the advice of an infectious diseases physician for inhalation in non-CF bronchiectasis patients with pseudomonas aeruginosa infection.</p> <p>Injection</p> <p>On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.</p> <p>* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p>
	powder for inhalation	28 mg	Specialist respiratory staff or physicians in regional centres with approval from the specialist cystic fibrosis physician for discharge and outpatient use (including use for training purposes in outpatient clinics) for the management of cystic fibrosis patients with Pseudomonas aeruginosa infections as per the PBS indications.
tocilizumab	injection	80 mg/4 mL	<p>(a) For use in accord with PBS Section 100 indications;</p> <p>(b) On advice of specialist oncology and haematology staff for the treatment of chimeric antigen receptor (CAR) T-cell induced severe or life-threatening cytokine release syndrome (CRS).</p> <p>(c) On the advice of a specialist physician for the treatment of COVID-19 where baricitinib cannot be used, in accordance with recommendations in the National Clinical Evidence Taskforce COVID-19 Guidelines</p>
		162 mg/0.9 mL (subcutaneous)	For use as per the PBS indications.
		200 mg/10 mL	<p>(a) For use in accord with PBS Section 100 indications;</p> <p>(b) On advice of specialist oncology and haematology staff for the treatment of chimeric antigen</p>

Drug	Form	Strength	Restriction
			receptor (CAR) T-cell induced severe or life-threatening cytokine release syndrome (CRS). (c) On the advice of a specialist physician for the treatment of COVID-19 where baricitinib cannot be used, in accordance with recommendations in the National Clinical Evidence Taskforce COVID-19 Guidelines
		400 mg/20 mL	See above
tolnaftate	cream		
	lotion	1%	
		1%	
topiramate	capsule		For epilepsy not controlled by other drugs
		15 mg	See above
		25 mg	See above
	tablet		See above
		25 mg	See above
		50 mg	See above
		100 mg	See above
		200 mg	See above
topiramate	oral liquid suspension		
		5mg/mL, 100mL (QH-CP)	For epilepsy not controlled by other medications where: (a) Solid dose forms cannot be swallowed whole; OR (b) Administration via an enteral feeding tube is required AND dispersing the tablet/capsule is considered inappropriate. Refer to 'Don't Rush to Crush' and local procedures for guidance. Note: Monitor patient on transition between different dose forms. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
topotecan	injection		
		4 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
trabectedin	injection		
		1 mg, vial	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
trace elements with iron - chromium + copper + iron + manganese + iodine + fluoride + molybdenum + selenium + zinc	injection		
		53.33 microgram/10 mL + 1.02 mg/10 mL + 5.4 mg/10 mL + ...	
tramadol	capsule		
		50 mg	For use in patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. A maximum quantity of 10 tablets for discharge and outpatient use, except for palliative care patients.
	injection		
		100 mg/2 mL	For use in patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated.

Drug	Form	Strength	Restriction
	modified release tablet	50 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or short acting first line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states.
		100 mg	See above
		150 mg	See above
		200 mg	See above
trametinib	tablet	2 mg	Specialist Oncologists for discharge and outpatient use as per the PBS indications.
		500 microgram	See above
tranexamic acid	injection	1 g/10 mL	Specialist Anaesthetists, Specialist Intensivists, Specialist Surgical Staff and Cardiac Perfusionists for: a) Major haemorrhage with concomitant hyperfibrinolysis, and b) Prophylaxis of intra- and post-operative bleeding during major surgical procedures where there is a high likelihood of transfusion requirement; or Credentialed Emergency Department Senior Medical Officers to treat hypotensive trauma patients with uncontrolled haemorrhage, preferably within one hour, but no later than 3 hours after trauma; or For use in severe to life threatening bleeding in line with Qld Department of Health guidelines for managing patients on novel oral anticoagulants; or ENT surgeons, or ED medical officers in consultation with the on-call ENT surgeon, for management of post-tonsillectomy haemorrhage (primary or secondary) in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet	500 mg/5 mL	See above
tranexamic acid	mouthwash	500 mg	
		5% 150mL	
tranylcypromine	tablet	10 mg	
trastuzumab (Herceptin SC)	injection	600 mg/5 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
trastuzumab (Kanjinti)	powder for injection	150 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		420 mg	See above
trastuzumab emtansine			See above

Drug	Form	Strength	Restriction
travoprost	injection	100 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		160 mg	<i>See above</i> <i>See above</i>
travoprost + timolol	eye drops	0.004%	Specialist Ophthalmologists as monotherapy for the reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are intolerant of, or insufficiently responsive to, other intraocular pressure medication.
travoprost + timolol	eye drops	0.004% + 0.5%	For reduction of elevated intra-ocular pressure as per the PBS indications.
tretinoin	capsule	10 mg	Specialist Haematologists and their advanced training registrars in accord with Health (Drugs and Poisons) Regulations 1996 for use in induction, consolidation and maintenance therapy in patients with newly diagnosed or relapsed acute promyelocytic leukaemia (APML).
triamcinolone	cream	0.02%	100g: Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
	injection	10 mg/mL	Intra-articular and intralesion injection
		40 mg/mL	<i>See above</i>
	ointment	0.02%	100g
	paste	0.1%	5g: Specialist Medical and Dental Staff and Country Medical Superintendents
triamcinolone + neomycin + gramicidin + nystatin	ointment	0.1% + 0.25% + 0.025% + ... ointment and ear ointment	Applies to 15g ointment and 5g ear ointment.
triamcinolone acetonide	intraocular injection	40mg in 1mL	Specialist ophthalmologists for intraocular oedematous and neovascular disease of the eye. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
triamcinolone hexacetonide	injection suspension	20mg/mL	Paediatric rheumatologists who have TGA authorisation to prescribe triamcinolone hexacetonide. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
			<i>See above</i> <i>See above</i>
triclosan	emulsion	1% 200mL	Not for use on neonates
	hand and body wash/skin cleanser	1% 1.5L	For use in areas at high risk from MRSA
		1% 125mL	<i>See above</i>
		1% 500mL	<i>See above</i>
	pre-op wash		

Drug	Form	Strength	Restriction
trifluridine + tipiracil	skin cleanser soap	1% 40mL	
		1% 125g	For use in areas at high risk from MRSA
trihexyphenidyl (benzhexol)	tablet	15 mg + 6.14 mg 20 mg + 8.19 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i>
		2 mg 5 mg	
trimethoprim	tablet	300 mg	
		80 mg/5 mL + 400 mg/5 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
trimethoprim + sulfamethoxazole	injection	80 mg/5 mL + 400 mg/5 mL	
		40 mg/5 mL + 200 mg/5 mL	Patients unable to swallow tablets
		80 mg + 400 mg 160 mg + 800 mg	
triptorelin	injection	3.75 mg	Outpatient: * For discharge and outpatient use as per the PBS indications *
		11.25 mg	<i>See above</i>
		22.5 mg	<i>See above</i>
trisodium edetate	injection	1g in 5mL	
		0.5%	0.5mL: For inpatient use only.
tropicamide	eye drops	0.5%	15mL
		0.5%	<i>See above</i>
		1%	0.5mL: For inpatient use only.
		1%	
trypan blue	injection	0.6mg in 0.5mL	Specialist ophthalmologists for use where standard capsulorrhexis is difficult to perform.
		50 tuberculin units/mL	
tuberculin PPD (Mantoux) acellular intradermal skin test	injection		
typhoid inactivated vaccine	injection	0.5 mL syringe	
ulipristal	tablet	30 mg	For use following alleged sexual assault for emergency contraception up to 120 hours post sexual assault.
urea + lactic acid			

Drug	Form	Strength	Restriction
urea pronalys BP	cream	10% + 5%	Specialist Endocrinology Staff for the oral treatment of mild to moderate symptoms of euvolemic hyponatraemia in patients unable to tolerate fluid restrictions or where fluid restrictions have failed
	crystals	99-100% w/w 500g	See above
urokinase	injection	10,000 units	Fibrinolytic management of obstructed IV access; Venous thrombosis; Peripheral arterial occlusion; Haemodialysis shunts See above
		100,000 units	See above
		500,000 units	See above
ursodeoxycholic acid	capsule	250 mg	(a) For proven primary biliary cholangitis (formerly primary biliary cirrhosis); (b) For relief of pruritus and improvement of liver function in biochemically proven intrahepatic cholestasis of pregnancy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	oral liquid	50 mg/mL	For proven primary biliary cholangitis (formerly primary biliary cirrhosis).
ustekinumab	injection	45 mg/0.5 mL (subcutaneous)	* For use as per the PBS indications *
		130 mg/26 mL	* For use in accord with PBS Section 100 indications *
valaciclovir	tablet	500 mg	a) On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for the treatment of herpes simplex virus in immunocompromised (haematology and oncology) paediatric patients (up to 18 years of age); b) Treatment of immunocompetent patients with herpes zoster in whom the duration of rash is less than 72 hours; c) Intermittent treatment of moderate to severe recurrent genital herpes; d) Herpes zoster in immunocompromised patients; e) Ophthalmic herpes zoster; f) Use in accord with PBS Section 100 indications; g) For prophylaxis of viral infection for up to 12 months following stem cell transplant h) For prophylaxis of viral infection in solid organ transplant (SOT) patients: for up to 3 months following SOT; and for 1 month following treatment of acute rejection of SOT i) For prophylaxis of viral infection in patients receiving chemotherapy for haematological malignancy, during, and up to 3 months post completion of treatment * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
valganciclovir	powder for oral liquid	50 mg/mL	* For use in accord with PBS Section 100 indications *
	tablet		See above

Drug	Form	Strength	Restriction
valproate		450 mg	See above
	enteric tablet	200 mg 500 mg	
	injection	400 mg	(a) For maintenance treatment of epilepsy not controlled by other drugs when oral sodium valproate has already been established but is temporarily not feasible. (b) Status epilepticus in adults, and also in children (as per the statewide paediatric guidelines) * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	oral liquid	200 mg/5 mL	Caution: There are reports of fatal hepatotoxicity with this preparation particularly in children
	tablet	100 mg	
vancomycin	capsule	125 mg	For the treatment of antibiotic associated colitis due to C. difficile as per the PBS indications. See above
		250 mg	See above
	injection	1 g	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		500 mg	See above
varenicline	tablet	1 mg	a) For use in Primary Health Care Clinics registered for the PBS Section 100 Remote Area Aboriginal Health Services program b) For use in either community mental health or community alcohol and other drug services as per the PBS indications.
		500 microgram	For use in Primary Health Care Clinics registered for the PBS Section 100 Remote Area Aboriginal Health Services program. Note - Varenicline 500microgram tablet is only available in combination with varenicline 1mg tablet.
varicella-zoster live vaccine	injection	1 each	(a) For use in accord with QH policy for staff immunisation; (b) For haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded vaccines; (c) For patients planned for solid-organ transplantation who are not eligible for National Immunisation Program (NIP) funded vaccines. Seek expert opinion if vaccination is required within four weeks of the scheduled date of transplant.
		1 vial	
varicella-zoster virus immunoglobulin	injection	200 units	Specialist Staff by special arrangement from Red Cross Blood Bank
vasopressin	injection	20 pressor Units in 1mL	
vecuronium	injection	4 mg	Specialist Anaesthetists and Country Medical Superintendents

Drug	Form	Strength	Restriction
vedolizumab	injection	10 mg	Specialist Anaesthetists; ICU and Country Medical Superintendents
		300 mg	* For use in accord with PBS Section 100 indications *
velaglucerase alfa	injection	400 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
venetoclax	tablet	10 mg	Specialist Haematologists for use as per the PBS indications. Note: This strength also available as part of the venetoclax titration pack. Titration pack restriction: Specialist Haematologists for discharge and outpatient use as per the PBS indications.
		50 mg	<i>See above</i>
		100 mg	Specialist Haematologists for discharge and outpatient use as per the PBS indications. Note: This strength also available as part of the venetoclax titration pack. Titration pack restriction: Specialist Haematologists for discharge and outpatient use as per the PBS indications.
venlafaxine	modified release capsule	37.5 mg	For major depressive disorders <i>See above</i>
		75 mg	<i>See above</i>
		150 mg	<i>See above</i>
verapamil	injection	5 mg/2 mL	
	modified release capsule	160 mg	
	modified release tablet	180 mg	
		240 mg	
	tablet	40 mg	
		80 mg	
vericiguat	tablet		On the advice of a cardiologist as per the PBS indications. <i>See above</i>
		2.5 mg	<i>See above</i>
		5 mg	<i>See above</i>
		10 mg	<i>See above</i>
vigabatrin	powder for oral liquid	500 mg	For epilepsy not controlled by other drugs <i>See above</i>
			<i>See above</i>
	tablet	500 mg	<i>See above</i>
vinblastine	injection	10 mg/10 mL	* For use in accord with PBS Section 100 indications *
vincristine	injection	1 mg/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *



Drug	Form	Strength	Restriction
vindesine	injection		
		5 mg	
vinorelbine	capsule	20 mg	* For discharge and outpatient use as per the PBS indications *
		30 mg	See above
	injection	10 mg/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		50 mg/5 mL	See above
vitamin A	capsule 5000 units	5,000 units	
vitamin A	capsule 50 000 units	50 000 units	* For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
vitamin A	injection (SAS)		Use where enteral therapy is inappropriate or contraindicated. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		100,000 units/ 2mL	See above
vitamin A	oral solution		
		5,000 units/ 0.2mL	
vitamin B group with ascorbic acid (ascorbic acid + nicotinamide + pyridoxine + riboflavin + thiamine)	tablet		
		45 mg + 45 mg + 700 microgram + ...	
vitamin compound "Penta-vite" 30mL			Patients unable to swallow tablets
	liquid		See above
		"Penta-vite"	See above
vitamin compound "VitABDECK"	capsule		For treatment of patients with cystic fibrosis or pancreatic insufficiency
		"VitABDECK"	See above
vitamin compound (containing fat and water soluble vitamins excluding vitamin K) "Cernevit" 5mL	injection		
		"Cernevit"	
vitamin compound (fat soluble vitamins) "Vitalipid N Adult" 10mL			For a complete PN multivitamin, use a fat soluble vitamin preparation together with a water soluble vitamin preparation.
	injection		See above
		"Vitalipid N Adult"	See above

Drug	Form	Strength	Restriction
vitamin compound (water soluble vitamins) "Soluvit N"	injection	"Soluvit N"	For a complete PN multivitamin, use a fat soluble vitamin preparation together with a water soluble vitamin preparation. <i>See above</i> <i>See above</i>
vitamin compound with minerals "Centrum Advance"	tablet	"Centrum Advance"	For use in patients with a designated clinical need where Vitaminorum brand is considered unsuitable. <i>See above</i> <i>See above</i>
vitamin compound with minerals "Centrum Kids"	chewable tablet	"Centrum Kids"	Patients unable to swallow tablets  <i>See above</i> <i>See above</i>
vitamin compound with minerals "Supradyn"	effervescent tablet	"Supradyn"	For use in patients unable to tolerate tablets.  <i>See above</i> <i>See above</i>
vitamin compound with minerals "Vitaminorum"	tablet	"Vitaminorum"	
vitamin compound with minerals RENAL "Kidney Vital"	tablet	"Kidney Vital"	Nephrologists or nephrology nurse practitioners for use in patients on dialysis as replacement for the combination of folic acid, vitamin B group with ascorbic acid and cholecalciferol. <i>See above</i> <i>See above</i>
vitamin, fat soluble compound in tocopherol peg suspension	chewable tablet	"AquaDEKs"	Paediatricians, in consultation with CHQ's Paediatric Gastroenterology and Hepatology Service or Cystic Fibrosis Clinic, for infants and children with cholestasis (biliary atresia, alagilles, cystic fibrosis) and FSV deficiency resistant to standard oral FSV supplements. (Children should have documented deficiency of Vit K [abnormal Prothrombin time correctable with Vit K IMI], A, D and E on blood testing.) * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i>
	liquid	"AquaDEKs"	<i>See above</i>
	soft capsule	"AquaDEKs"	<i>See above</i> <i>See above</i>
vitamins, minerals and trace elements with carbohydrate	powder for oral liquid	6 g sachet	Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of the QCH neurosciences or using the protocols of the tertiary referral centre for ketogenic diet.
voriconazole	injection	200 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved protocol for: a) treatment of fungal infections as per the PBS indications for oral voriconazole formulations; b) prophylaxis of invasive fungal infections including both yeasts and moulds - in patients unable to tolerate posaconazole - as per the PBS indications for oral voriconazole formulations, and in lung

Drug	Form	Strength	Restriction
			transplant patients.
	powder for oral liquid	40 mg/mL	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved protocol for: a) treatment of fungal infections as per the PBS indications; b) prophylaxis of invasive fungal infections including both yeasts and moulds as per the PBS indications and in lung transplant patients.
	tablet	50 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved protocol for: a) treatment of fungal infections as per the PBS indications; b) prophylaxis of invasive fungal infections including both yeasts and moulds - in patients unable to tolerate posaconazole - as per the PBS indications and in lung transplant patients.
		200 mg	<i>See above</i>
vorinostat	capsule	100 mg	Haematologists for discharge and outpatient use as per the PBS indications
warfarin	tablet		Note: Marevan® brand continues to be the preferred brand of warfarin for use in QH facilities. As warfarin brands are NOT bioequivalent and should not be interchanged, hospital pharmacies may hold small stocks of Coumadin® brand for continuation of therapy in inpatients, if patient's own supply is unavailable.
		1 mg	<i>See above</i>
		3 mg	<i>See above</i>
		5 mg	<i>See above</i>
water for injections	injection	1 L bag 2 mL glass ampoule 5 mL ampoule 10 mL ampoule 20 mL ampoule 100 mL vial	
water for irrigation	solution	1 L bottle 2 L bag 100 mL bottle 500 mL bottle	Urology and Renal Units
wool fat	ointment	1 g/g	
zanamivir	powder for inhalation	5 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for a) treatment of laboratory-proven influenza in hospitalised patients within 48 hours of onset of symptoms and b) prophylaxis of hospitalised contacts of laboratory-proven influenza cases in contacts who are at high risk of influenza related morbidity
zanubrutinib	capsule	80 mg	Specialist haematologists for discharge and outpatient use for Waldenstrom macroglobulinaemia (WM) and mantle cell lymphoma (MCL), as per the PBS indications.
zidovudine			

Drug	Form	Strength	Restriction
	capsule	100 mg 250 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
	oral liquid	50 mg/5 mL	<i>See above</i> <i>See above</i>
zinc	capsule	50 mg	
zinc chloride	injection	10.6 mg/2 mL (5.1mg/2mL elemental zinc)	
zinc oxide	cream	15.25% w/w, 25g 15.25% w/w, 60g 100g	
	ointment	100g	
zinc oxide + maize starch + purified talc + chlorphenesin	powder	25% + 55.85% + 18.07% + ...	
zinc oxide + peru balsam + benzyl benzoate	suppository	300 mg + 50 mg + 33 mg	
zinc oxide compound paste (paraffin base) with	paste	Clioquinol 1%, 50g Salicylic Acid 2% and Dithranol 0.1% 100g Salicylic Acid 2% and Dithranol 0.25% 100g Coal Tar Solution 3% 50g 100g Dusting Powder 100g	
zinc sulfate	oral liquid	11.3mg (elemental zinc) per mL, 50mL	For use when prescribed by a Burns Unit specialist and when zinc sulfate capsules cannot be used
ziprasidone	capsule	20 mg 40 mg 60 mg 80 mg	For use as per the PBS indications following failure of aripiprazole, risperidone, olanzapine, amisulpride or lurasidone. <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
zoledronic acid	injection	4 mg/5 mL	(a) For use in accord with PBS Section 100 indications; (b) Severe hypercalcaemia; (c) Paediatricians for the treatment of (i) Osteogenesis imperfecta OR (ii) Primary or secondary osteoporosis in paediatrics with evidence of significant skeletal fragility (e.g. vertebral compression fractures or ≥ 2 low trauma long bone fractures). * When medicines are used in ways other than as specified in the TGA approved product

Drug	Form	Strength	Restriction
		5 mg/100 mL	information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * For outpatient or day therapy use for osteoporosis when oral bisphosphonates cannot be tolerated or their use is inappropriate; and for Paget disease as per the PBS indications.
zonisamide	capsule	25 mg 50 mg 100 mg	Neurology Staff for the treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptics as per the PBS indications. <i>See above</i> <i>See above</i> <i>See above</i>
zuclopenthixol acetate	injection	50 mg/mL 100 mg/2 mL	Specialist psychiatrists for prolonged acute behavioural disturbance that has not responded to initial treatments as per the Queensland Health guidelines for acute behavioural disturbance management <i>See above</i> <i>See above</i> <i>See above</i>
zuclopenthixol decanoate	injection	200 mg/mL	Specialist Psychiatrists where other antipsychotic agents are ineffective or contraindicated